Multispecific antibodies for treating CD47-associated diseases

JP2024541961APending Publication Date: 2024-11-13VIRTUOSO BINCO INC
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2024525203
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-27
Filing Date
2022-10-26
Publication Date
2024-11-13

AI Technical Summary

Technical Problem

Current anti-CD47 antibodies face limitations such as interaction with red blood cells, leading to hemagglutination and anemia, and there is a need for improved methods to treat CD47+ malignant cells while minimizing off-tumor effects.

Method used

Development of multispecific antibodies, including a CD47 binding domain and an EpCAM or EGFR binding domain, which exhibit higher affinity for tumor cells, reducing binding to red blood cells and enhancing phagocytosis and cytotoxicity of CD47+ tumor cells.

Benefits of technology

The multispecific antibodies effectively target CD47+ tumor cells, increasing phagocytosis and cytotoxicity while minimizing off-tumor effects, offering a more effective treatment approach for various cancers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541961000001_ABST
    Figure 2024541961000001_ABST
Patent Text Reader

Abstract

The present disclosure describes a multispecific antibody comprising a first targeting moiety that specifically binds to CD47 and a second targeting moiety. The second targeting moiety can specifically bind to EpCAM or EGFR.Furthermore, the present disclosure also describes a pharmaceutical composition comprising the multispecific antibody, and a method of use for killing CD47+ cells, for example, CD47+EpCAM+ cells or CD47+EGFR+ cells, and for treating proliferative diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] cross reference This application claims priority to PCT Application No. PCT / CN2021 / 126743, filed October 27, 2021, the entire contents of which are incorporated herein by reference.

[0002] Sequence Listing This application contains a Sequence Listing, which has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. The ASCII copy, created on October 24, 2022, has the filename txt_55429-739_602_SL.txt and is 16 kilobytes in size.

[0003] Incorporation by Reference All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. Summary of the Invention

[0004] The present disclosure provides a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain. In some embodiments, the multispecific antibody is bispecific, trispecific, or tetraspecific. In some embodiments, the multispecific antibody is bispecific. In some embodiments, the multispecific antibody is bivalent, trivalent, or tetravalent. In some embodiments, the multispecific antibody is bivalent.

[0005] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain, the multispecific antibody has a higher affinity for CD47 expressed on the surface of tumor cells than for CD47 expressed on the surface of normal cells, such as erythrocytes, platelets, T cells, or NK cells. In some embodiments, the tumor cells express EpCAM. In some embodiments, the concentration of the multispecific antibody required for half-maximal binding to (e.g., human) erythrocytes is greater than about 500 nanomolar (nM).

[0006] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain, the multispecific antibody binds to (e.g., human) CD47 with a dissociation constant (KD) of less than about 100 nanomolar (nM). In some embodiments, the multispecific antibody binds to (e.g., human) CD47 with a dissociation constant (KD) of about 1 nanomolar (nM) to about 100 nM, about 1 nM to about 50 nM, or about 5 nM to about 50 nM. In some embodiments, the multispecific antibody binds to EpCAM with a dissociation constant (KD) of less than about 500 nanomolar (nM). In some embodiments, the multispecific antibody binds to EpCAM with a dissociation constant (KD) of about 0.2 nanomolar (nM) to about 500 nM, about 1 nM to about 300 nM, about 5 nM to about 200 nM, or about 10 nM to about 150 nM. In some embodiments, the dissociation constant (KD) is determined by surface plasmon resonance.

[0007] In some embodiments of multispecific antibodies comprising a CD47-binding domain and an EpCAM-binding domain, the EpCAM-binding domain is a human or engineered human EpCAM-binding domain. In some embodiments, the EpCAM-binding domain comprises an antibody that specifically binds to EpCAM, or a functional fragment or functional variant thereof. In some embodiments, the antibody that specifically binds to EpCAM, or a functional fragment or functional variant thereof, comprises an anti-EpCAM heavy chain and an anti-EpCAM light chain. In some embodiments, the anti-EpCAM heavy chain comprises an anti-EpCAM heavy chain variable domain. In some embodiments, the anti-EpCAM heavy chain variable domain comprises the variable domain of an IgG1, IgG2, IgG3, or IgG4 heavy chain. In some embodiments, the anti-EpCAM light chain comprises an anti-EpCAM light chain variable domain. In some embodiments, the anti-EpCAM light chain variable domain comprises a kappa or lambda light chain. In some embodiments, the EpCAM-binding domain comprises a single-chain variable fragment (scFv). In some embodiments, the EpCAM-binding domain comprises an antigen-binding fragment (Fab).

[0008] In some embodiments of multispecific antibodies comprising a CD47-binding domain and an EpCAM-binding domain, the EpCAM-binding domain comprises a T cell receptor (TCR) constant region. In some embodiments, the TCR constant region of the EpCAM-binding domain comprises a TCRα constant domain and a TCRβ constant domain. In some embodiments, the EpCAM-binding domain comprises a VH-EpCAM domain and a VL-EpCAM domain, wherein the VH-EpCAM domain is fused to a TCRα constant domain and the VL-EpCAM domain is fused to a TCRβ constant domain. In some embodiments, the EpCAM-binding domain comprises a VH-EpCAM domain and a VL-EpCAM domain, wherein the VH-EpCAM domain is fused to a TCRβ constant domain and the VL-EpCAM domain is fused to a TCRα constant domain. In some embodiments, the EpCAM-binding domain comprises a VH-EpCAM domain and a VL-EpCAM domain, wherein the VH-EpCAM domain is fused to a CH1 IgG domain and the VL-EpCAM domain is fused to a CL IgG domain.

[0009] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain, the EpCAM-binding domain comprises three heavy chain (HC) complementarity-determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein HC-CDR1, HC-CDR2, and HC-CDR3 of the EpCAM-binding domain comprise amino acid sequences selected from those set forth in Table 9. In some embodiments, HC-CDR1 of the EpCAM-binding domain comprises an amino acid sequence selected from SEQ ID NOs: 222, 225, 231, 234, 243, and 246. In some embodiments, HC-CDR2 of the EpCAM-binding domain comprises an amino acid sequence selected from SEQ ID NOs: 223, 226, 232, 235, 244, and 247. In some embodiments, HC-CDR3 of the EpCAM-binding domain comprises an amino acid sequence selected from SEQ ID NOs: 224, 227, 233, 236, 245, and 248.

[0010] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain, the EpCAM-binding domain comprises three light chain (LC) complementarity-determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein LC-CDR1, LC-CDR2, and LC-CDR3 of the EpCAM-binding domain comprise an amino acid sequence selected from those set forth in Table 10. In some embodiments, LC-CDR1 of the EpCAM-binding domain comprises an amino acid sequence selected from SEQ ID NOs: 276, 279, 285, 288, 297, and 300. In some embodiments, LC-CDR2 of the EpCAM-binding domain comprises an amino acid sequence selected from SEQ ID NOs: 277, 280, 286, 289, 298, and 301. In some embodiments, LC-CDR3 of the EpCAM-binding domain comprises an amino acid sequence selected from SEQ ID NOs: 278, 281, 287, 290, 299, and 302.

[0011] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain, the EpCAM-binding domain comprises a heavy chain framework region (HFR) comprising an amino acid sequence selected from those set forth in Table 11, wherein the HFR comprises 0 to 3 amino acid modifications. In some embodiments, the EpCAM-binding domain comprises a heavy chain framework region (HFR) comprising an amino acid sequence selected from SEQ ID NOs: 331-334, 335-338, 343-346, 347-350, 355-358, and 359-362, wherein the HFR comprises 0 to 3 amino acid modifications. In some embodiments, the EpCAM-binding domain comprises a heavy chain framework region (HFR) comprising the set of amino acid sequences of SEQ ID NOs: 331-334, wherein at least one set of amino acid sequences comprises 0 to 3 amino acid modifications. In some embodiments, the EpCAM-binding domain comprises a heavy chain framework region (HFR) comprising the set of amino acid sequences of SEQ ID NOs: 335-338, wherein at least one set of amino acid sequences comprises 0 to 3 amino acid modifications. In some embodiments, the EpCAM-binding domain comprises a heavy chain framework region (HFR) comprising the set of amino acid sequences of SEQ ID NOs: 343-346, wherein at least one set of amino acid sequences comprises 0-3 amino acid modifications. In some embodiments, the EpCAM-binding domain comprises a heavy chain framework region (HFR) comprising the set of amino acid sequences of SEQ ID NOs: 347-350, wherein at least one set of amino acid sequences comprises 0-3 amino acid modifications. In some embodiments, the EpCAM-binding domain comprises a heavy chain framework region (HFR) comprising the set of amino acid sequences of SEQ ID NOs: 355-358, wherein at least one set of amino acid sequences comprises 0-3 amino acid modifications. In some embodiments, the EpCAM-binding domain comprises a heavy chain framework region (HFR) comprising the set of amino acid sequences of SEQ ID NOs: 359-362, wherein at least one set of amino acid sequences comprises 0-3 amino acid modifications. In some embodiments, the HFR of the EpCAM-binding domain comprises 0-2 amino acid modifications. In some embodiments, the HFR of the EpCAM-binding domain comprises 0-1 amino acid modification.

[0012] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain, the EpCAM-binding domain comprises a light chain framework region (LFR) comprising an amino acid sequence selected from those set forth in Table 12, wherein the LFR comprises 0 to 3 amino acid modifications. In some embodiments, the EpCAM-binding domain comprises a light chain framework region (LFR) comprising an amino acid sequence selected from SEQ ID NOs: 367-370, 371-374, 379-382, 383-386, 391-394, and 395-398, wherein the LFR comprises 0 to 3 amino acid modifications. In some embodiments, the EpCAM-binding domain comprises a light chain framework region (LFR) comprising the set of amino acid sequences of SEQ ID NOs: 367-370, wherein at least one set of amino acid sequences comprises 0 to 3 amino acid modifications. In some embodiments, the EpCAM-binding domain comprises a light chain framework region (LFR) comprising the set of amino acid sequences of SEQ ID NOs: 371-374, wherein at least one set of amino acid sequences comprises 0 to 3 amino acid modifications. In some embodiments, the EpCAM-binding domain comprises a light chain framework region (LFR) comprising the set of amino acid sequences of SEQ ID NOs: 379-382, wherein at least one set of amino acid sequences comprises 0-3 amino acid modifications. In some embodiments, the EpCAM-binding domain comprises a light chain framework region (LFR) comprising the set of amino acid sequences of SEQ ID NOs: 383-386, wherein at least one set of amino acid sequences comprises 0-3 amino acid modifications. In some embodiments, the EpCAM-binding domain comprises a light chain framework region (LFR) comprising the set of amino acid sequences of SEQ ID NOs: 391-394, wherein at least one set of amino acid sequences comprises 0-3 amino acid modifications. In some embodiments, the EpCAM-binding domain comprises a light chain framework region (LFR) comprising the set of amino acid sequences of SEQ ID NOs: 395-398, wherein at least one set of amino acid sequences comprises 0-3 amino acid modifications. In some embodiments, the LFR of the EpCAM-binding domain comprises 0-2 amino acid modifications. In some embodiments, the LFR of the EpCAM-binding domain comprises 0-1 amino acid modification.

[0013] In some embodiments of multispecific antibodies comprising a CD47-binding domain and an EpCAM-binding domain, the EpCAM-binding domain comprises a heavy chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 13. In some embodiments, the EpCAM-binding domain comprises a light chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 14. In some embodiments, the EpCAM-binding domain comprises a full-length heavy chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 15. In some embodiments, the EpCAM-binding domain comprises a full-length light chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 16. In some embodiments, the EpCAM-binding domain comprises a single-chain variable fragment (scFv) comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 17.

[0014] In some embodiments of multispecific antibodies comprising a CD47 domain and an EpCAM domain, the EpCAM-binding domain comprises a TCR constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 18. In some embodiments, the EpCAM-binding domain comprises a TCR alpha constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 18. In some embodiments, the EpCAM binding domain comprises a TCR β constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 18.

[0015] In some embodiments of multispecific antibodies comprising a CD47-binding domain and an EpCAM-binding domain, the CD47-binding domain is a human or engineered human CD47-binding domain. In some embodiments, the CD47-binding domain comprises an antibody that specifically binds to CD47, or a functional fragment or functional variant thereof. In some embodiments, the antibody that specifically binds to CD47, or a functional fragment or functional variant thereof, comprises an anti-CD47 heavy chain and an anti-CD47 light chain. In some embodiments, the anti-CD47 heavy chain comprises an anti-CD47 heavy chain variable domain. In some embodiments, the anti-CD47 heavy chain variable domain comprises the variable domain of an IgG1, IgG2, IgG3, or IgG4 heavy chain. In some embodiments, the anti-CD47 light chain comprises an anti-CD47 light chain variable domain. In some embodiments, the anti-CD47 light chain variable domain comprises the variable domain of a kappa or lambda light chain. In some embodiments, the anti-CD47 heavy chain variable domain comprises the variable domain of an IgG1 heavy chain and the anti-CD47 light chain variable domain comprises a kappa light chain. In some embodiments, the anti-CD47 heavy chain variable domain comprises the variable domain of an IgG1 heavy chain and the anti-CD47 light chain variable domain comprises a lambda light chain. In some embodiments, the CD47 binding domain comprises a single-chain variable fragment (scFv). In some embodiments, the CD47 binding domain comprises an antigen-binding fragment (Fab).

[0016] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain, the CD47-binding domain comprises a T cell receptor (TCR) constant region. In some embodiments, the TCR constant region of the CD47-binding domain comprises a TCRα constant domain and a TCRβ constant domain. In some embodiments, the CD47-binding domain comprises a VH-CD47 domain and a VL-CD47 domain, wherein the VH-CD47 domain is fused to the TCRα constant domain and the VL-CD47 domain is fused to the TCRβ constant domain. In some embodiments, the CD47-binding domain comprises a VH-CD47 domain and a VL-CD47 domain, wherein the VH-CD47 domain is fused to the TCRβ constant domain and the VL-CD47 domain is fused to the TCRα constant domain. In some embodiments, the CD47 binding domain comprises a VH-CD47 domain and a VL-CD47 domain, wherein the VH-CD47 domain is fused to a CH1 IgG domain and the VL-CD47 domain is fused to a CL IgG domain.

[0017] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain, the CD47-binding domain comprises three heavy chain (HC) complementarity-determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47-binding domain comprise an amino acid sequence selected from those set forth in Table 1, and at least one of the HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 amino acid modifications. In some embodiments, at least one of the HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47-binding domain comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47-binding domain comprises 0 to 1 amino acid modifications.

[0018] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain, the CD47-binding domain comprises three light chain (LC) complementarity-determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47-binding domain comprise an amino acid sequence selected from those set forth in Table 2, and at least one of the LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 amino acid modifications. In some embodiments, at least one of the LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47-binding domain comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47-binding domain comprises 0 to 1 amino acid modifications.

[0019] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain, the CD47-binding domain comprises a heavy chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 3. In some embodiments, the CD47-binding domain comprises a light chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 4. In some embodiments, the CD47 binding domain comprises a full-length heavy chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 5. In some embodiments, the CD47 binding domain comprises a full-length light chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 6. In some embodiments, the CD47 binding domain comprises a single chain variable fragment (scFv) comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 7.

[0020] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain, the CD47-binding domain comprises a TCR constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 8. In some embodiments, the CD47-binding domain comprises a TCR alpha constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 8. In some embodiments, the CD47 binding domain comprises a TCR β constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 8.

[0021] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain, the multispecific antibody further comprises an Fc domain. In some embodiments, the Fc domain is a human Fc domain. In some embodiments, the isotype of the Fc domain is IgG1, IgG2, IgG3, or IgG4. In some embodiments, the Fc domain is a heterodimeric Fc domain, wherein the heterodimeric Fc region comprises a knob chain and a hole chain, forming a knob-into-hole (KiH) structure. In some embodiments, the knob chain comprises an IgG1, IgG2, IgG3, or IgG4 domain. In some embodiments, the knob chain comprises the mutation T366W, and the hole chain comprises the mutations T366S, L368A, and Y407V, where the numbering of amino acid positions is according to the EU index of Kabat et al. In some embodiments, the hole chain comprises an IgG1, IgG2, IgG3, or IgG4 domain. In some embodiments, the multispecific antibody has an asymmetric three-chain knobs-into-holes structure.

[0022] In some embodiments of multispecific antibodies comprising a CD47-binding domain and an EpCAM-binding domain, the multispecific antibody comprises one or more sequences each having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the corresponding sequence set forth in Table 26.

[0023] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain, the multispecific antibody comprises one or more sequences each having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the corresponding sequence set forth in Table 27.

[0024] In some embodiments of multispecific antibodies comprising a CD47-binding domain and an EpCAM-binding domain, the multispecific antibody comprises one or more sequences each having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the corresponding sequence set forth in Table 28.

[0025] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain, the multispecific antibody comprises one or more sequences each having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the corresponding sequence set forth in Table 29.

[0026] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain, the multispecific antibody comprises one or more sequences each having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the corresponding sequence set forth in Table 30.

[0027] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain, the multispecific antibody comprises one or more sequences each having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the corresponding sequence set forth in Table 31.

[0028] In some embodiments of multispecific antibodies comprising a CD47-binding domain and an EpCAM-binding domain, the multispecific antibody comprises one or more sequences each having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the corresponding sequence set forth in Table 32.

[0029] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain, concentrations of less than about 1 nanomolar (nM) or less than about 0.001 nM of the multispecific antibody increase the percentage of HCT-15 cells phagocytosed by macrophages by at least four-fold compared to a nonspecific IgG1 antibody control. In some embodiments, the concentration of antibody required to mediate antibody-dependent cellular phagocytosis of EpCAM-positive, CD47-positive tumor cells by macrophages is between about 0.001 nanomolar (nM) and about 3 nM. In some embodiments, the EpCAM-positive, CD47-positive tumor cells are OVISE cells or HCT15 cells. In some embodiments, the EpCAM-positive CD47-positive tumor cells are selected from ductal pancreatic adenocarcinoma cells, ovarian clear cell adenocarcinoma cells, colon adenocarcinoma cells, lung adenocarcinoma cells, lung squamous cell carcinoma cells, small cell lung carcinoma cells, hepatocellular carcinoma cells, gastric adenocarcinoma cells, cholangiocarcinoma cells, head and neck squamous cell carcinoma cells, prostate cancer cells, endometrial cancer cells, esophageal cancer cells, ovarian adenocarcinoma cells, and vulvar squamous cell carcinoma cells.

[0030] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain, about 100 nanomolar (nM) of the multispecific antibody inhibits SIRPα binding to CD47 on the surface of the cell by at least about 30%. In some embodiments, the cell is a CD47+EpCAM+ tumor cell. In some embodiments, the cell expresses at least the same number of EpCAM proteins on its surface as HCC-44 cells. In some embodiments, the cell expresses at least 50,000, at least 100,000, at least 300,000, at least 600,000, or at least 1,500,000 EpCAM proteins on its surface. In some embodiments, about 1000 nanomolar (nM) of the multispecific antibody does not induce hemolysis of red blood cells in a hemagglutination assay.

[0031] The present disclosure provides a complex comprising a multispecific antibody comprising a CD47 binding domain and an EpCAM binding domain (described herein) and a CD47+EpCAM target cell. In some embodiments, the target cell expresses at least the same number of EpCAM proteins on its surface as HCC-44 cells. In some embodiments, the target cell expresses at least 50,000, at least 100,000, at least 300,000, at least 600,000, or at least 1,500,000 EpCAM proteins on its surface. In some embodiments, the CD47+EpCAM+ target cell is a cancer cell. In some embodiments, the cancer cells are ductal pancreatic adenocarcinoma cells, ovarian clear cell adenocarcinoma cells, ovarian adenocarcinoma cells, colon adenocarcinoma cells, rectal adenocarcinoma cells, esophageal cancer cells, gastric cancer cells, non-small cell lung cancer cells, small cell lung cancer cells, endometrial cancer cells, prostate adenocarcinoma cells, thyroid cancer cells, breast cancer cells, cervical cancer cells, renal cell carcinoma cells, testicular cancer cells, or vulvar squamous cell carcinoma cells.

[0032] The present disclosure provides methods of inducing phagocytosis of CD47+EpCAM+ target cells, the methods comprising administering a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain (described herein). In some embodiments, the multispecific antibody is administered at a concentration of less than about 5 nanomolar (nM), less than about 2 nM, less than about 1 nM, less than about 0.5 nM, less than about 0.2 nM, less than about 0.1 nM, or less than about 0.05 nM.

[0033] The present disclosure provides methods for killing CD47+EpCAM+ target cells, comprising administering a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain (described herein), wherein the multispecific antibody inhibits binding of SIRPα to CD47 on the surface of the CD47+EpCAM+ target cells. In some embodiments, the antibody is administered at a concentration of about 0.01 nanomolar (nM) to about 1 nM, about 0.01 nM to about 0.5 nM, about 0.01 nM to about 0.25 nM, about 0.01 nM to about 0.1 nM, about 0.01 to about 0.05 nM, or less than about 0.01 nM. In some embodiments, the CD47+EpCAM+ target cells are selected from HCT-15 cells, A431 cells, HCC-44 cells, SKOV-3 cells, OVISE cells, or CFPAC-1 cells. In some embodiments, the CD47+EpCAM+ target cell is a ductal pancreatic adenocarcinoma cell, an ovarian clear cell adenocarcinoma cell, an ovarian adenocarcinoma cell, a colon adenocarcinoma cell, a rectal adenocarcinoma cell, an esophageal cancer cell, a gastric cancer cell, a non-small cell lung cancer cell, a small cell lung cancer cell, an endometrial cancer cell, a prostate adenocarcinoma cell, a thyroid cancer cell, a breast cancer cell, a cervical cancer cell, a renal cell carcinoma cell, a testicular cancer cell, or a vulvar squamous cell carcinoma cell.

[0034] The present disclosure provides methods for killing CD47+EpCAM+ target cells, comprising administering a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain (described herein), wherein the multispecific antibody induces antibody-dependent cellular cytotoxicity, killing the CD47+EpCAM+ target cells. In some embodiments, the antibody is administered at a concentration of about 0.01 nanomolar (nM) to about 1 nM, about 0.01 nM to about 0.5 nM, about 0.01 nM to about 0.25 nM, about 0.01 nM to about 0.1 nM, about 0.01 to about 0.05 nM, or less than about 0.01 nM. In some embodiments, the CD47+EpCAM+ target cells are selected from HCT-15 cells, A431 cells, HCC-44 cells, SKOV-3 cells, OVISE cells, or CFPAC-1 cells. In some embodiments, the CD47+EpCAM+ target cell is a ductal pancreatic adenocarcinoma cell, an ovarian clear cell adenocarcinoma cell, an ovarian adenocarcinoma cell, a colon adenocarcinoma cell, a rectal adenocarcinoma cell, an esophageal cancer cell, a gastric cancer cell, a non-small cell lung cancer cell, a small cell lung cancer cell, an endometrial cancer cell, a prostate adenocarcinoma cell, a thyroid cancer cell, a breast cancer cell, a cervical cancer cell, a renal cell carcinoma cell, a testicular cancer cell, or a vulvar squamous cell carcinoma cell.

[0035] The present disclosure provides pharmaceutical compositions comprising a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain (described herein).

[0036] The present disclosure provides a method of treating a subject with cancer, the method comprising administering to the subject a pharmaceutical composition comprising a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain (described herein). In some embodiments, the cancer is ductal pancreatic adenocarcinoma cells, ovarian clear cell adenocarcinoma cells, ovarian adenocarcinoma cells, colon adenocarcinoma cells, lung adenocarcinoma, rectal adenocarcinoma, esophageal cancer, gastric cancer, non-small cell lung cancer, small cell lung cancer, endometrial cancer, prostate cancer, thyroid cancer, breast cancer, cervical cancer, renal cell carcinoma, testicular cancer, or vulvar squamous cell carcinoma.

[0037] The present disclosure provides a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain. In some embodiments, the multispecific antibody is bispecific, trispecific, or tetraspecific. In some embodiments, the multispecific antibody is bispecific. In some embodiments, the multispecific antibody is bivalent, trivalent, or tetravalent. In some embodiments, the multispecific antibody is bivalent.

[0038] In some embodiments, the multispecific antibody has a higher affinity for CD47 expressed on the surface of tumor cells than for CD47 expressed on the surface of normal cells, such as red blood cells, platelets, T cells, B cells, or NK cells. In some embodiments, the tumor cells express EGFR. In some embodiments, the concentration of the multispecific antibody required for half-maximal binding to (e.g., human) red blood cells is greater than about 200 nanomolar (nM).

[0039] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain, the multispecific antibody binds to (e.g., human) CD47 with a dissociation constant (KD) of less than about 100 nanomolar (nM). In some embodiments, the multispecific antibody binds to (e.g., human) CD47 with a dissociation constant (KD) of about 1 nanomolar (nM) to about 100 nM, about 1 nM to about 50 nM, or about 5 nM to about 50 nM. In some embodiments, the multispecific antibody binds to EGFR with a dissociation constant (KD) of less than about 25 nanomolar (nM). In some embodiments, the multispecific antibody binds to EGFR with a dissociation constant (KD) of about 0.2 nanomolar (nM) to about 25 nM, about 0.2 nM to about 10 nM, about 0.2 nM to about 2 nM, or about 2 nM to about 10 nM. In some embodiments, the dissociation constant (KD) is determined by surface plasmon resonance.

[0040] In some embodiments of multispecific antibodies comprising a CD47-binding domain and an EGFR-binding domain, the CD47-binding domain is a human or engineered human CD47-binding domain. In some embodiments, the CD47-binding domain comprises an antibody that specifically binds to CD47, or a functional fragment or functional variant thereof. In some embodiments, the antibody that specifically binds to CD47, or a functional fragment or functional variant thereof, comprises an anti-CD47 heavy chain and an anti-CD47 light chain. In some embodiments, the anti-CD47 heavy chain comprises an anti-CD47 heavy chain variable domain. In some embodiments, the anti-CD47 heavy chain variable domain comprises the variable domain of an IgG1, IgG2, IgG3, or IgG4 heavy chain. In some embodiments, the anti-CD47 light chain comprises an anti-CD47 light chain variable domain. In some embodiments, the anti-CD47 light chain variable domain comprises a kappa or lambda light chain. In some embodiments, the anti-CD47 heavy chain variable domain comprises the variable domain of an IgG1 heavy chain and the anti-CD47 light chain variable domain comprises a kappa light chain. In some embodiments, the anti-CD47 heavy chain variable domain comprises the variable domain of an IgG1 heavy chain and the anti-CD47 light chain variable domain comprises a lambda light chain. In some embodiments, the CD47 binding domain comprises a single-chain variable fragment (scFv). In some embodiments, the CD47 binding domain comprises an antigen-binding fragment (Fab).

[0041] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain, the CD47-binding domain comprises a T cell receptor (TCR) constant region. In some embodiments, the TCR constant region of the CD47-binding domain comprises a TCRα constant domain and a TCRβ constant domain. In some embodiments, the CD47-binding domain comprises a VH-CD47 domain and a VL-CD47 domain, wherein the VH-CD47 domain is fused to the TCRα constant domain and the VL-CD47 domain is fused to the TCRβ constant domain. In some embodiments, the CD47-binding domain comprises a VH-CD47 domain and a VL-CD47 domain, wherein the VH-CD47 domain is fused to the TCRβ constant domain and the VL-CD47 domain is fused to the TCRα constant domain. In some embodiments, the CD47 binding domain comprises a VH-CD47 domain and a VL-CD47 domain, wherein the VH-CD47 domain is fused to a CH1 IgG domain and the VL-CD47 domain is fused to a CL IgG domain.

[0042] In some embodiments of a multispecific antibody comprising a CD47 domain and an EGFR-binding domain, the CD47-binding domain comprises three heavy chain (HC) complementarity-determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47-binding domain comprise an amino acid sequence selected from those set forth in Table 1, and at least one of the HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 amino acid modifications. In some embodiments, at least one of the HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47-binding domain comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47-binding domain comprises 0 to 1 amino acid modifications.

[0043] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain, the CD47-binding domain comprises three light chain (LC) complementarity-determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47-binding domain comprise an amino acid sequence selected from those set forth in Table 2, and at least one of the LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 amino acid modifications. In some embodiments, at least one of the LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47-binding domain comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47-binding domain comprises 0 to 1 amino acid modifications.

[0044] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain, the CD47-binding domain comprises a heavy chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 3. In some embodiments, the CD47-binding domain comprises a light chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 4. In some embodiments, the CD47 binding domain comprises a full-length heavy chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 5. In some embodiments, the CD47 binding domain comprises a full-length light chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 6. In some embodiments, the CD47 binding domain comprises a single chain variable fragment (scFv) comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 7.

[0045] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain, the CD47-binding domain comprises a TCR constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 8. In some embodiments, the CD47-binding domain comprises a TCR alpha constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 8. In some embodiments, the CD47 binding domain comprises a TCR β constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 8.

[0046] In some embodiments of multispecific antibodies comprising a CD47-binding domain and an EGFR-binding domain, the EGFR-binding domain comprises a T cell receptor (TCR) constant region. In some embodiments, the TCR constant region of the EGFR-binding domain comprises a TCRα constant domain and a TCRβ constant domain. In some embodiments, the EGFR-binding domain comprises a VH-EGFR domain and a VL-EGFR domain, wherein the VH-EGFR domain is fused to a TCRα constant domain and the VL-EGFR domain is fused to a TCRβ constant domain. In some embodiments, the EGFR-binding domain comprises a VH-EGFR domain and a VL-EGFR domain, wherein the VH-EGFR domain is fused to a TCRβ constant domain and the VL-EGFR domain is fused to a TCRα constant domain. In some embodiments, the EGFR-binding domain comprises a VH-EGFR domain and a VL-EGFR domain, wherein the VH-EGFR domain is fused to a CH1 IgG domain and the VL-EGFR domain is fused to a CL IgG domain.

[0047] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain, the EGFR-binding domain comprises three heavy chain (HC) complementarity-determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, HC-CDR2, and HC-CDR3 of the EGFR-binding domain comprise an amino acid sequence selected from those set forth in Table 19, and at least one of the HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 amino acid modifications. In some embodiments, at least one of the HC-CDR1, HC-CDR2, and HC-CDR3 of the EGFR-binding domain comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the HC-CDR1, HC-CDR2, and HC-CDR3 of the EGFR-binding domain comprises 0 to 1 amino acid modifications.

[0048] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain, the EGFR-binding domain comprises three light chain (LC) complementarity-determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, LC-CDR2, and LC-CDR3 of the EGFR-binding domain comprise an amino acid sequence selected from those set forth in Table 20, and at least one of the LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 amino acid modifications. In some embodiments, at least one of the LC-CDR1, LC-CDR2, and LC-CDR3 of the EGFR-binding domain comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the LC-CDR1, LC-CDR2, and LC-CDR3 of the EGFR-binding domain comprises 0 to 1 amino acid modifications.

[0049] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain, the EGFR-binding domain comprises a heavy chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 21. In some embodiments, the EGFR-binding domain comprises a light chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 22. In some embodiments, the EGFR-binding domain comprises a full-length heavy chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 23. In some embodiments, the EGFR-binding domain comprises a full-length light chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 24.

[0050] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain, the EGFR-binding domain comprises a heavy chain variable domain and a light chain variable domain. In some embodiments, the EGFR-binding domain comprises a single-chain variable fragment (scFv). In some embodiments, the EGFR-binding domain comprises an antigen-binding fragment (Fab). In some embodiments, the EGFR-binding domain comprises a Fab domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 25.

[0051] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain, the multispecific antibody further comprises an Fc domain. In some embodiments, the Fc domain is a human Fc domain. In some embodiments, the isotype of the Fc domain is IgG1, IgG2, IgG3, or IgG4. In some embodiments, the Fc domain is a heterodimeric Fc domain, wherein the heterodimeric Fc region comprises a knob chain and a hole chain, forming a knob-into-hole (KiH) structure. In some embodiments, the knob chain comprises an IgG1, IgG2, IgG3, or IgG4 domain. In some embodiments, the knob chain comprises the mutation T366W, and the hole chain comprises the mutations T366S, L368A, and Y407V, where the numbering of amino acid positions is according to the EU index of Kabat et al. In some embodiments, the hole chain comprises an IgG1, IgG2, IgG3, or IgG4 domain. In some embodiments, the multispecific antibody has an asymmetric three-chain knobs-into-holes structure.

[0052] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain, the multispecific antibody comprises one or more sequences each having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the corresponding sequence set forth in Table 33.

[0053] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain, the multispecific antibody comprises one or more sequences each having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the corresponding sequence set forth in Table 34.

[0054] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain, the multispecific antibody comprises one or more sequences each having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the corresponding sequence set forth in Table 35.

[0055] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain, concentrations of less than about 1 nanomolar (nM) or less than about 0.01 nM of the multispecific antibody increase the percentage of A431 cells phagocytosed by macrophages by at least four-fold compared to a nonspecific IgG1 antibody control. In some embodiments, the concentration of antibody required to mediate antibody-dependent cellular phagocytosis of EGFR-positive, CD47-positive tumor cells by macrophages is between about 0.01 nanomolar (nM) and about 3 nM. In some embodiments, the EGFR-positive, CD47-positive tumor cells are OVISE cells or A431 cells. In some embodiments, the EGFR-positive, CD47-positive tumor cells are selected from ductal pancreatic adenocarcinoma cells, ovarian clear cell adenocarcinoma cells, colon adenocarcinoma cells, lung adenocarcinoma cells, lung squamous cell carcinoma cells, small cell lung carcinoma cells, hepatocellular carcinoma cells, gastric adenocarcinoma cells, cholangiocarcinoma cells, head and neck squamous cell carcinoma cells, prostate cancer cells, endometrial cancer cells, ovarian adenocarcinoma cells, and vulvar squamous cell carcinoma cells.

[0056] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain, about 100 nanomolar (nM) of the multispecific antibody inhibits SIRPα binding to CD47 on the surface of the cell by at least about 30%. In some embodiments, the cell is a CD47+EGFR+ tumor cell. In some embodiments, the cell expresses at least the same number of EGFR proteins on its surface as HCC-44 cells. In some embodiments, the cell expresses at least 50,000, at least 100,000, at least 300,000, at least 600,000, or at least 1,500,000 EGFR proteins on its surface. In some embodiments, about 400 nanomolar (nM) of the multispecific antibody does not induce hemolysis of red blood cells in a hemagglutination assay.

[0057] The present disclosure provides a complex comprising a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain (described herein) and a CD47+EGFR+ target cell. In some embodiments, the target cell expresses at least the same number of EGFR proteins on its surface as HCC-44 cells. In some embodiments, the target cell expresses at least 50,000, at least 100,000, at least 300,000, at least 600,000, or at least 1,500,000 EGFR proteins on its surface. In some embodiments, the CD47+EGFR+ target cell is a cancer cell. In some embodiments, the cancer cells are epidermoid carcinoma cells, colon adenocarcinoma cells, head and neck squamous cell carcinoma cells, bladder adenocarcinoma cells, pancreatic adenocarcinoma cells, lung squamous cell carcinoma, gastric cancer cells, ductal pancreatic adenocarcinoma cells, ovarian clear cell carcinoma cells, ovarian adenocarcinoma cells, colon adenocarcinoma cells, lung adenocarcinoma, rectal adenocarcinoma, esophageal cancer, gastric cancer, non-small cell lung carcinoma, small cell lung carcinoma, endometrial cancer, prostate adenocarcinoma, thyroid cancer, breast cancer, cervical cancer, renal cell carcinoma, testicular cancer, or vulvar squamous cell carcinoma.

[0058] The present disclosure provides methods of inducing phagocytosis of CD47+EGFR+ target cells, the methods comprising administering a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain (described herein). In some embodiments, the multispecific antibody is administered at a concentration of less than about 5 nanomolar (nM), less than about 2 nM, less than about 1 nM, less than about 0.5 nM, less than about 0.2 nM, less than about 0.1 nM, or less than about 0.05 nM.

[0059] The present disclosure provides methods for killing CD47+EGFR+ target cells, comprising administering a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain (described herein), wherein the multispecific antibody inhibits binding of SIRPα to CD47 on the surface of the CD47+EGFR+ target cells. In some embodiments, the antibody is administered at a concentration of about 0.01 nanomolar (nM) to about 1 nM, about 0.01 nM to about 0.5 nM, about 0.01 nM to about 0.25 nM, about 0.01 nM to about 0.1 nM, about 0.01 nM to about 0.05 nM, or less than about 0.01 nM. In some embodiments, the CD47+EGFR+ target cells are selected from A431 cells, NCI-H747 cells, ASPC-1 cells, EBC-1 cells, or SNU-5 cells. In some embodiments, the CD47+EGFR+ target cells are selected from epidermoid carcinoma cells, colon adenocarcinoma cells, head and neck squamous cell carcinoma cells, bladder carcinoma cells, pancreatic adenocarcinoma cells, lung squamous cell carcinoma cells, lung adenocarcinoma cells, gastric cancer cells, ductal pancreatic adenocarcinoma cells, ovarian clear cell adenocarcinoma cells, ovarian adenocarcinoma cells, colon adenocarcinoma cells, rectal adenocarcinoma cells, esophageal cancer cells, gastric cancer cells, non-small cell lung carcinoma cells, small cell lung carcinoma cells, endometrial cancer cells, prostate adenocarcinoma cells, thyroid cancer cells, breast cancer cells, cervical cancer cells, renal cell carcinoma cells, testicular cancer cells, and vulvar squamous cell carcinoma cells.

[0060] The present disclosure provides methods for killing CD47+EGFR+ target cells, comprising administering a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain (described herein), wherein the multispecific antibody induces antibody-dependent cellular cytotoxicity, killing the CD47+EGFR+ target cells. In some embodiments, the antibody is administered at a concentration of about 0.01 nanomolar (nM) to about 1 nM, about 0.01 nM to about 0.5 nM, about 0.01 nM to about 0.25 nM, about 0.01 nM to about 0.1 nM, about 0.01 nM to about 0.05 nM, or less than about 0.01 nM. In some embodiments, the CD47+EGFR+ target cells are selected from A431 cells, NCI-H747 cells, ASPC-1 cells, EBC-1 cells, or SNU-5 cells. In some embodiments, the CD47+EGFR+ target cells are selected from epidermoid carcinoma cells, colon adenocarcinoma cells, head and neck squamous cell carcinoma cells, bladder carcinoma cells, pancreatic adenocarcinoma cells, lung squamous cell carcinoma cells, lung adenocarcinoma cells, gastric cancer cells, ductal pancreatic adenocarcinoma cells, ovarian clear cell adenocarcinoma cells, ovarian adenocarcinoma cells, colon adenocarcinoma cells, rectal adenocarcinoma cells, esophageal cancer cells, gastric cancer cells, non-small cell lung carcinoma cells, small cell lung carcinoma cells, endometrial cancer cells, prostate adenocarcinoma cells, thyroid cancer cells, breast cancer cells, cervical cancer cells, renal cell carcinoma cells, testicular cancer cells, and vulvar squamous cell carcinoma cells.

[0061] The present disclosure provides pharmaceutical compositions comprising a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain (as described herein).

[0062] The present disclosure provides a method of treating a subject with cancer, the method comprising administering to the subject a pharmaceutical composition comprising a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain (described herein). In some embodiments, the cancer is epidermoid carcinoma, colorectal adenocarcinoma, head and neck squamous cell carcinoma, bladder cancer, pancreatic adenocarcinoma, lung squamous cell carcinoma, lung adenocarcinoma, gastric cancer, ductal pancreatic adenocarcinoma, ovarian clear cell carcinoma, ovarian adenocarcinoma, colon adenocarcinoma, rectal adenocarcinoma, esophageal cancer, gastric cancer, non-small cell lung carcinoma, small cell lung carcinoma, endometrial cancer, prostate adenocarcinoma, thyroid cancer, breast cancer, cervical cancer, renal cell carcinoma, testicular cancer, or vulvar squamous cell carcinoma.

[0063] Incorporation by Reference All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. To the extent that the publications and patents or patent applications incorporated by reference conflict with the disclosure contained herein, the present specification is intended to supersede and / or take precedence over such conflicting material. [Brief explanation of the drawings]

[0064] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings (also referred to herein as "Figures" and "FIG.") [Figure 1A] 1 shows an exemplary three-chain, knob-into-hole, CD47xEpCAM or CD47xEGFR bispecific antibody. [Figure 1B] 1 shows an exemplary four-chain, knob-into-hole, CD47xEpCAM or CD47xEGFR bispecific antibody in a TCR-chimeric antibody format. [Figure 2A] ELISA binding of an exemplary CD47xEpCAM bispecific antibody to human CD47 (FIG. 2A) and human EpCAM recombinant protein (FIG. 2B) is shown. Both arms of the antibody were shown to strongly bind to their respective target antigens. [Figure 2B] ELISA binding of an exemplary CD47xEpCAM bispecific antibody to human CD47 (FIG. 2A) and human EpCAM recombinant protein (FIG. 2B) is shown. Both arms of the antibody were shown to strongly bind to their respective target antigens. [Figure 3A]An exemplary CD47xEpCAM bispecific antibody ("CD47xEpCAM_v5") is shown to have very weak SIRPα blocking activity against CD47+ only Raji tumor cells (Figure 3A), but strong blocking activity against EpCAM+ / CD47+ HCT15 tumor cells (Figure 3B). [Figure 3B] An exemplary CD47xEpCAM bispecific antibody ("CD47xEpCAM_v5") is shown to have very weak SIRPα blocking activity against CD47+ only Raji tumor cells (Figure 3A), but strong blocking activity against EpCAM+ / CD47+ HCT15 tumor cells (Figure 3B). [Figure 4] 1 shows an exemplary CD47xEpCAM bispecific antibody ("CD47xEpCAM_v5") with potent antibody-dependent cellular phagocytosis (ADCP) activity against EpCAM+ / CD47+ tumor cells. [Figure 5] 1 shows an exemplary CD47xEpCAM bispecific antibody ("CD47xEpCAM_v5") with potent antibody-dependent cellular cytotoxicity (ADCC) activity against EpCAM+ / CD47+ tumor cells. [Figure 6A] Figure 6A shows the reduction in red blood cell (RBC) binding of an exemplary CD47xEpCAM bispecific antibody (CD47xEpCAM_v5) compared to binding of a reference antibody "BMK-1" (such as those described herein) as measured by mean fluorescence intensity (MFI) (Figure 6A) and % selective binding (Figure 6B). As shown in Figure 6C, no red blood cell agglutination was observed with "CD47xEpCAM_v5" bispecific antibody treatment. [Figure 6B] Figure 6A shows the reduction in red blood cell (RBC) binding of an exemplary CD47xEpCAM bispecific antibody (CD47xEpCAM_v5) compared to binding of a reference antibody "BMK-1" (such as those described herein) as measured by mean fluorescence intensity (MFI) (Figure 6A) and % selective binding (Figure 6B). As shown in Figure 6C, no red blood cell agglutination was observed with "CD47xEpCAM_v5" bispecific antibody treatment. [Figure 6C]Figure 6A shows the reduction in red blood cell (RBC) binding of an exemplary CD47xEpCAM bispecific antibody (CD47xEpCAM_v5) compared to binding of a reference antibody "BMK-1" (such as those described herein) as measured by mean fluorescence intensity (MFI) (Figure 6A) and % selective binding (Figure 6B). As shown in Figure 6C, no red blood cell agglutination was observed with "CD47xEpCAM_v5" bispecific antibody treatment. [Figure 7] 1 shows reduced T cell binding of an exemplary CD47xEpCAM bispecific antibody ("CD47xEpCAM_v5") compared to the reference "BMK-1" (such as those described herein) and "VIR47.V8." [Figure 8A] Even at lower doses, complete tumor inhibition in the OE-19 model by the exemplary CD47xEpCAM bispecific antibody ("CD47xEpCAM_v5") is shown to be superior to reference antibodies "BMK-1" and "BMK-2" (such as those described herein). [Figure 8B] We show that the "CD47xEpCAM_v5" bispecific antibody induced complete tumor regression in the KATO III model and demonstrated superior efficacy to reference antibodies: monospecific EpCAM mAb (mAb002-11), CD47 mAb ("VIR47.V8"), "BMK-1" and "BMK-2" (such as those described herein). All mice in the bispecific antibody group were tumor-free, even 10 days after the last dose. [Figure 9A] 9A and 9B show ELISA binding of the exemplary CD47xEGFR bispecific antibody "panitumumabxVIR47.V8" on human EGFR (FIG. 9A) and human CD47 (FIG. 9B) recombinant proteins. [Figure 9B] 9A and 9B show ELISA binding of the exemplary CD47xEGFR bispecific antibody "panitumumabxVIR47.V8" on human EGFR (FIG. 9A) and human CD47 (FIG. 9B) recombinant proteins. [Figure 10A]10A-10C show the antitumor activity of CD47xEpCAM_v5 bispecific antibody as a single agent and in combination with oxaliplatin (FIG. 10A), 5-fluorouracil (5-FU, FIG. 10B), or irinotecan (FIG. 10C) in the colon cancer xenograft model DLD-1. [Figure 10B] 10A-10C show the antitumor activity of CD47xEpCAM_v5 bispecific antibody as a single agent and in combination with oxaliplatin (FIG. 10A), 5-fluorouracil (5-FU, FIG. 10B), or irinotecan (FIG. 10C) in the colon cancer xenograft model DLD-1. [Figure 10C] 10A and 10B show the antitumor activity of the CD47xEpCAM_v5 bispecific antibody as a single agent and in combination with oxaliplatin (FIG. 10A), 5-fluorouracil (5-FU, FIG. 10B), or irinotecan (FIG. 10C) in the colon cancer xenograft model DLD-1. [Figure 11A] We show the antitumor activity of irinotecan in combination with a benchmark CD47 antibody (BMK-1), an anti-CD47 bivalent antibody (VIR47.V8), and two CD47xEpCAM bispecific antibodies CD47xEpCAM_v5 and CD47xEpCAM_v6 in the colorectal cancer xenograft model DLD-1. [Figure 11B] We show the antitumor activity of irinotecan in combination with a benchmark CD47 antibody (BMK-1), an anti-CD47 bivalent antibody (VIR47.V8), and two CD47xEpCAM bispecific antibodies CD47xEpCAM_v5 and CD47xEpCAM_v6 in the colorectal cancer xenograft model DLD-1. [Figure 12] 1 shows the antitumor activity of irinotecan and the CD47xEpCAM bispecific antibody CD47xEpCAM_v5 as single agents or in combination in the hepatocellular carcinoma xenograft model Hep3B2.1-7. [Figure 13A]ELISA binding of CD47xEpCAM bispecific antibodies v9, v10, v11 on human EpCAM (FIG. 13A) and human CD47 recombinant protein (FIG. 13B) is shown. Both arms of the antibodies were shown to bind strongly to their respective target antigens. [Figure 13B] ELISA binding of CD47xEpCAM bispecific antibodies v9, v10, v11 on human EpCAM (FIG. 13A) and human CD47 recombinant protein (FIG. 13B) is shown. Both arms of the antibodies were shown to bind strongly to their respective target antigens. DETAILED DESCRIPTION OF THE INVENTION

[0065] While various embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Many modifications, changes, and substitutions may occur to those skilled in the art without departing from the invention. It is understood that various alternatives to the embodiments of the invention described herein may be utilized.

[0066] Cluster of differentiation 47 (CD47), also known as integrin-associated protein (IAP), is a 50 kDa immunoglobulin superfamily membrane glycoprotein that is overexpressed in many hematological cancers and solid tumors. High CD47 expression often correlates with more aggressive disease and poorer clinical outcomes.

[0067] CD47 on the surface of CD47+ cells interacts with signal regulatory protein alpha (SIRPα), which is expressed on cells of the innate and adaptive immune systems, such as macrophages and dendritic cells. This interaction sends a "don't eat me" signal that inhibits phagocytosis, thereby allowing CD47+ cells to evade immune surveillance.

[0068] These data suggest that CD47 may serve as an immune checkpoint and that blocking the CD47-SIRPα interaction may have therapeutic value by switching off the "don't eat me" signal. Thus, blocking CD47 has emerged as a promising therapeutic strategy, with numerous studies demonstrating that interrupting the CD47-SIRPα signaling pathway promotes antitumor activity against human cancers in vitro and in vivo.

[0069] Several anti-CD47 monoclonal antibodies (mAbs) have been shown to increase phagocytosis of acute myeloid leukemia cells, non-Hodgkin's lymphoma cells, breast cancer cells, and ovarian cancer cells. In clinical trials, CD47 mAbs enhanced the antitumor activity of other therapeutic antibodies. At least six anti-CD47 mAbs and three SIRPα fusion proteins are currently in phase I or II clinical trials for the treatment of human hematological malignancies and solid tumors.

[0070] The effectiveness of anti-CD47 mAbs is limited by their interaction with red blood cells (RBCs), which also express CD47. RBCs act as a sink that sequesters anti-CD47 antibodies, thereby preventing them from binding to malignant CD47-expressing (CD47+) cells. Furthermore, anti-CD47 mAb binding to RBCs leads to hemagglutination and RBC lysis, resulting in anemia. Therefore, improved methods for treating malignant diseases mediated by CD47+ cells while reducing off-tumor effects are needed.

[0071] Epithelial cell adhesion molecule (EpCAM), also known as CD236, is a type I transmembrane glycoprotein of approximately 35 kDa that functions as a homophilic, Ca2+-independent intercellular adhesion molecule. EpCAM is also involved in cell signaling, proliferation, differentiation, and the formation and maintenance of organ morphology. Its overexpression is observed in many metastatic epithelial cancers, including breast, prostate, ovarian, lung, colon, kidney, and gastric cancers, highlighting its potential as an ideal target for immunotherapy (Spizzo et al., Breast Cancer Res Treat 86:207-213).

[0072] The epidermal growth factor receptor (EGFR), also known as ErbB-1 or HER1, is a transmembrane protein that is the receptor for members of the epidermal growth factor family of extracellular protein ligands. EGFR is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR, Her2 / neu, Her3, and Her4. Overexpression of EGFR is associated with many cancers, including adenocarcinoma of the lung, colorectal cancer, glioblastoma, and epithelial tumors of the head and neck.

[0073] In some embodiments, disclosed herein are anti-CD47 antibodies, anti-EpCAM antibodies, and multispecific antibodies that comprise a targeting moiety for CD47 and a targeting moiety for EpCAM, or a combination thereof. Also described herein in some embodiments are multispecific (e.g., bispecific) antibodies that comprise a first targeting moiety for CD47 and a second targeting moiety for EpCAM. In further embodiments, further described herein are methods of treating cancer using anti-CD47 antibodies, anti-EpCAM antibodies, and multispecific antibodies (e.g., bispecific CD47 / EpCAM antibodies).

[0074] In some embodiments, disclosed herein are anti-CD47 antibodies, anti-EGFR antibodies, and multispecific antibodies that comprise a targeting moiety for CD47 and a targeting moiety for EGFR, or a combination thereof. Also described herein in some embodiments are multispecific (e.g., bispecific) antibodies that comprise a first targeting moiety for CD47 and a second targeting moiety for EGFR. In further embodiments, further described herein are methods of treating cancer using anti-CD47 antibodies, anti-EGFR antibodies, and multispecific antibodies (e.g., bispecific CD47 / EGFR antibodies).

[0075] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter belongs. It is understood that the foregoing general description and the following detailed description are exemplary and explanatory only and are not limiting of any subject matter. The paragraph headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. In this application, the use of the singular includes the plural unless expressly stated otherwise. It should be noted that in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise. In this application, the use of "or" means "and / or" unless expressly stated otherwise. Furthermore, the use of the word "including," as well as other forms such as "include," "includes," and "included," is non-limiting.

[0076] As used herein, ranges and amounts can be expressed as "about" a particular value or range. "About" includes the exact amount. Thus, "about 5 μL" also means "about 5 μL" and "5 μL." In general, the term "about" includes amounts that would be expected within experimental error. Unless otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and the like used in the specification and claims should be understood as being modified in all instances by the term "about." Thus, unless indicated to the contrary, the numerical parameters set forth in the specification and appended claims are approximations that may vary depending on the desired properties sought to be obtained by the present application. In general, when used herein to refer to a measurable value, such as an amount of weight, time, dose, or the like, the term "about" is intended to encompass variations from the specified amount, in one example, ±20% or ±10%, in another example, ±5%, in another example, ±1%, and in yet another example, ±0.1%, and therefore variations are appropriate for practicing the disclosed methods.

[0077] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0078] "Antibodies" and "immunoglobulins" (Igs) are glycoproteins with the same structural characteristics. The terms are used interchangeably. In some instances, the antigen specificity of an immunoglobulin is known.

[0079] The term "antibody" is used in the broadest sense and includes fully assembled antibodies, antibody fragments capable of binding antigen (e.g., Fab, F(ab'), Fv, single-chain antibodies, diabodies, antibody chimeras, hybrid antibodies, bispecific antibodies, etc.), and recombinant peptides containing the foregoing.

[0080] As used herein, the terms "monoclonal antibody" and "mAb" refer to an antibody obtained from a substantially homogeneous population of antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts.

[0081] "Native antibodies" and "native immunoglobulins" are typically heterotetrameric glycoproteins of approximately 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide bonds varies among the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has a variable domain (VH) at one end followed by a number of constant domains. Each light chain has a variable domain (VL) at one end and a constant domain at the other end, with the light chain constant domain aligned with the first constant domain of the heavy chain and the light chain variable domain aligned with the heavy chain variable domain. Particular amino acid residues are believed to form an interface between the light and heavy chain variable domains.

[0082] As used herein, the term "variable" refers to the fact that certain portions of the variable domains differ significantly in sequence among antibodies. The variable regions confer antigen-binding specificity. However, variability is not uniformly distributed throughout the variable domains of antibodies. The variability is concentrated in three segments called complementarity-determining regions (CDRs) or hypervariable regions, both in the light- and heavy-chain variable domains. The more highly conserved portions of the variable domains are called framework (FR) regions. Natural heavy- and light-chain variable domains each contain four FR regions, most of which adopt a β-pleated sheet configuration, connected by three CDRs that form loops connecting, and in some cases, forming part of, the β-pleated sheet configuration. The CDRs in each chain are held together in close proximity by the FR regions and, together with the CDRs of the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al. (1991) NIH PubL. No. 91-3242, Vol. I, pages 647-669). The constant domains are not directly involved in binding an antibody to an antigen, but exhibit various effector functions, such as Fc receptor (FcR) binding, participation of the antibody in antibody-dependent cellular cytotoxicity, induction of complement-dependent cytotoxicity, and mast cell degranulation.

[0083] As used herein, the term "hypervariable region" refers to the amino acid residues of an antibody which are responsible for antigen-binding. The hypervariable region comprises amino acid residues from the "complementarity determining regions" or "CDRs" (i.e., residues 24-34 (L1), 50-56 (L2), and 89-97 (L3) in the light chain variable domain and 31-35 (H1), 50-65 (H2), and 95-102 (H3) in the heavy chain variable domain; Kabat et al. (1991) Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md.) and / or from the "hypervariable loops" (i.e., residues 26-32 (L1), 50-52 (L2), and 91-96 (L3) in the light chain variable domain and (H1), 53-55 (H2), and 96-101 (H3) in the heavy chain variable domain; Clothia and Lesk, (1987) J. Mol. Biol., 196:901-917). "Framework" or "FR" residues are those variable domain residues other than the hypervariable region residues as considered herein.

[0084] An "antibody fragment" comprises a portion of an intact antibody, preferably the antigen-binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab, F(ab')2, and Fv fragments, diabodies, linear antibodies (Zapata et al. (1995) Protein Eng. 10:1057-1062), single-chain antibody molecules, and multispecific antibodies formed from antibody fragments. Papain digestion of an antibody produces two identical antigen-binding fragments called "Fab" fragments, each with a single antigen-binding site, and an "Fc" fragment, the name of which reflects its ability to readily crystallize. Pepsin treatment produces an F(ab')2 fragment that has two antigen-binding sites and is still capable of cross-linking antigen.

[0085] An "Fv" is the minimum antibody fragment that contains a complete antigen-recognition and binding site. This region consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs from each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv containing only three CDRs specific for an antigen) has the ability to recognize and bind antigen, albeit with lower affinity than the entire binding site.

[0086] Fab fragments also contain the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab fragments differ from Fab' fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain, including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine ​​residues of the constant domains bear a free thiol group. Fab' fragments are generated by reduction of the heavy chain disulfide bridges of the F(ab')2 fragment. Other chemical couplings of antibody fragments are also known.

[0087] The "light chains" of antibodies (immunoglobulins) of any vertebrate species can be assigned to one of two clearly distinct types, called kappa (κ) and lambda (λ), based on the amino acid sequences of their constant domains.

[0088] Depending on the amino acid sequence of the constant domain of the heavy chain, immunoglobulins can be assigned to different classes. There are five major classes of human immunoglobulins: IgA, IgD, IgE, IgG, IgM, and IgY. Some of these may be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains corresponding to different classes of immunoglobulins are called alpha, delta, epsilon, gamma, and mu, respectively. The subunit structures and three-dimensional configurations of various classes of immunoglobulins are well known. Different isotypes have different effector functions. For example, human IgG1 and IgG3 isotypes have ADCC (antibody-dependent cell-mediated cytotoxicity) activity.

[0089] The CDR sequences of the antibodies disclosed herein, or the anti-CD47 or anti-ICAM1 binding domain sequences disclosed herein, may be numbered according to (i) the Kabat numbering system (Kabat et al. (1977) Ann. NY Acad. Sci. 190:382-391 and, Kabat et al. (1991) Sequences of Proteins of Immunological Interest Fifth Edition, USDapartment of Health and Human Services, NIH Publication No. 91-3242), or (ii) the Chothia numbering scheme, also referred to herein as "Chothia CRD" (e.g., Chothia and Lesk, 1987, J. Mol. Biol., 196:901-917; Al-Lazikani et al., 1997, J. Mol. Biol., 273:927-948; Chothia et al., 1997, J. Mol. Biol., 273:927-948). al., 1992, J. Mol. Biol., 227:799-817; Tramontano A et al., 1990, J. Mol. Biol. 215(1):175-82; and US Patent No. 7,709,226); or (iii) the ImMunoGeneTics (IMGT) numbering system ("IMGT CDRs"), as described, for example, in Lefranc, M.-P., 1999, The Immunologist, 7:132-136, and Lefranc, M.-P. et al., 1999, Nucleic Acids Res., 27:209-212; or (iv) may be defined or determined according to MacCallum et al., 1996, J. Mol. Biol., 262:732-745. See further, for example, Martin, A., "Protein Sequence and Structure Analysis of Antibody Variable Domains," in Antibody Engineering, Kontermann and Diibel, eds., Chapter 31, pp. 422-439, Springer-Verlag, Berlin (2001).

[0090] With respect to the Kabat numbering system, the CDRs in an antibody heavy chain molecule are typically located at amino acid positions 31-35 (CDR1), 50-65 (CDR2), and 95-102 (CDR3), which may optionally include one or two additional amino acids after 35 (referred to as 35A and 35B in the Kabat numbering scheme). Using the Kabat numbering system, the CDRs in an antibody light chain molecule are typically located at amino acid positions 24-34 (CDR1), 50-56 (CDR2), and 89-97 (CDR3). As is well known to those skilled in the art, using the Kabat numbering system, the actual linear amino acid sequence of an antibody variable domain may contain fewer or additional amino acids due to shortening or elongation of FRs and / or CDRs, and therefore the Kabat number of an amino acid is not necessarily the same as its linear amino acid number.

[0091] The term "chimeric" antibody refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.

[0092] The term "human antibody" or "humanized antibody" as used herein is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. Human antibodies are well known in the art (van Dijk, MA, and van de Winkel, JG, Curr. Opin. Chem. Biol. 5 (2001) 368-374). In some examples, human antibodies are also produced in transgenic animals (e.g., mice) that, upon immunization, can produce a full repertoire or selection of human antibodies in the absence of endogenous immunoglobulin production. Transfer of the human germline immunoglobulin gene array in such germline mutant mice results in the production of human antibodies upon antigen challenge (see, e.g., Jakobovits, A. et al., Proc. Natl. Acad. Sci. USA 90 (1993) 2551-2555; Jakobovits, A., et al., Nature 362 (1993) 255-258; , et al., Year Immunol. 7 (1993) 33-40). In a further example, human antibodies are also produced in phage display libraries (Hoogenboom, H.R., and Winter, G., J. Mol. Biol. 227 (1992) 381-388; , et al., J. Mol. Biol. 222 (1991) 581-597). The techniques of Cole et al. and Boerner et al. can also be used to prepare human monoclonal antibodies (Cole, et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985); and Boerner, P., et al., J. Immunol. 147 (1991) 86-95).

[0093] The term "recombinant human antibody" as used herein is intended to include all human antibodies prepared, expressed, generated, or isolated by recombinant means, such as antibodies isolated from host cells such as NSO or CHO cells, or from animals (e.g., mice) transgenic for human immunoglobulin genes, or antibodies expressed using a recombinant expression vector transfected into a host cell. Such recombinant human antibodies have rearranged variable and constant regions. In some cases, the recombinant human antibody has been subjected to in vivo somatic hypermutation. Thus, the amino acid sequences of the VH and VL regions of the recombinant antibody are derived from and related to human germline VH and VL sequences, but are sequences that may not naturally occur within the human antibody germline repertoire in vivo.

[0094] The term "valent" as used herein refers to the presence of a specific number of binding sites in an antigen-binding molecule. Thus, the terms "bivalent," "tetravalent," and "hexavalent" refer to the presence of two binding sites, four binding sites, and six binding sites, respectively, in an antigen-binding molecule. Bispecific antibodies according to the present invention are at least "bivalent" and may be "trivalent" or "multivalent" (e.g., "tetravalent" or "hexavalent"). In certain embodiments, antibodies of the present invention have two or more binding sites and are bispecific. That is, antibodies can be bispecific even when there are more than two binding sites (i.e., the antibody is trivalent or multivalent). In particular, the present invention relates to bispecific, bivalent antibodies that have one binding site for each antigen to which they specifically bind.

[0095] The term "bispecific" means that an antibody can specifically bind to two different antigenic determinants, for example, two binding sites formed by a pair of antibody heavy chain variable domains (VH) and antibody light chain variable domains (VL) that bind to different antigens. Such bispecific antibodies are in a 1+1 format. Other bispecific antibody formats are the 2+1 format (comprising two binding sites for a first antigen or epitope and one binding site for a second antigen or epitope) or the 2+2 format (comprising two binding sites for a first antigen or epitope and two binding sites for a second antigen or epitope). Typically, a bispecific antibody contains two antigen-binding sites, each specific for a different antigenic determinant. The term "multispecific" means that an antibody can specifically bind to at least two binding sites formed by a pair of antibody heavy chain variable domains (VH) and antibody light chain variable domains (VL) that bind to two or more different antigenic determinants, for example, different antigens.

[0096] The terms "individual," "subject," and "patient" are used interchangeably herein and refer to any mammal. In some embodiments, the mammal is a human. In some embodiments, the mammal is a non-human. None of the terms require or are limited to situations characterized by the supervision (e.g., full-time or intermittent) of a health care professional (e.g., a physician, registered nurse, bedside nurse, physician assistant, nursing assistant, or hospice worker).

[0097] As used herein, the term "percent (%) amino acid sequence identity" for a sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in a specific sequence, after aligning the sequences and introducing gaps as necessary to achieve the maximum percent sequence identity, and without considering any conservative substitutions as part of the sequence identity. Alignment for the purpose of determining percent amino acid sequence identity can be achieved in a variety of ways within the art, for example, using publicly available computer software such as EMBOSS MATCHER, EMBOSS WATER, EMBOSS STRETCHER, EMBOSS NEEDLE, EMBOSS LALIGN, BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms required to achieve maximum alignment across the full length of the sequences being compared.

[0098] In situations where ALIGN-2 is used for amino acid sequence comparison, the % amino acid sequence identity of a given amino acid sequence A to a given amino acid sequence B (which may alternatively be expressed as a given amino acid sequence A having or containing a particular % amino acid sequence identity to a given amino acid sequence B) is calculated as follows: 100 × fraction X / Y, where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It should be understood that if the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not be equal to the % amino acid sequence identity of B to A. Unless otherwise specified, all % amino acid sequence identity values ​​used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.

[0099] The terms "cancer" and "tumor" are used interchangeably herein and include all types of oncogenic processes and / or cancerous growths. In embodiments, cancer includes primary tumors and metastatic tissues or malignantly transformed cells, tissues, or organs. In embodiments, cancer includes all histopathological diagnoses and stages of cancer, e.g., stages of invasiveness / severity. In embodiments, cancer includes recurrent and / or resistant cancers.

[0100] As used herein, "treatment" (and grammatical variations thereof, such as "treat" or "treating") refers to clinical intervention in an attempt to alter the natural course of the treated individual and can be performed prophylactically or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, prevention of disease onset or recurrence, alleviation of symptoms, reduction of any direct or indirect pathological consequences of the disease, prevention of metastasis, reduction in the rate of disease progression, improvement or palliation of the disease state, and remission or improved prognosis. In some embodiments, the molecules of the invention are used to delay the onset of disease or to slow the progression of the disease.

[0101] As used herein, the terms "antibody-dependent cellular cytotoxicity" and "ADCC" refer to a cell-mediated reaction in which nonspecific cytotoxic cells (e.g., natural killer (NK) cells, neutrophils, and macrophages) recognize bound antibodies on target cells and subsequently cause lysis of the target cells.

[0102] Anti-CD47 binding domain In certain embodiments, anti-CD47 binding domains are disclosed herein. In some embodiments, the CD47 binding domain is a human or engineered human CD47 binding domain. In some embodiments, the CD47 binding domain comprises an antibody that specifically binds to CD47, or a functional fragment or functional variant thereof. In some embodiments, the antibody that specifically binds to CD47, or a functional fragment or functional variant thereof, comprises an anti-CD47 heavy chain and an anti-CD47 light chain. In some embodiments, the anti-CD47 heavy chain comprises an anti-CD47 heavy chain variable domain. In some embodiments, the anti-CD47 heavy chain variable domain comprises the variable domain of an IgG1, IgG2, IgG3, or IgG4 heavy chain. In some embodiments, the anti-CD47 light chain comprises an anti-CD47 light chain variable domain. In some embodiments, the anti-CD47 light chain variable domain comprises a kappa or lambda light chain. In some embodiments, the anti-CD47 heavy chain variable domain comprises the variable domain of an IgG1 heavy chain and the anti-CD47 light chain variable domain comprises a kappa light chain. In some embodiments, the anti-CD47 heavy chain variable domain comprises the variable domain of an IgG1 heavy chain and the anti-CD47 light chain variable domain comprises a lambda light chain. In some embodiments, the CD47 binding domain comprises a single-chain variable fragment (scFv). In some embodiments, the CD47 binding domain comprises an antigen-binding fragment (Fab).

[0103] In some embodiments, the CD47 binding domain comprises three heavy chain (HC) complementarity determining regions (CDRs), HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise an amino acid sequence selected from those set forth in Table 1, and at least one of the HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 amino acid modifications. In some embodiments, at least one of the HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprises 0 to 1 amino acid modifications.

[0104] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 1-3, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0105] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 4-6, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0106] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 7-9, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0107] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 10-12, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0108] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 13-15, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0109] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 16-18, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0110] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 19-21, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0111] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 22-24, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0112] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 25-27, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0113] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 28-30, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0114] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 31-33, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0115] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 34-36, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0116] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 37-39, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0117] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 40-42, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0118] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 43-45, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0119] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 46-48, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0120] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 49-51, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0121] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 52-54, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0122] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 55-57, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0123] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 58-60, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0124] [Table 1]

[0125] In some embodiments, the CD47-binding domain comprises three light chain (LC) complementarity-determining regions (CDRs), LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47-binding domain comprise an amino acid sequence selected from those set forth in Table 2, and at least one of the LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 amino acid modifications. In some embodiments, at least one of the LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47-binding domain comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47-binding domain comprises 0 to 1 amino acid modifications.

[0126] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 61-63, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0127] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 64-66, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0128] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 67-69, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0129] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 70-72, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0130] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 73-75, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0131] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 76-78, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0132] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 79-81, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0133] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 82-84, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0134] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 85-87, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0135] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 88-90, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0136] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 91-93, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0137] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 94-96, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0138] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 97-99, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0139] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 100-102, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0140] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 103-105, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0141] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 106-108, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0142] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 109-111, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0143] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 112-114, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0144] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 115-117, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0145] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 118-120, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0146] [Table 2]

[0147] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47-binding domain comprise the amino acid sequences of SEQ ID NOs: 1-3, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47-binding domain comprise the amino acid sequences of SEQ ID NOs: 61-63, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0148] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 4 to 6, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 64 to 66, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0149] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47-binding domain comprise the amino acid sequences of SEQ ID NOs: 7-9, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47-binding domain comprise the amino acid sequences of SEQ ID NOs: 67-69, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0150] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 10-12, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 70-72, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0151] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 13-15, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 73-75, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0152] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 16-18, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 76-78, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0153] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 19-21, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 79-81, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0154] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47-binding domain comprise the amino acid sequences of SEQ ID NOs: 22-24, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47-binding domain comprise the amino acid sequences of SEQ ID NOs: 82-84, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0155] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47-binding domain comprise the amino acid sequences of SEQ ID NOs: 25-27, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47-binding domain comprise the amino acid sequences of SEQ ID NOs: 85-87, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0156] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47-binding domain comprise the amino acid sequences of SEQ ID NOs: 28-30, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47-binding domain comprise the amino acid sequences of SEQ ID NOs: 88-90, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0157] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47-binding domain comprise the amino acid sequences of SEQ ID NOs: 31-33, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47-binding domain comprise the amino acid sequences of SEQ ID NOs: 91-93, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0158] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 34-36, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 94-96, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0159] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 37-39, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 97-99, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0160] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47-binding domain comprise the amino acid sequences of SEQ ID NOs: 40-42, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47-binding domain comprise the amino acid sequences of SEQ ID NOs: 100-102, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0161] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 43-45, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 103-105, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0162] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 46-48, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 106-108, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0163] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 49-51, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 109-111, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0164] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 52-54, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 112-114, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0165] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 55-57, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 115-117, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0166] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 58-60, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 118-120, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0167] In some embodiments, the CD47 binding domain comprises a heavy chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 3.

[0168] In some embodiments, the CD47 binding domain comprises a heavy chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence selected from SEQ ID NOs: 121-143.

[0169] In some embodiments, the CD47 binding domain comprises a light chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 4.

[0170] In some embodiments, the CD47 binding domain comprises a light chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence selected from SEQ ID NOs: 144-164.

[0171] In some embodiments, the CD47 binding domain comprises a heavy chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 3; and a light chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 4.

[0172] In some embodiments, the CD47 binding domain comprises a heavy chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence selected from SEQ ID NOs: 121-143, and a light chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence selected from SEQ ID NOs: 144-164.

[0173] In some embodiments, the CD47 binding domain comprises a full-length heavy chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 5.

[0174] In some embodiments, the CD47 binding domain comprises a full-length heavy chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence selected from SEQ ID NOs: 165-188.

[0175] In some embodiments, the CD47 binding domain comprises a full-length light chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 6.

[0176] In some embodiments, the CD47 binding domain comprises a full-length light chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence selected from SEQ ID NOs: 189-212.

[0177] In some embodiments, the CD47 binding domain comprises a full-length heavy chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 5, and a full-length light chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 6.

[0178] In some embodiments, the CD47 binding domain comprises a full-length heavy chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence selected from SEQ ID NOs: 165-188, and a full-length light chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence selected from SEQ ID NOs: 189-212.

[0179] In some embodiments, the CD47 binding domain comprises a single chain variable fragment (scFv) comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 7.

[0180] In some embodiments, the CD47 binding domain comprises a single chain variable fragment (scFv) comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:213.

[0181] [Table 3-1]

[0182] [Table 3-2]

[0183] [Table 4-1]

[0184] [Table 4-2]

[0185] [Table 5-1]

[0186] [Table 5-2]

[0187] [Table 5-3]

[0188] [Table 5-4]

[0189] [Table 6-1]

[0190] [Table 6-2]

[0191] [Table 6-3]

[0192] [Table 7]

[0193] [Table 8]

[0194] In some embodiments of the anti-CD47 binding domains described herein, the heavy chain variable fragment (VH) of the anti-CD47 binding domain is fused to a first T cell receptor (TCR) constant region, and the light chain variable domain (VL) of the anti-CD47 binding domain is fused to a second TCR constant region, wherein the first and second TCR constant regions can form a dimer. In some embodiments, the TCR constant regions are TCR alpha and TCR beta constant regions. In some embodiments, the VH-TCR fusion polypeptide is fused to a human IgG (e.g., IgG1) Fc domain. See WO2019 / 057122.

[0195] In some embodiments, the anti-CD47 binding domain described herein comprises a T cell receptor (TCR) constant region. In some embodiments, the TCR constant region comprises a TCR alpha constant domain and a TCR beta constant domain. In some embodiments, the anti-CD47 binding domain comprises a VH-CD47 domain and a VL-CD47 domain, wherein the VH-CD47 domain is fused to a TCR beta constant domain and the VL-CD47 domain is fused to a TCR alpha constant domain. In some embodiments, the anti-CD47 binding domain comprises a VH-CD47 domain and a VL-CD47 domain, wherein the VH-CD47 domain is fused to the first constant domain of a heavy chain (CH1) IgG domain and the VL-CD47 domain is fused to the constant domain of a light chain (CL) IgG domain.

[0196] In some embodiments, the anti-CD47 binding domain described herein comprises a T cell receptor (TCR) constant region. In some embodiments, the TCR constant region comprises a TCR alpha constant domain and a TCR beta constant domain. In some embodiments, the anti-CD47 binding domain described herein comprises a VH-CD47 domain and a VL-CD47 domain, wherein the VH-CD47 domain is fused to the TCR alpha constant domain and the VL-CD47 domain is fused to the TCR beta constant domain. In some embodiments, the anti-CD47 binding domain comprises a VH-CD47 domain and a VL-CD47 domain, wherein the VH-CD47 domain is fused to the first constant domain of the heavy chain (CH1) IgG domain and the VL-CD47 domain is fused to the constant domain of the light chain (CL) IgG domain.

[0197] In some embodiments, the CD47 binding domain comprises a TCR constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 8. In some embodiments, the CD47 binding domain comprises a TCR constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence selected from SEQ ID NOs: 214-218. In some embodiments, the CD47 binding domain comprises a TCR alpha constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 8. In some embodiments, the CD47 binding domain comprises a TCR alpha constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:214. In some embodiments, the CD47 binding domain comprises a TCR β constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 8. In some embodiments, the CD47 binding domain comprises a TCR β constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:215.

[0198] In some embodiments, the CD47 binding domain comprises a TCR alpha constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 8, and a TCR beta constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 8.

[0199] In some embodiments, the CD47 binding domain comprises a TCR alpha constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 214, and a TCR beta constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 215.

[0200] In some embodiments, the CD47 binding domain comprises a TCR constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 216.

[0201] In some embodiments, the CD47 binding domain comprises a TCR constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 217.

[0202] In some embodiments, the CD47 binding domain comprises a TCR constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 218.

[0203] In some embodiments, the CD47 binding domain comprises a TCR constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:217, and a TCR constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:218.

[0204] In some embodiments, the anti-CD47 binding domain comprises a full-length antibody. In other embodiments, the anti-CD47 binding domain comprises a binding fragment. In some examples, the anti-CD47 binding domain comprises an antibody or binding fragment thereof, a monoclonal antibody or binding fragment thereof, a chimeric antibody or binding fragment thereof, a humanized antibody or binding fragment thereof, or an engineered antibody or binding fragment thereof. In some cases, the anti-CD47 binding domain comprises a monovalent Fab, a bivalent Fab'2, a single-chain variable fragment (scFv), or a binding fragment thereof.

[0205] In some embodiments, the anti-CD47 binding domains described herein have an EC 50 In some embodiments, the anti-CD47 binding domains described herein have an EC 50In some embodiments, the anti-CD47 binding domains described herein have an EC 50 In some embodiments, the anti-CD47 binding domains described herein are used in a phagocytosis assay or in vivo assay to determine ADCP activity, for example, using macrophages and targeting cancer cells, such as metastatic cancer cells from colon cancer, e.g., HCT-15 cells, or metastatic cancer cells from the esophagus, e.g., KYSE-150 cells. In vitro phagocytosis assay, about 0.02nM to about 0.16nM, about 0.02nM to about 0.21nM, about 0.02nM to about 1.03nM , about 0.02nM to about 1.2nM, about 0.02nM to about 2.27nM, about 0.16nM to about 0.21nM, about 0.16nM to about 1.03nM, Approximately 0.16nM to approximately 1.2nM, approximately 0.16nM to approximately 2.27nM, approximately 0.21nM to approximately 1.03nM, approximately 0.21nM to approximately 1.2nM, approximately 0 EC of .21nM to about 2.27nM, about 1.03nM to about 1.2nM, about 1.03nM to about 2.27nM, or about 1.2nM to about 2.27nM 50 It has.

[0206] In some embodiments, the anti-CD47 binding domains described herein have an EC 50 In some embodiments, the anti-CD47 binding domains described herein have an EC 50 In some embodiments, the anti-CD47 binding domains described herein have an EC 50In some embodiments, the anti-CD47 binding domains described herein are used in cytotoxicity assays or in vivo assays to determine ADCC activity, e.g., using NK92 / CD16a176V or PBMC effector cells and targeting cancer cells such as metastatic cancer cells from colon cancer, e.g., HCT-15 cells, or metastatic cancer cells from the esophagus, e.g., KYSE-150 cells. In an in vitro cytotoxicity assay, the compound has an EC 50 It has.

[0207] In some embodiments, the anti-CD47 binding domains described herein have reduced red blood cell (RBC) binding compared to CD47 BMK-1 (such as described herein). In some cases, the reduction in RBC binding is at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100% compared to the reference antibody CD47 BMK-1.

[0208] In some embodiments, the anti-CD47 antibodies described herein have an improved serum half-life compared to a reference antibody CD47 BMK-2 or CD47 BMK-1 (such as those described herein). In some embodiments, the anti-CD47 antibodies described herein have an improved serum half-life compared to a reference antibody CD47 BMK-2 or CD47 BMK-1. In some examples, the improved serum half-life is at least 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 12 hours, 18 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 14 days, 30 days, or more, longer than the reference antibody CD47 BMK-2 or CD47 BMK-1. In some examples, the improved serum half-life is at least 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 12 hours, 18 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 14 days, 30 days, or more, longer than the reference antibody CD47BMK-2 or CD47BMK-1.

[0209] In some cases, the serum half-life of an anti-CD47 binding domain described herein is at least 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 12 hours, 18 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 14 days, 30 days, or more. In some cases, the serum half-life of an anti-CD47 binding domain described herein is about 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 12 hours, 18 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 14 days, 30 days, or more.

[0210] Anti-EpCAM binding domain In certain embodiments, anti-EpCAM binding domains are disclosed herein. In some embodiments, the EpCAM binding domain is a human or engineered human EpCAM binding domain. In some embodiments, the EpCAM binding domain comprises an antibody that specifically binds to EpCAM, or a functional fragment or functional variant thereof. In some embodiments, the antibody that specifically binds to EpCAM, or a functional fragment or functional variant thereof, comprises an anti-EpCAM heavy chain and an anti-EpCAM light chain. In some embodiments, the anti-EpCAM heavy chain comprises an anti-EpCAM heavy chain variable domain. In some embodiments, the anti-EpCAM heavy chain variable domain comprises the variable domain of an IgG1, IgG2, IgG3, or IgG4 heavy chain. In some embodiments, the anti-EpCAM light chain comprises an anti-EpCAM light chain variable domain. In some embodiments, the anti-EpCAM light chain variable domain comprises a kappa or lambda light chain. In some embodiments, the anti-EpCAM light chain variable domain comprises a kappa light chain. In some embodiments, the anti-EpCAM light chain variable domain comprises a lambda light chain. In some embodiments, the EpCAM binding domain comprises a single-chain variable fragment (scFv). In some embodiments, the EpCAM-binding domain comprises an antigen-binding fragment (Fab).

[0211] In some embodiments, the EpCAM-binding domain comprises three heavy chain (HC) complementarity-determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein HC-CDR1, HC-CDR2, and HC-CDR3 of the EpCAM-binding domain comprise amino acid sequences selected from those set forth in Table 9. In some embodiments, HC-CDR1 of the EpCAM-binding domain comprises an amino acid sequence selected from SEQ ID NOs: 222, 225, 231, 234, 243, and 246. In some embodiments, HC-CDR2 of the EpCAM-binding domain comprises an amino acid sequence selected from SEQ ID NOs: 223, 226, 232, 235, 244, and 247. In some embodiments, HC-CDR3 of the EpCAM-binding domain comprises an amino acid sequence selected from SEQ ID NOs: 224, 227, 233, 236, 245, and 248. In some embodiments, at least one of the HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprises 0 to 1 amino acid modifications.

[0212] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 219-221, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0213] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 222-224, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0214] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 225-227, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0215] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 228-230, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0216] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 231-233, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0217] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 234-236, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0218] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 237-239, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0219] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 240-242, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0220] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 243-245, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0221] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 246-248, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0222] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 249-251, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0223] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 252-254, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0224] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 255-257, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0225] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 258-260, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0226] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 261-263, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0227] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 264-266, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0228] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 267-269, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0229] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 270-272, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0230] In some embodiments, the EpCAM-binding domain comprises three light chain (LC) complementarity-determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, wherein LC-CDR1, LC-CDR2, and LC-CDR3 of the EpCAM-binding domain comprise amino acid sequences selected from those set forth in Table 10. In some embodiments, LC-CDR1 of the EpCAM-binding domain comprises an amino acid sequence selected from SEQ ID NOs: 276, 279, 285, 288, 297, and 300. In some embodiments, LC-CDR2 of the EpCAM-binding domain comprises an amino acid sequence selected from SEQ ID NOs: 277, 280, 286, 289, 298, and 301. In some embodiments, LC-CDR3 of the EpCAM-binding domain comprises an amino acid sequence selected from SEQ ID NOs: 278, 281, 287, 290, 299, and 302. In some embodiments, at least one of the HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprises 0 to 1 amino acid modifications.

[0231] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 273-275, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0232] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 276-278, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0233] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 279-281, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0234] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 282-284, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0235] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 285-287, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0236] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 288-290, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0237] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 291-293, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0238] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 294-296, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0239] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 297-299, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0240] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 300-302, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0241] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 303-305, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0242] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 306-308, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0243] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 309-311, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0244] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 312-314, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0245] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 315-317, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0246] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 318-320, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0247] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 321-323, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0248] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 324-326, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0249] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 219-221, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 273-275, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0250] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 222-224, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 276-278, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0251] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 225-227, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 279-281, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0252] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 228-230, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 282-284, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0253] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 231-233, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 285-287, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0254] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 234-236, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 288-290, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0255] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 237-239, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 291-293, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0256] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 240-242, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 294-296, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0257] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 243-245, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 297-299, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0258] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 246-248, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 300-302, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0259] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 249-251, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 300-305, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0260] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 252-254, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 306-308, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0261] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 255-257, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 309-311, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0262] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 258-260, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 312-314, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0263] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 261-263, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 315-317, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0264] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 264-266, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 318-320, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0265] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 267-269, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 321-323, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0266] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 270-272, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 324-326, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0267] In some embodiments, the EpCAM-binding domain comprises a heavy chain framework region (HFR) comprising an amino acid sequence selected from those set forth in Table 11, wherein the HFR comprises 0 to 3 amino acid modifications. In some embodiments, the EpCAM-binding domain comprises a heavy chain framework region (HFR) comprising an amino acid sequence selected from SEQ ID NOs: 331-334, 335-338, 343-346, 347-350, 355-358, and 359-362, wherein the HFR comprises 0 to 3 amino acid modifications. In some embodiments, the HFR of the EpCAM-binding domain comprises 0 to 2 amino acid modifications. In some embodiments, the HFR of the EpCAM-binding domain comprises 0 to 1 amino acid modification.

[0268] In some embodiments, the heavy chain framework region (HFR) of the EpCAM-binding domain comprises a pre-CDR1 region, an inter-CDR1 / 2 region, an inter-CDR2 / 3 region, and a post-CDR3 region. In some embodiments, the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprise the amino acid sequences of SEQ ID NOs: 327-330, and at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-5 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-4 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-3 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 1 amino acid modifications.

[0269] In some embodiments, the heavy chain framework region (HFR) of the EpCAM-binding domain comprises a pre-CDR1 region, an inter-CDR1 / 2 region, an inter-CDR2 / 3 region, and a post-CDR3 region. In some embodiments, the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprise the amino acid sequences of SEQ ID NOs: 331-334, and at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-5 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-4 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-3 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 1 amino acid modifications.

[0270] In some embodiments, the heavy chain framework region (HFR) of the EpCAM-binding domain comprises a pre-CDR1 region, an inter-CDR1 / 2 region, an inter-CDR2 / 3 region, and a post-CDR3 region. In some embodiments, the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprise the amino acid sequences of SEQ ID NOs: 335-338, and at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-5 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-4 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-3 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 1 amino acid modifications.

[0271] In some embodiments, the heavy chain framework region (HFR) of the EpCAM-binding domain comprises a pre-CDR1 region, an inter-CDR1 / 2 region, an inter-CDR2 / 3 region, and a post-CDR3 region. In some embodiments, the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprise the amino acid sequences of SEQ ID NOs: 339-342, and at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-5 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-4 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-3 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 1 amino acid modifications.

[0272] In some embodiments, the heavy chain framework region (HFR) of the EpCAM-binding domain comprises a pre-CDR1 region, an inter-CDR1 / 2 region, an inter-CDR2 / 3 region, and a post-CDR3 region. In some embodiments, the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprise the amino acid sequences of SEQ ID NOs: 343-346, and at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-5 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-4 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-3 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 1 amino acid modifications.

[0273] In some embodiments, the heavy chain framework region (HFR) of the EpCAM-binding domain comprises a pre-CDR1 region, an inter-CDR1 / 2 region, an inter-CDR2 / 3 region, and a post-CDR3 region. In some embodiments, the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprise the amino acid sequences of SEQ ID NOs: 347-350, and at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-5 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-4 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-3 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 1 amino acid modifications.

[0274] In some embodiments, the heavy chain framework region (HFR) of the EpCAM-binding domain comprises a pre-CDR1 region, an inter-CDR1 / 2 region, an inter-CDR2 / 3 region, and a post-CDR3 region. In some embodiments, the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprise the amino acid sequences of SEQ ID NOs: 351-354, and at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-5 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-4 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-3 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 1 amino acid modifications.

[0275] In some embodiments, the heavy chain framework region (HFR) of the EpCAM-binding domain comprises a pre-CDR1 region, an inter-CDR1 / 2 region, an inter-CDR2 / 3 region, and a post-CDR3 region. In some embodiments, the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprise the amino acid sequences of SEQ ID NOs: 355-358, and at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-5 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-4 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-3 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 1 amino acid modifications.

[0276] In some embodiments, the heavy chain framework region (HFR) of the EpCAM-binding domain comprises a pre-CDR1 region, an inter-CDR1 / 2 region, an inter-CDR2 / 3 region, and a post-CDR3 region. In some embodiments, the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprise the amino acid sequences of SEQ ID NOs: 359-362, and at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-5 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-4 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-3 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 1 amino acid modifications.

[0277] In some embodiments, the EpCAM-binding domain comprises a light chain framework region (LFR) comprising an amino acid sequence selected from those set forth in Table 12, wherein the LFR comprises 0 to 3 amino acid modifications. In some embodiments, the EpCAM-binding domain comprises a light chain framework region (LFR) comprising an amino acid sequence selected from SEQ ID NOs: 367-370, 371-374, 379-382, 383-386, 391-394, and 395-398, wherein the LFR comprises 0 to 3 amino acid modifications. In some embodiments, the LFR of the EpCAM-binding domain comprises 0 to 2 amino acid modifications. In some embodiments, the LFR of the EpCAM-binding domain comprises 0 to 1 amino acid modification.

[0278] In some embodiments, the light chain framework region (LFR) of the EpCAM-binding domain comprises a pre-CDR1 region, an inter-CDR1 / 2 region, an inter-CDR2 / 3 region, and a post-CDR3 region. In some embodiments, the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprise the amino acid sequences of SEQ ID NOs: 363-366, and at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-5 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-4 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-3 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 1 amino acid modifications.

[0279] In some embodiments, the light chain framework region (LFR) of the EpCAM-binding domain comprises a pre-CDR1 region, an inter-CDR1 / 2 region, an inter-CDR2 / 3 region, and a post-CDR3 region. In some embodiments, the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprise the amino acid sequences of SEQ ID NOs: 367-370, and at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-5 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-4 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-3 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 1 amino acid modifications.

[0280] In some embodiments, the light chain framework region (LFR) of the EpCAM-binding domain comprises a pre-CDR1 region, an inter-CDR1 / 2 region, an inter-CDR2 / 3 region, and a post-CDR3 region. In some embodiments, the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprise the amino acid sequences of SEQ ID NOs: 371-374, and at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-5 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-4 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-3 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 1 amino acid modifications.

[0281] In some embodiments, the light chain framework region (LFR) of the EpCAM-binding domain comprises a pre-CDR1 region, an inter-CDR1 / 2 region, an inter-CDR2 / 3 region, and a post-CDR3 region. In some embodiments, the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprise the amino acid sequences of SEQ ID NOs: 375-378, and at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-5 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-4 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-3 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 1 amino acid modifications.

[0282] In some embodiments, the light chain framework region (LFR) of the EpCAM-binding domain comprises a pre-CDR1 region, an inter-CDR1 / 2 region, an inter-CDR2 / 3 region, and a post-CDR3 region. In some embodiments, the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprise the amino acid sequences of SEQ ID NOs: 379-382, and at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-5 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-4 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-3 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 1 amino acid modifications.

[0283] In some embodiments, the light chain framework region (LFR) of the EpCAM-binding domain comprises a pre-CDR1 region, an inter-CDR1 / 2 region, an inter-CDR2 / 3 region, and a post-CDR3 region. In some embodiments, the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprise the amino acid sequences of SEQ ID NOs: 383-386, and at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-5 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-4 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-3 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 1 amino acid modifications.

[0284] In some embodiments, the light chain framework region (LFR) of the EpCAM-binding domain comprises a pre-CDR1 region, an inter-CDR1 / 2 region, an inter-CDR2 / 3 region, and a post-CDR3 region. In some embodiments, the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprise the amino acid sequences of SEQ ID NOs: 387-390, and at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-5 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-4 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-3 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 1 amino acid modifications.

[0285] In some embodiments, the light chain framework region (LFR) of the EpCAM-binding domain comprises a pre-CDR1 region, an inter-CDR1 / 2 region, an inter-CDR2 / 3 region, and a post-CDR3 region. In some embodiments, the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprise the amino acid sequences of SEQ ID NOs: 391-394, and at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-5 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-4 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-3 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 1 amino acid modifications.

[0286] In some embodiments, the light chain framework region (LFR) of the EpCAM-binding domain comprises a pre-CDR1 region, an inter-CDR1 / 2 region, an inter-CDR2 / 3 region, and a post-CDR3 region. In some embodiments, the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprise the amino acid sequences of SEQ ID NOs: 395-398, and at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-5 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-4 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0-3 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the pre-CDR1 region, the inter-CDR1 / 2 region, the inter-CDR2 / 3 region, and the post-CDR3 region comprises 0 to 1 amino acid modifications.

[0287] In some embodiments, the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the heavy chain framework region (HFR) of the EpCAM-binding domain comprise the amino acid sequences of SEQ ID NOs: 327 to 330, and the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the light chain framework region (LFR) of the EpCAM-binding domain comprise the amino acid sequences of SEQ ID NOs: 363 to 366, and the heavy chain framework region of the EpCAM-binding domain At least one of the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the light chain framework region (HFR) contains 0 to 5 (e.g., 0 to 4, 0 to 3, 0 to 2, or 0 to 1) amino acid modifications, and at least one of the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the light chain framework region (LFR) of the EpCAM-binding domain contains 0 to 5 (e.g., 0 to 4, 0 to 3, 0 to 2, or 0 to 1) amino acid modifications.

[0288] In some embodiments, the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the heavy chain framework region (HFR) of the EpCAM-binding domain comprise the amino acid sequences of SEQ ID NOs: 331 to 334, and the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the light chain framework region (LFR) of the EpCAM-binding domain comprise the amino acid sequences of SEQ ID NOs: 367 to 370. At least one of the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the light chain framework region (HFR) contains 0 to 5 (e.g., 0 to 4, 0 to 3, 0 to 2, or 0 to 1) amino acid modifications, and at least one of the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the light chain framework region (LFR) of the EpCAM-binding domain contains 0 to 5 (e.g., 0 to 4, 0 to 3, 0 to 2, or 0 to 1) amino acid modifications.

[0289] In some embodiments, the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the heavy chain framework region (HFR) of the EpCAM-binding domain comprise the amino acid sequences of SEQ ID NOs: 335 to 338, the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the light chain framework region (LFR) of the EpCAM-binding domain comprise the amino acid sequences of SEQ ID NOs: 371 to 374, and the heavy chain framework region of the EpCAM-binding domain At least one of the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the light chain framework region (HFR) contains 0 to 5 (e.g., 0 to 4, 0 to 3, 0 to 2, or 0 to 1) amino acid modifications, and at least one of the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the light chain framework region (LFR) of the EpCAM-binding domain contains 0 to 5 (e.g., 0 to 4, 0 to 3, 0 to 2, or 0 to 1) amino acid modifications.

[0290] In some embodiments, the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the heavy chain framework region (HFR) of the EpCAM-binding domain comprise the amino acid sequences of SEQ ID NOs: 339 to 342, and the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the light chain framework region (LFR) of the EpCAM-binding domain comprise the amino acid sequences of SEQ ID NOs: 375 to 378. At least one of the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the light chain framework region (HFR) contains 0 to 5 (e.g., 0 to 4, 0 to 3, 0 to 2, or 0 to 1) amino acid modifications, and at least one of the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the light chain framework region (LFR) of the EpCAM-binding domain contains 0 to 5 (e.g., 0 to 4, 0 to 3, 0 to 2, or 0 to 1) amino acid modifications.

[0291] In some embodiments, the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the heavy chain framework region (HFR) of the EpCAM-binding domain comprise the amino acid sequences of SEQ ID NOs: 343 to 346, the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the light chain framework region (LFR) of the EpCAM-binding domain comprise the amino acid sequences of SEQ ID NOs: 379 to 382, ​​and the heavy chain framework region of the EpCAM-binding domain At least one of the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the light chain framework region (HFR) contains 0 to 5 (e.g., 0 to 4, 0 to 3, 0 to 2, or 0 to 1) amino acid modifications, and at least one of the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the light chain framework region (LFR) of the EpCAM-binding domain contains 0 to 5 (e.g., 0 to 4, 0 to 3, 0 to 2, or 0 to 1) amino acid modifications.

[0292] In some embodiments, the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the heavy chain framework region (HFR) of the EpCAM-binding domain comprise the amino acid sequences of SEQ ID NOs: 347 to 350, and the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the light chain framework region (LFR) of the EpCAM-binding domain comprise the amino acid sequences of SEQ ID NOs: 383 to 386. At least one of the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the light chain framework region (HFR) contains 0 to 5 (e.g., 0 to 4, 0 to 3, 0 to 2, or 0 to 1) amino acid modifications, and at least one of the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the light chain framework region (LFR) of the EpCAM-binding domain contains 0 to 5 (e.g., 0 to 4, 0 to 3, 0 to 2, or 0 to 1) amino acid modifications.

[0293] In some embodiments, the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the heavy chain framework region (HFR) of the EpCAM-binding domain comprise the amino acid sequences of SEQ ID NOs: 351 to 354, the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the light chain framework region (LFR) of the EpCAM-binding domain comprise the amino acid sequences of SEQ ID NOs: 387 to 390, and the heavy chain framework region of the EpCAM-binding domain At least one of the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the light chain framework region (HFR) contains 0 to 5 (e.g., 0 to 4, 0 to 3, 0 to 2, or 0 to 1) amino acid modifications, and at least one of the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the light chain framework region (LFR) of the EpCAM-binding domain contains 0 to 5 (e.g., 0 to 4, 0 to 3, 0 to 2, or 0 to 1) amino acid modifications.

[0294] In some embodiments, the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the heavy chain framework region (HFR) of the EpCAM-binding domain comprise the amino acid sequences of SEQ ID NOs: 355 to 358, and the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the light chain framework region (LFR) of the EpCAM-binding domain comprise the amino acid sequences of SEQ ID NOs: 391 to 394. At least one of the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the light chain framework region (HFR) contains 0 to 5 (e.g., 0 to 4, 0 to 3, 0 to 2, or 0 to 1) amino acid modifications, and at least one of the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the light chain framework region (LFR) of the EpCAM-binding domain contains 0 to 5 (e.g., 0 to 4, 0 to 3, 0 to 2, or 0 to 1) amino acid modifications.

[0295] In some embodiments, the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the heavy chain framework region (HFR) of the EpCAM-binding domain comprise the amino acid sequences of SEQ ID NOs: 359 to 362, and the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the light chain framework region (LFR) of the EpCAM-binding domain comprise the amino acid sequences of SEQ ID NOs: 395 to 398. At least one of the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the light chain framework region (HFR) contains 0 to 5 (e.g., 0 to 4, 0 to 3, 0 to 2, or 0 to 1) amino acid modifications, and at least one of the pre-CDR1 region, inter-CDR1 / 2 region, inter-CDR2 / 3 region, and post-CDR3 region of the light chain framework region (LFR) of the EpCAM-binding domain contains 0 to 5 (e.g., 0 to 4, 0 to 3, 0 to 2, or 0 to 1) amino acid modifications.

[0296] In some embodiments, the EpCAM-binding domain comprises a heavy chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 13.

[0297] In some embodiments, the EpCAM-binding domain comprises a heavy chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence selected from SEQ ID NOs: 399-416.

[0298] In some embodiments, the EpCAM-binding domain comprises a light chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 14.

[0299] In some embodiments, the EpCAM-binding domain comprises a light chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence selected from SEQ ID NOs: 417-434.

[0300] In some embodiments, the EpCAM-binding domain comprises a heavy chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 13, and a light chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 14.

[0301] In some embodiments, the EpCAM-binding domain comprises a heavy chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence selected from SEQ ID NOs: 399-416, and a light chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence selected from SEQ ID NOs: 417-434 or 513-514.

[0302] In some embodiments, the EpCAM binding domain comprises a full-length heavy chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 15.

[0303] In some embodiments, the EpCAM binding domain comprises a full-length heavy chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence selected from SEQ ID NOs: 435-443 or 515-516.

[0304] In some embodiments, the EpCAM-binding domain comprises a full-length light chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 16.

[0305] In some embodiments, the EpCAM binding domain comprises a full-length light chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence selected from SEQ ID NOs: 444-452 or 517-518.

[0306] In some embodiments, the EpCAM-binding domain comprises a full-length heavy chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence listed in Table 15, and a full-length light chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence listed in Table 16.

[0307] In some embodiments, the EpCAM-binding domain comprises a full-length heavy chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence selected from SEQ ID NOs: 435-443, and a full-length light chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence selected from SEQ ID NOs: 444-452.

[0308] In some embodiments, the EpCAM-binding domain comprises a single-chain variable fragment (scFv) comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 17.

[0309] In some embodiments, the EpCAM-binding domain comprises a single-chain variable fragment (scFv) comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence selected from SEQ ID NOs: 453-457.

[0310] In some embodiments of the anti-EpCAM binding domain described herein, the heavy chain variable fragment (VH) of the anti-EpCAM binding domain is fused to a first T cell receptor (TCR) constant region, and the light chain variable domain (VL) of the anti-EpCAM binding domain is fused to a second TCR constant region, wherein the first and second TCR constant regions can form a dimer. In some embodiments, the TCR constant regions are TCR alpha and TCR beta constant regions. In some embodiments, the VH-TCR fusion polypeptide is fused to a human IgG (e.g., IgG1) Fc domain. See WO2019 / 057122.

[0311] In some embodiments, the anti-EpCAM binding domain described herein comprises a T cell receptor (TCR) constant region. In some embodiments, the TCR constant region comprises a TCR alpha constant domain and a TCR beta constant domain. In some embodiments, the anti-EpCAM binding domain comprises a VH-EpCAM domain and a VL-EpCAM domain, wherein the VH-EpCAM domain is fused to the TCR beta constant domain and the VL-EpCAM domain is fused to the TCR alpha constant domain. In some embodiments, the anti-EpCAM binding domain comprises a VH-EpCAM domain and a VL-EpCAM domain, wherein the VH-EpCAM domain is fused to the first constant domain of the heavy chain (CH1) IgG domain and the VL-EpCAM domain is fused to the constant domain of the light chain (CL) IgG domain.

[0312] In some embodiments, the anti-EpCAM binding domain described herein comprises a T cell receptor (TCR) constant region. In some embodiments, the TCR constant region comprises a TCR alpha constant domain and a TCR beta constant domain. In some embodiments, the anti-EpCAM binding domain described herein comprises a VH-EpCAM domain and a VL-EpCAM domain, wherein the VH-EpCAM domain is fused to the TCR alpha constant domain and the VL-EpCAM domain is fused to the TCR beta constant domain. In some embodiments, the anti-EpCAM binding domain comprises a VH-EpCAM domain and a VL-EpCAM domain, wherein the VH-EpCAM domain is fused to the first constant domain of the heavy chain (CH1) IgG domain and the VL-EpCAM domain is fused to the constant domain of the light chain (CL) IgG domain.

[0313] In some embodiments, the EpCAM-binding domain comprises a TCR alpha constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 18. In some embodiments, the EpCAM-binding domain comprises a TCR beta constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 18.

[0314] In some embodiments, the EpCAM-binding domain comprises a TCR alpha constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 18, and a TCR beta constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 18.

[0315] In some embodiments, the EpCAM-binding domain comprises a TCR alpha constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:458.

[0316] In some embodiments, the EpCAM-binding domain comprises a TCR β constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:459.

[0317] In some embodiments, the EpCAM-binding domain comprises a TCR alpha constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:458, and a TCR beta constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:459.

[0318] [Table 9]

[0319] [Table 10]

[0320] [Table 11]

[0321] [Table 12]

[0322] [Table 13-1]

[0323] [Table 13-2]

[0324] [Table 14]

[0325] [Table 15-1]

[0326] [Table 15-2]

[0327] [Table 16]

[0328] [Table 17]

[0329] [Table 18]

[0330] Anti-EGFR binding domain In certain embodiments, anti-EGFR binding domains are disclosed herein. In some embodiments, the EGFR binding domain comprises a heavy chain variable domain and a light chain variable domain. In some embodiments, the EGFR binding domain comprises a single-chain variable fragment (scFv). In some embodiments, the EGFR binding domain comprises an antigen-binding fragment (Fab).

[0331] In some embodiments, the EGFR-binding domain comprises three heavy chain (HC) complementarity-determining regions (CDRs), HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, HC-CDR2, and HC-CDR3 of the EGFR-binding domain comprise an amino acid sequence selected from those set forth in Table 19, and at least one of the HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 amino acid modifications. In some embodiments, at least one of the HC-CDR1, HC-CDR2, and HC-CDR3 of the EGFR-binding domain comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the HC-CDR1, HC-CDR2, and HC-CDR3 of the EGFR-binding domain comprises 0 to 1 amino acid modifications.

[0332] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 460-462, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0333] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 463-465, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0334] In some embodiments, the EGFR-binding domain comprises three light chain (LC) complementarity determining regions (CDRs), LC-CDR1, LC-CDR2, and LC-CDR3, wherein the LC-CDR1, LC-CDR2, and LC-CDR3 of the EGFR-binding domain comprise an amino acid sequence selected from those set forth in Table 20, and at least one of the LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 amino acid modifications. In some embodiments, at least one of the LC-CDR1, LC-CDR2, and LC-CDR3 of the EGFR-binding domain comprises 0 to 2 amino acid modifications. In some embodiments, at least one of the LC-CDR1, LC-CDR2, and LC-CDR3 of the EGFR-binding domain comprises 0 to 1 amino acid modifications.

[0335] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 466-468, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0336] In some embodiments, LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 469-471, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 (e.g., 0 to 2 or 0 to 1) amino acid modifications.

[0337] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 460-462, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 466-468, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0338] In some embodiments, HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 463-465, and LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences of SEQ ID NOs: 469-471, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0-3 (e.g., 0-2 or 0-1) amino acid modifications.

[0339] In some embodiments, the EGFR binding domain comprises a heavy chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 21.

[0340] In some embodiments, the EGFR binding domain comprises a heavy chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 472 or 473.

[0341] In some embodiments, the EGFR binding domain comprises a light chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 22.

[0342] In some embodiments, the EGFR binding domain comprises a light chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 474 or 475.

[0343] In some embodiments, the EGFR-binding domain comprises a heavy chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 21; and a light chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 22.

[0344] In some embodiments, the EGFR binding domain comprises a heavy chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 472 or 473, and a light chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 474 or 475.

[0345] In some embodiments, the EGFR binding domain comprises a full-length heavy chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 23.

[0346] In some embodiments, the EGFR binding domain comprises a full-length heavy chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 476 or 477.

[0347] In some embodiments, the EGFR binding domain comprises a full-length light chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 24.

[0348] In some embodiments, the EGFR binding domain comprises a full-length light chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 478 or 479.

[0349] In some embodiments, the EGFR-binding domain comprises a full-length heavy chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 23, and a full-length light chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 24.

[0350] In some embodiments, the EGFR binding domain comprises a full-length heavy chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 476 or 477, and a full-length light chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 478 or 479.

[0351] In some embodiments, the EGFR binding domain comprises a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 25.

[0352] In some embodiments, the EGFR binding domain comprises a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 480 or 481.

[0353] In some embodiments of the anti-EGFR binding domains described herein, the heavy chain variable fragment (VH) of the anti-EGFR binding domain is fused to a first T cell receptor (TCR) constant region, and the light chain variable domain (VL) of the anti-EGFR binding domain is fused to a second TCR constant region, wherein the first and second TCR constant regions can form a dimer. In some embodiments, the TCR constant regions are TCR alpha and TCR beta constant regions. In some embodiments, the VH-TCR fusion polypeptide is fused to a human IgG (e.g., IgG1) Fc domain. See WO2019 / 057122.

[0354] In some embodiments, the anti-EGFR binding domain described herein comprises a T cell receptor (TCR) constant region. In some embodiments, the TCR constant region comprises a TCR alpha constant domain and a TCR beta constant domain. In some embodiments, the anti-EGFR binding domain comprises a VH-EGFR domain and a VL-EGFR domain, wherein the VH-EGFR domain is fused to a TCR beta constant domain and the VL-EGFR domain is fused to a TCR alpha constant domain. In some embodiments, the anti-EGFR binding domain comprises a VH-EGFR domain and a VL-EGFR domain, wherein the VH-EGFR domain is fused to a first constant domain of a heavy chain (CH1) IgG domain and the VL-EGFR domain is fused to a constant domain of a light chain (CL) IgG domain.

[0355] In some embodiments, the anti-EGFR binding domain described herein comprises a T cell receptor (TCR) constant region. In some embodiments, the TCR constant region comprises a TCRα constant domain and a TCRβ constant domain. In some embodiments, the anti-EGFR binding domain described herein comprises a VH-EGFR domain and a VL-EGFR domain, wherein the VH-EGFR domain is fused to the TCRα constant domain and the VL-EGFR domain is fused to the TCRβ constant domain. In some embodiments, the anti-EGFR binding domain comprises a VH-EGFR domain and a VL-EGFR domain, wherein the VH-EGFR domain is fused to the first constant domain of the heavy chain (CH1) IgG domain and the VL-EGFR domain is fused to the constant domain of the light chain (CL) IgG domain.

[0356] In some embodiments, the anti-EGFR binding domains described herein have enhanced binding to human EGFR protein compared to a reference antibody. In some cases, the enhanced binding is at least a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% decrease in KD compared to the reference antibody.

[0357] In some embodiments, the anti-EGFR binding domains described herein have an EC 50 In some embodiments, the anti-EGFR binding domains described herein have an EC 50 In some embodiments, the anti-EGFR binding domains described herein have an EC 50In some embodiments, the anti-EGFR binding domain described herein has a cytotoxicity assay or in vitro cytotoxicity assay to determine ADCC activity, e.g., using NK92 / CD16a176V effector cells and targeting metastatic cancer cells from vulvar squamous cell carcinoma, e.g., A431 cells, of about 0.023 nM to about 0.024 nM, about 0.023 nM to about 0.036 nM, about 0.023 nM to about 0.038 nM, about 0.023 nM to about 0.04 nM, about 0.023 nM to about 0.059 nM, about 0.023 nM to about 0.069 nM, about 0.023 nM to about 0.086 nM, about 0.023 nM to about 3.07 nM, or about 0. 024nM to about 0.036nM, about 0.024nM to about 0.038nM, about 0.024nM to about 0.04nM, about 0.024nM to about 0.059nM, about 0.024nM to about 0.06 9nM, about 0.024nM to about 0.086nM, about 0.024nM to about 3.07nM, about 0.036nM to about 0.038nM, about 0.036nM to about 0.04nM, about 0.036nM ~about 0.059nM, about 0.036nM to about 0.069nM, about 0.036nM to about 0.086nM, about 0.036nM to about 3.07nM, about 0.038nM to about 0.04nM, about 0 .038nM to about 0.059nM, about 0.038nM to about 0.069nM, about 0.038nM to about 0.086nM, about 0.038nM to about 3.07nM, about 0.04nM to about 0.05 EC50 of about 9 nM, about 0.04 nM to about 0.069 nM, about 0.04 nM to about 0.086 nM, about 0.04 nM to about 3.07 nM, about 0.059 nM to about 0.069 nM, about 0.059 nM to about 0.086 nM, about 0.059 nM to about 3.07 nM, about 0.069 nM to about 0.086 nM, about 0.069 nM to about 3.07 nM, or about 0.086 nM to about 3.07 nM 50 It has.

[0358] [Table 19]

[0359] [Table 20]

[0360] Table 21

[0361] Table 22

[0362] Table 23

[0363] Table 24

[0364] Table 25

[0365] Multispecific antibodies In certain embodiments, multispecific anti-CD47 and anti-EpCAM antibodies, or binding fragments thereof, are described herein. In some examples, the multispecific anti-CD47 and anti-EpCAM antibodies comprise at least one targeting moiety that specifically binds to CD47 and at least one targeting moiety that specifically binds to EpCAM. In some embodiments, the multispecific antibody comprises a CD47-binding domain described herein. In some embodiments, the multispecific antibody comprises an EpCAM-binding domain described herein. In some embodiments, the multispecific antibody comprises a CD47-binding domain described herein and an EpCAM-binding domain described herein. In some embodiments, the multispecific antibody is bispecific, trispecific, or tetraspecific. In some embodiments, the multispecific antibody is bispecific. In some embodiments, the multispecific antibody is bivalent, trivalent, or tetravalent. In some embodiments, the multispecific antibody is bivalent. In some examples, the multispecific antibody has more than one binding site that binds to CD47. In some examples, the multispecific antibody has more than one binding site that binds to EpCAM. In some examples, the multispecific antibody or binding fragment thereof is a multispecific antibody conjugate, a hybrid multispecific IgG, a variable domain-only multispecific antibody, a CH1 / CL fusion protein, a Fab fusion protein, a non-immunoglobulin fusion protein, an Fc-modified IgG, an adducted and Fc-modified IgG, a modified Fc and CH3 fusion protein, an adducted IgG-HC fusion, an Fc fusion, a CH3 fusion, an IgE / IgM CH2 fusion, or an F(ab')2 fusion. In some embodiments, the multispecific antibody further comprises an Fc domain. In some embodiments, the Fc domain is a human Fc domain. In some embodiments, the Fc domain is of the IgG1, IgG2, IgG3, or IgG4 isotype. In some embodiments, the Fc domain is a heterodimeric Fc domain, wherein the heterodimeric Fc region comprises a knob chain and a hole chain, forming a knob-into-hole (KiH) structure.In some embodiments, the knob chain comprises an IgG1, IgG2, IgG3, or IgG4 domain. In some embodiments, the knob chain comprises the mutation T366W and the hole chain comprises the mutations T366S, L368A, and Y407V, where the numbering of amino acid positions is according to the EU index of Kabat et al. In some embodiments, the hole chain comprises an IgG1, IgG2, IgG3, or IgG4 domain. In some embodiments, the multispecific antibody has an asymmetric three-chain knob-into-hole structure.

[0366] In certain embodiments, multispecific anti-CD47 and anti-EGFR antibodies, or binding fragments thereof, are described herein. In some examples, the multispecific anti-CD47 and anti-EGFR antibodies comprise at least one targeting moiety that specifically binds to CD47 and at least one targeting moiety that specifically binds to EGFR. In some embodiments, the multispecific antibody comprises a CD47 binding domain described herein. In some embodiments, the multispecific antibody comprises an EGFR binding domain described herein. In some embodiments, the multispecific antibody comprises a CD47 binding domain described herein and an EGFR binding domain described herein. In some embodiments, the multispecific antibody is bispecific, trispecific, or tetraspecific. In some embodiments, the multispecific antibody is bispecific. In some embodiments, the multispecific antibody is bivalent, trivalent, or tetravalent. In some embodiments, the multispecific antibody is bivalent. In some examples, the multispecific antibody has more than one binding site that binds to CD47. In some examples, the multispecific antibody has more than one binding site that binds to EGFR. In some examples, the multispecific antibody or binding fragment thereof is a multispecific antibody conjugate, a hybrid multispecific IgG, a variable domain-only multispecific antibody, a CH1 / CL fusion protein, a Fab fusion protein, a non-immunoglobulin fusion protein, an Fc-modified IgG, an adducted and Fc-modified IgG, a modified Fc and CH3 fusion protein, an adducted IgG-HC fusion, an Fc fusion, a CH3 fusion, an IgE / IgM CH2 fusion, or an F(ab')2 fusion. In some embodiments, the multispecific antibody further comprises an Fc domain. In some embodiments, the Fc domain is a human Fc domain. In some embodiments, the Fc domain is of the IgG1, IgG2, IgG3, or IgG4 isotype. In some embodiments, the Fc domain is a heterodimeric Fc domain, wherein the heterodimeric Fc region comprises a knob chain and a hole chain, forming a knob-into-hole (KiH) structure.In some embodiments, the knob chain comprises an IgG1, IgG2, IgG3, or IgG4 domain. In some embodiments, the knob chain comprises the mutation T366W and the hole chain comprises the mutations T366S, L368A, and Y407V, where the numbering of amino acid positions is according to the EU index of Kabat et al. In some embodiments, the hole chain comprises an IgG1, IgG2, IgG3, or IgG4 domain. In some embodiments, the multispecific antibody has an asymmetric three-chain knob-into-hole structure.

[0367] In some cases, the multispecific antibody comprises one or more mutations in the framework region, e.g., in the CH1 domain, CH2 domain, CH3 domain, hinge region, or a combination thereof. In some examples, the one or more mutations are to stabilize the antibody and / or increase half-life. In some examples, the one or more mutations are to modulate Fc receptor interactions to increase ADCC or antibody-dependent cellular phagocytosis (ADCP). In other examples, the one or more mutations are to reduce or eliminate Fc effector function, e.g., FcγR binding, ADCC, or ADCP. In further examples, the one or more mutations are to modify glycosylation. In some cases, the one or more mutations are to enhance stability, increase half-life, reduce glycosylation, and / or modulate Fc receptor interactions to, e.g., increase or decrease ADCC and / or ADCP.

[0368] In some cases, the multispecific antibody comprises an IgG1 framework. In some embodiments, the constant region of an anti-CD47 or anti-EpCAM or EGFR antibody is modified at one or more amino acid positions to alter Fc receptor interaction. Exemplary residues that modulate or alter Fc receptor interaction include, but are not limited to, G236, S239, T250, M252, S254, T256, K326, A330, I332, E333A, M428, H433, or N434 (Kabat numbering; Kabat et al. 1991 Sequences of Proteins of Immunological Interest, EU Index). In some examples, the mutations include G236A, S239D, T250Q, M252Y, S254T, T256E, K326W, A330L, I332E, E333A, E333S, M428L, H433K, or N434F.

[0369] In some embodiments, modifications at one or more amino acid positions in the IgG1 constant region to alter Fc receptor interactions result in increased half-life. In some examples, the modifications at one or more amino acid positions include T250, M252, S254, T256, M428, H433, N434, or combinations thereof, such as T250Q / M428L, or M252Y / S254T / T256E, and H433K / N434F.

[0370] In some embodiments, the multispecific antibodies described above comprise a knob-in-hole (KIH) format. In some cases, the KIH is located in the Fc region, where residues in the CH3 domain are optionally modified based on the disclosures in WO96 / 027011; Ridgway, et al., Protein Eng. 9 (1996) 617-621, or Merchant, et al., Nat. Biotechnol. 16 (1998) 677-681. In some cases, one of the CH3 domain pairs is the "knob" strand and the other is the "hole" strand, and additional disulfide bridges are optionally introduced to further stabilize the antibody and / or increase yield.

[0371] In some examples, the multispecific antibody is an IgG1, wherein the CH3 domain of the "knob" chain contains a T366W mutation, and the CH3 domain of the "hole" chain contains the mutations T366S, L368A, and Y407V. In some cases, the CH3 domain of the "knob" chain further contains a Y349C mutation that forms an interchain disulfide bridge with either E356C or S354C in the CH3 domain of the "hole" chain.

[0372] In some instances, the CH3 domain of the "knob" chain contains R409D and K370E mutations, and the CH3 domain of the "hole" chain contains D399K and E357K. In some instances, the CH3 domain of the "knob" chain further contains a T366W mutation, and the CH3 domain of the "hole" chain further contains the mutations T366S, L368A, and Y407V.

[0373] In some embodiments, modifications at one or more amino acid positions in the IgG1 constant region to alter Fc receptor interactions result in increased ADCC and / or ADCP. In some examples, modifications at one or more amino acid positions include S239, K326, A330, I332, E333, or a combination thereof. In some examples, modifications at one or more amino acid positions to increase ADCC and / or ADCP include, for example, E333A, S239D / A330L / I332E, or K326W / E333S. In some cases, modifications at one or more amino acid positions to increase ADCC include S239D / A330L / I332E. In some cases, modifications at one or more amino acid positions to increase ADCP include K326W / E333S.

[0374] In some embodiments, the IgG1 constant region is afucosylated. In other embodiments, the IgG1 is expressed in cells that are incapable of fucosylation. In some embodiments, the cells are mammalian cells, such as a Chinese hamster ovary cell line. In some embodiments, the cells are incapable of expressing fucosyltransferase 8 (FUT8).

[0375] In some embodiments, the multispecific antibody comprises an IgG2 framework. In some instances, one or more amino acid positions in the IgG2 framework are modified to alter Fc receptor interactions, for example, to increase ADCC and / or CDC. Optionally, one or more amino acid positions in the IgG2 framework are modified to stabilize the antibody and / or increase half-life. In some instances, one or more amino acid positions in the IgG2 framework are modified to regulate glycosylation. Optionally, the IgG2 constant region is defucosylated. In some embodiments, the IgG2 constant region is expressed in cells that are incapable of fucosylation. In some embodiments, the cells are mammalian cells, such as a Chinese hamster ovary cell line. In some embodiments, the cells are incapable of expressing fucosyltransferase 8 (FUT8).

[0376] In some embodiments, the multispecific antibody comprises an IgG3 framework. In some instances, one or more amino acid positions in the IgG3 framework are modified to alter Fc receptor interactions, for example, to increase ADCC and / or ADCP. In some instances, one or more amino acid positions in the IgG3 framework are modified to stabilize the antibody and / or increase half-life. In some instances, one or more amino acid positions in the IgG3 framework are modified to regulate glycosylation. In some instances, the constant region of the antibody is modified at amino acid R435 to extend half-life (e.g., R435H) (Kabat numbering). In some instances, the constant region is deglycosylated at residue N297. In some instances, the IgG3 constant region is expressed in cells that are incapable of fucosylation. In some embodiments, the cells are mammalian cells, such as a Chinese hamster ovary cell line. In some embodiments, the cells are incapable of expressing fucosyltransferase 8 (FUT8).

[0377] In some embodiments, the multispecific antibody comprises an IgG4 framework. In some examples, one or more amino acid positions in the IgG4 framework are modified to alter Fc receptor interactions, e.g., to increase ADCC and / or ADCP. For example, mutations that increase ADCC in some embodiments include S239D, I332E, and A330L (amino acid numbering is according to the EU index of Kabat et al.), such as those described in U.S. Pat. No. 8,093,359. In some embodiments, one or more amino acid positions in the IgG4 framework are modified to stabilize the antibody and / or increase half-life. In some examples, one or more amino acid positions in the IgG4 framework are modified to regulate glycosylation. In some cases, the constant region is modified in the hinge region to prevent or reduce chain exchange. In some examples, the modified amino acid is S228 (e.g., S228P). In some examples, the IgG4 constant region is expressed in a cell that is incapable of fucosylation. In some embodiments, the cell is a mammalian cell, such as a Chinese hamster ovary cell line. In some embodiments, the cells are unable to express fucosyltransferase 8 (FUT8).

[0378] In some embodiments, the human IgG constant region is selected from the group consisting of, for example, Natsume et al., 2008 Cancer Res, 68(10):3863-72; Idusogie et al., 2001 J Immunol, 166(4):2571-5; Moore et al., 2010 mAbs, 2(2):181-189; Lazar et al., 2006 PNAS, 103(11):4005-4010, Shields et al., 2001 JBC, 276(9):6591-6604; Stavenhagen et al., 2007 Cancer Res, 67(18):8882-8890; Stavenhagen et al., 2008 Advan. Enzyme Regul., 48:152-164; Alegre et al., 1992 J Immunol, 148:3461-3468; Reviewed in Kaneko and Niwa, 2011 Biodrugs, 25(1):1-11, modified to alter its ADCC and / or ADCP activity.

[0379] In some embodiments, the human IgG constant region is modified to induce heterodimerization. For example, an amino acid modification in the CH3 domain at Thr366, when substituted with a bulkier amino acid, such as Trp (T366W), can preferentially pair with a second CH3 domain that has less bulky amino acids at positions Thr366, Leu368, and Tyr407, such as Ser, Ala, and Val (T366S / L368A / Y407V). In some cases, heterodimerization via CH3 modification can be further stabilized by introducing disulfide bonds, for example, by changing Ser354 to Cys (S354C) and Y349 to Cys (Y349C) on the opposite CH3 domain (reviewed in Carter, 2001 Journal of Immunological Methods, 248:7-15).

[0380] In some examples, the multispecific antibodies described herein have reduced or no glycosylation, but are not modified at amino acid Asn297 (Kabat numbering). In these examples, glycosylation is eliminated, for example, by producing the antibody in a host cell lacking post-translational glycosylation capabilities, such as a bacterial or yeast-derived system, or a modified mammalian cell expression system. In some embodiments, the cell is a mammalian cell, such as a Chinese hamster ovary cell line. In some embodiments, the cell is unable to express fucosyltransferase 8 (FUT8). In certain aspects, such a system is a cell-free expression system.

[0381] In some embodiments, multispecific proteins comprising a first component that binds CD47 and a second component that binds EpCAM have different affinities (KD) for their respective target antigens as measured by surface plasmon resonance.

[0382] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain, the multispecific antibody has a higher affinity for CD47 expressed on the surface of tumor cells than for CD47 expressed on the surface of normal cells, such as erythrocytes, platelets, T cells, or NK cells. In some embodiments, the tumor cells express EpCAM. In some embodiments, the concentration of the multispecific antibody required for half-maximal binding to (e.g., human) erythrocytes is greater than about 500 nanomolar (nM). In some embodiments, the multispecific antibody binds to (e.g., human) CD47 with a dissociation constant (KD) of less than about 100 nanomolar (nM). In some embodiments, the multispecific antibody binds to (e.g., human) CD47 with a dissociation constant (KD) of about 1 nanomolar (nM) to about 100 nM, about 1 nM to about 50 nM, or about 5 nM to about 50 nM. In some embodiments, the multispecific antibody binds to EpCAM with a dissociation constant (KD) of less than about 500 nanomolar (nM). In some embodiments, the multispecific antibody binds to EpCAM with a dissociation constant (KD) of about 0.2 nanomolar (nM) to about 500 nM, about 1 nM to about 300 nM, about 5 nM to about 200 nM, or about 10 nM to about 150 nM. In some embodiments, the dissociation constant (KD) is determined by surface plasmon resonance. In some embodiments, a multispecific antibody of less than about 1 nanomolar (nM) or less than about 0.01 nM increases the percentage of A431 cells phagocytosed by macrophages by at least four-fold compared to a nonspecific IgG1 antibody control.

[0383] In some embodiments, a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain is characterized by a ratio of the KD of the CD47-binding domain to the KD of the EpCAM-binding domain of at least 2:1, at least 5:1, at least 10:1, at least 20:1, or at least 100:1.

[0384] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain, the concentration of antibody required to mediate antibody-dependent cellular phagocytosis of EpCAM-positive, CD47-positive tumor cells by macrophages is about 0.01 nanomolar (nM) to about 3 nM. In some embodiments, the EpCAM-positive, CD47-positive tumor cells are OVISE cells or A431 cells. In some embodiments, the EpCAM-positive, CD47-positive tumor cells are selected from ductal pancreatic adenocarcinoma cells, ovarian clear cell adenocarcinoma cells, colon adenocarcinoma cells, lung adenocarcinoma cells, lung squamous cell carcinoma cells, small cell lung carcinoma cells, hepatocellular carcinoma cells, gastric adenocarcinoma cells, cholangiocarcinoma cells, head and neck squamous cell carcinoma cells, prostate cancer cells, endometrial cancer cells, esophageal cancer cells, ovarian adenocarcinoma cells, and vulvar squamous cell carcinoma cells. In some embodiments, about 100 nanomolar (nM) of the multispecific antibody inhibits binding of SIRPα to CD47 on the surface of cells by at least about 30%. In some embodiments, the cells are CD47+EpCAM+ tumor cells. In some embodiments, the cells express at least the same number of EpCAM proteins on their surface as HCC-44 cells. In some embodiments, the cells express at least 50,000, at least 100,000, at least 300,000, at least 600,000, or at least 1,500,000 EpCAM proteins on their surface. In some embodiments, about 400 nanomolar (nM) of the polyspecific antibody does not induce hemolysis of red blood cells in a hemagglutination assay.

[0385] In some embodiments relating to multispecific antibodies comprising a CD47-binding domain and an EpCAM-binding domain, the multispecific antibody comprises one or more sequences (e.g., two or more, or three) each having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the corresponding sequences set forth in Table 26.

[0386] In some embodiments relating to a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain, the multispecific antibody comprises a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 482 and at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 483. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:484, and sequences having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:484.

[0387] In some embodiments relating to multispecific antibodies comprising a CD47-binding domain and an EpCAM-binding domain, the multispecific antibody comprises one or more sequences (e.g., two or more, or three) each having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the corresponding sequences set forth in Table 27.

[0388] In some embodiments relating to a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain, the multispecific antibody comprises a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 485 and at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 486. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:487, and sequences having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:487.

[0389] [Table 26]

[0390] [Table 27]

[0391] In some embodiments relating to multispecific antibodies comprising a CD47-binding domain and an EpCAM-binding domain, the multispecific (e.g., bispecific) antibodies and binding fragments thereof comprise a heavy chain variable fragment (VH) of the anti-CD47-binding domain fused to a first T cell receptor (TCR) constant region and a light chain variable domain (VL) of the anti-CD47-binding domain fused to a second TCR constant region, wherein the first and second TCR constant regions are capable of dimerization. In some embodiments, the TCR constant regions are TCRα and TCRβ constant regions. In some embodiments, the anti-CD47VH-TCR fusion polypeptide is fused to a human IgG (e.g., IgG1) Fc domain. See WO2019 / 057122. In some embodiments, the anti-EpCAM-binding domain comprises an antigen-binding fragment (Fab) domain. In some embodiments, the anti-EpCAM-binding domain comprises a single-chain variable fragment (scFv) domain.

[0392] In some embodiments of multispecific antibodies comprising a CD47-binding domain and an EpCAM-binding domain, the anti-CD47 binding domain comprises a VH-CD47 domain and a VL-CD47 domain, wherein the VH-CD47 domain is fused to a TCR β constant domain and the VL-CD47 domain is fused to a TCR α constant domain. In some embodiments, the anti-CD47 binding domain comprises a VH-CD47 domain and a VL-CD47 domain, wherein the VH-CD47 domain is fused to a CH1 IgG domain and the VL-CD47 domain is fused to a CL IgG domain. In some embodiments, the anti-EpCAM binding domain comprises an antigen-binding fragment (Fab) domain. In some embodiments, the anti-EpCAM binding domain comprises a single-chain variable fragment (scFv) domain.

[0393] In some embodiments relating to multispecific antibodies comprising a CD47-binding domain and an EpCAM-binding domain, the multispecific (e.g., bispecific) antibodies and binding fragments thereof comprise a heavy chain variable fragment (VH) of the anti-EpCAM-binding domain fused to a first T cell receptor (TCR) constant region and a light chain variable domain (VL) of the anti-EpCAM-binding domain fused to a second TCR constant region, wherein the first and second TCR constant regions are capable of dimerization. In some embodiments, the TCR constant regions are TCRα and TCRβ constant regions. In some embodiments, the anti-EpCAM VH-TCR fusion polypeptide is fused to a human IgG (e.g., IgG1) Fc domain. See WO2019 / 057122. In some embodiments, the anti-CD47-binding domain comprises an antigen-binding fragment (Fab) domain. In some embodiments, the anti-CD47-binding domain comprises a single-chain variable fragment (scFv) domain.

[0394] In some embodiments of multispecific antibodies comprising a CD47-binding domain and an EpCAM-binding domain, the anti-EpCAM-binding domain comprises a VH-EpCAM domain and a VL-EpCAM domain, wherein the VH-EpCAM domain is fused to the TCR β constant domain of the anti-EpCAM-binding domain, and the VL-EpCAM domain is fused to the TCR α constant domain of the anti-EpCAM-binding domain. In some embodiments, the anti-EpCAM-binding domain comprises a VH-EpCAM domain and a VL-EpCAM domain, wherein the VH-EpCAM domain is fused to the CH1 IgG domain of the anti-EpCAM-binding domain, and the VL-EpCAM domain is fused to the CL IgG domain of the anti-EpCAM-binding domain. In some embodiments, the anti-CD47-binding domain comprises an antigen-binding fragment (Fab) domain. In some embodiments, the anti-CD47-binding domain comprises a single-chain variable fragment (scFv) domain.

[0395] In some embodiments relating to multispecific antibodies comprising a CD47-binding domain and an EpCAM-binding domain, the multispecific antibody comprises one or more sequences (e.g., two or more, or three) each having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the corresponding sequences set forth in Table 28.

[0396] In some embodiments relating to a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain, the multispecific antibody comprises a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:488 and at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:489. 97%, 98%, or 99% identity to SEQ ID NO:490; and sequences having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:490; and sequences having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:491.

[0397] [Table 28]

[0398] In some embodiments relating to multispecific antibodies comprising a CD47-binding domain and an EpCAM-binding domain, the multispecific antibody comprises one or more sequences (e.g., two or more, or three) each having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the corresponding sequences set forth in Table 29.

[0399] In some embodiments relating to a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain, the multispecific antibody comprises a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 492 and at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 493. 97%, 98%, or 99% identity to SEQ ID NO:494; and sequences having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:495.

[0400] [Table 29]

[0401] In some embodiments relating to multispecific antibodies comprising a CD47-binding domain and an EpCAM-binding domain, the multispecific antibody comprises one or more sequences (e.g., two or more, or three) each having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the corresponding sequences set forth in Table 30.

[0402] In some embodiments relating to a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain, the multispecific antibody comprises a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 503 and at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 504. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:505, and sequences having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:505.

[0403] [Table 30]

[0404] In some embodiments relating to multispecific antibodies comprising a CD47-binding domain and an EpCAM-binding domain, the multispecific antibody comprises one or more sequences (e.g., two or more, or three) each having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the corresponding sequences set forth in Table 31.

[0405] In some embodiments relating to a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain, the multispecific antibody comprises a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 482 and at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 483. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:506, and sequences having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:506.

[0406] [Table 31]

[0407] In some embodiments relating to multispecific antibodies comprising a CD47-binding domain and an EpCAM-binding domain, the multispecific antibody comprises one or more sequences (e.g., two or more, or three) each having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the corresponding sequences set forth in Table 32.

[0408] In some embodiments relating to a multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain, the multispecific antibody comprises a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 482 and at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 483. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:507, and sequences having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:507.

[0409] [Table 32]

[0410] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain, the multispecific antibody has a higher affinity for CD47 expressed on the surface of tumor cells than for CD47 expressed on the surface of normal cells, such as erythrocytes, platelets, T cells, B cells, or NK cells. In some embodiments, the tumor cells express EGFR. In some embodiments, the concentration of the multispecific antibody required for half-maximal binding to (e.g., human) erythrocytes is greater than about 500 nanomolar (nM). In some embodiments, the multispecific antibody binds to (e.g., human) CD47 with a dissociation constant (KD) of less than about 100 nanomolar (nM). In some embodiments, the multispecific antibody binds to (e.g., human) CD47 with a dissociation constant (KD) of about 1 nanomolar (nM) to about 100 nM, about 1 nM to about 50 nM, or about 5 nM to about 50 nM. In some embodiments, the dissociation constant (KD) is determined by surface plasmon resonance. In some embodiments, the multispecific antibody binds to EGFR with a dissociation constant (KD) of less than about 25 nanomolar (nM). In some embodiments, the multispecific antibody binds to EGFR with a dissociation constant (KD) of about 0.2 nanomolar (nM) to about 25 nM, about 0.2 nM to about 10 nM, about 0.2 nM to about 2 nM, or about 2 nM to about 10 nM. In some embodiments, the dissociation constant (KD) is determined by surface plasmon resonance. In some embodiments, a multispecific antibody of less than about 1 nanomolar (nM) or less than about 0.01 nM increases the percentage of A431 cells phagocytosed by macrophages by at least four-fold compared to a nonspecific IgG1 antibody control.

[0411] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain, the concentration of antibody required to mediate antibody-dependent cellular phagocytosis of EGFR-positive, CD47-positive tumor cells by macrophages is about 0.01 nanomolar (nM) to about 3 nM. In some embodiments, the EGFR-positive, CD47-positive tumor cells are OVISE cells or A431 cells. In some embodiments, the EGFR-positive, CD47-positive tumor cells are selected from epidermoid carcinoma cells, colorectal adenocarcinoma cells, head and neck squamous cell carcinoma cells, bladder cancer cells, pancreatic adenocarcinoma cells, lung squamous cell carcinoma cells, lung adenocarcinoma cells, renal cell carcinoma cells, esophageal cancer cells, or gastric cancer cells. In some embodiments, about 100 nanomolar (nM) of the multispecific antibody inhibits binding of SIRPα to CD47 on the surface of the cells by at least about 30%. In some embodiments, the cells are CD47+EGFR+ tumor cells. In some embodiments, the cells express at least as many EGFR proteins on their surface as HCC-44 cells. In some embodiments, the cells express at least 50,000, at least 100,000, at least 300,000, at least 600,000, or at least 1,500,000 EGFR proteins on their surface. In some embodiments, about 400 nanomolar (nM) of the multispecific antibody does not induce hemolysis of red blood cells in a hemagglutination assay.

[0412] In some embodiments relating to multispecific antibodies comprising a CD47-binding domain and an EGFR-binding domain, the multispecific antibody comprises one or more (e.g., two or more, or three) sequences each having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the corresponding sequences set forth in Table 33.

[0413] In some embodiments relating to a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain, the multispecific antibody comprises a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:496 and a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:497. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:498, and sequences having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:498.

[0414] In some embodiments relating to multispecific antibodies comprising a CD47-binding domain and an EGFR-binding domain, the multispecific (e.g., bispecific) antibodies and binding fragments thereof comprise a heavy chain variable fragment (VH) of the anti-CD47-binding domain fused to a first T cell receptor (TCR) constant region and a light chain variable fragment (VL) of the anti-CD47-binding domain fused to a second TCR constant region, wherein the first and second TCR constant regions are capable of dimerization. In some embodiments, the TCR constant regions are TCRα and TCRβ constant regions. In some embodiments, the anti-CD47VH-TCR fusion polypeptide is fused to a human IgG (e.g., IgG1) Fc domain. See WO2019 / 057122. In some embodiments, the anti-EGFR-binding domain comprises an antigen-binding fragment (Fab) domain. In some embodiments, the anti-EGFR-binding domain comprises a single-chain variable fragment (scFv) domain.

[0415] In some embodiments of multispecific antibodies comprising a CD47-binding domain and an EGFR-binding domain, the anti-CD47 binding domain comprises a VH-CD47 domain and a VL-CD47 domain, wherein the VH-CD47 domain is fused to a TCR β constant domain and the VL-CD47 domain is fused to a TCR α constant domain. In some embodiments, the anti-CD47 binding domain comprises a VH-CD47 domain and a VL-CD47 domain, wherein the VH-CD47 domain is fused to a CH1 IgG domain and the VL-CD47 domain is fused to a CL IgG domain. In some embodiments, the anti-EGFR binding domain comprises an antigen-binding fragment (Fab) domain. In some embodiments, the anti-EGFR binding domain comprises a single-chain variable fragment (scFv) domain.

[0416] In some embodiments relating to multispecific antibodies comprising a CD47-binding domain and an EGFR-binding domain, the multispecific (e.g., bispecific) antibodies and binding fragments thereof comprise a heavy chain variable fragment (VH) of the anti-EGFR-binding domain fused to a first T cell receptor (TCR) constant region and a light chain variable domain (VL) of the anti-EGFR-binding domain fused to a second TCR constant region, wherein the first and second TCR constant regions are capable of dimerization. In some embodiments, the TCR constant regions are TCRα and TCRβ constant regions. In some embodiments, the anti-EGFR VH-TCR fusion polypeptide is fused to a human IgG (e.g., IgG1) Fc domain. See WO2019 / 057122. In some embodiments, the anti-CD47-binding domain comprises an antigen-binding fragment (Fab) domain. In some embodiments, the anti-CD47-binding domain comprises a single-chain variable fragment (scFv) domain.

[0417] In some embodiments of a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain, the anti-EGFR binding domain comprises a VH-EGFR domain and a VL-EGFR domain, wherein the VH-EGFR domain is fused to the TCR β constant domain of the anti-EGFR binding domain and the VL-EGFR domain is fused to the TCR α constant domain of the anti-EGFR binding domain. In some embodiments, the anti-EGFR binding domain comprises a VH-EGFR domain and a VL-EGFR domain, wherein the VH-EGFR domain is fused to the CH1 IgG domain of the anti-EGFR binding domain and the VL-EGFR domain is fused to the CL IgG domain of the anti-EGFR binding domain. In some embodiments, the anti-CD47 binding domain comprises an antigen-binding fragment (Fab) domain. In some embodiments, the anti-CD47 binding domain comprises a single-chain variable fragment (scFv) domain.

[0418] In some embodiments relating to a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain, the multispecific antibody comprises one or more (e.g., two or more, three or more, or four) sequences having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 34.

[0419] In some embodiments relating to a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain, the multispecific antibody comprises a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 499 and at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 500. 97%, 98%, or 99% identity to SEQ ID NO:501; and sequences having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:502.

[0420] In some embodiments relating to a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain, the multispecific antibody comprises one or more (e.g., two or more, three or more, or four) sequences having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 35.

[0421] In some embodiments relating to a multispecific antibody comprising a CD47-binding domain and an EGFR-binding domain, the multispecific antibody comprises a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 508 and at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 509. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:510, and sequences having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:510.

[0422] [Table 33]

[0423] [Table 34]

[0424] [Table 35]

[0425] In some embodiments, multispecific (e.g., bispecific) antibodies, and binding fragments thereof, are derived from non-human (e.g., rabbit or mouse) antibodies. In some examples, humanized forms of non-human antibodies contain minimal non-human sequences to maintain the original antigen specificity. In some cases, humanized antibodies are human immunoglobulins (acceptor antibodies) in which the CDRs of the acceptor antibody are replaced by residues from the CDRs of a non-human immunoglobulin (donor antibody), such as a rat, rabbit, or mouse donor, having the desired specificity, affinity, avidity, binding kinetics, and / or capacity. In some cases, one or more framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues from the donor antibody.

[0426] Multispecific antibodies that bind to target cells In some embodiments, multispecific (e.g., bispecific) antibodies of the present disclosure comprising a first component that binds CD47 and a second component that binds EpCAM bind (e.g., preferentially bind) to cells expressing the target antigen of the multispecific (e.g., bispecific) protein on their surface with at least 2-50 fold, 10-100 fold, 2 fold, 5 fold, 10 fold, 25 fold, 50 fold, or 100 fold, or 20-50%, 50-100%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% or more greater affinity than the binding affinity of an antibody that is bivalent for only one of CD47 or EpCAM to the cells.

[0427] In some embodiments, the multispecific (e.g., bispecific) proteins provided herein bind to target cells that express higher levels of EpCAM than CD47 on their surface, e.g., the ratio of EpCAM to CD47 protein expression on the target cell surface is about 1, 1.5, 2.0, 2.5, 5, 10, 15, 20, 25, 50, 100, or greater than 200, as measured by flow cytometry.

[0428] In some embodiments, the multispecific (e.g., bispecific) proteins provided herein bind to target cells that express higher levels of CD47 than EpCAM on their surface, e.g., the ratio of CD47 to EpCAM protein expression on the target cell surface is about 1, 1.5, 2.0, 2.5, 5, 10, 15, 20, 50, 100, or greater than 200, as measured by flow cytometry.

[0429] In some embodiments, the multispecific (e.g., bispecific) proteins provided herein bind to target cells that express equal levels of CD47 and EpCAM on their surface, e.g., the ratio of CD47 to EpCAM protein expression on the target cell surface is about 1, as measured by flow cytometry.

[0430] In some cases, the cells express between about 35,000 CD47 proteins and about 250,000 CD47 proteins. In some cases, the cells express at least about 35,000 CD47 proteins. In some cases, the cells express up to about 250,000 CD47 proteins. In some cases, the cells express between about 35,000 CD47 proteins and about 40,000 CD47 proteins, between about 35,000 CD47 proteins and about 45,000 CD47 proteins, between about 35,000 CD47 proteins and about 60,000 CD47 proteins, between about 35,000 CD47 proteins and about 100,000 CD47 proteins, between about 35,000 CD47 proteins and about 150,000 CD47 proteins, between about 35,0 00 CD47 proteins to about 250,000 CD47 proteins, about 40,000 CD47 proteins to about 45,000 CD47 proteins, about 40,000 CD47 proteins to about 60,000 CD47 proteins, about 40,000 CD47 proteins to about 120,000 CD47 proteins, about 40,000 CD47 proteins to about 150,000 CD47 proteins, about 40,000 CD47 proteins to about 2 50,000 CD47 proteins, approximately 45,000 CD47 proteins to approximately 60,000 CD47 proteins, approximately 45,000 CD47 proteins to approximately 120,000 CD47 proteins, approximately 45,000 CD47 proteins to approximately 150,000 CD47 proteins, approximately 45,000 CD47 proteins to approximately 250,000 CD47 proteins, approximately 60,000 CD47 proteins to approximately 120,000 CD47 proteins The CD47 proteins express about 60,000 to about 150,000 CD47 proteins, about 60,000 to about 250,000 CD47 proteins, about 120,000 to about 150,000 CD47 proteins, about 120,000 to about 250,000 CD47 proteins, or about 150,000 to about 250,000 CD47 proteins.In some cases, the CD47 protein is expressed on the surface of the cell. In some cases, the cell is a tumor cell. In some cases, the cell is derived from ductal pancreatic adenocarcinoma, ovarian clear cell adenocarcinoma, colon adenocarcinoma, lung adenocarcinoma, lung squamous cell carcinoma, small cell lung carcinoma, hepatocellular carcinoma, gastric adenocarcinoma, esophageal carcinoma, cholangiocarcinoma, head and neck squamous cell carcinoma, prostate cancer, endometrial cancer, ovarian adenocarcinoma, or vulvar squamous cell carcinoma. In some cases, the number of CD47 proteins expressed on the cell is measured by flow cytometry. In some cases, the number of CD47 proteins expressed on the cell is measured by quantitative flow cytometry.

[0431] In some cases, cells contain between about 35,000 EpCAM proteins and about 2x10 7 EpCAM proteins. In some cases, the cells express at least about 35,000 EpCAM proteins. In some cases, the cells express at most about 2x10 7 In some cases, the cells express between about 35,000 EpCAM proteins and about 85,000 EpCAM proteins, between about 35,000 EpCAM proteins and about 170,000 EpCAM proteins, between about 35,000 EpCAM proteins and about 300,000 EpCAM proteins, between about 35,000 EpCAM proteins and about 400,000 EpCAM proteins, between about 35,000 EpCAM proteins and about 650,000 EpCAM proteins, between about 35,000 EpCAM proteins and about 750,000 EpCAM proteins, between about 35,000 EpCAM proteins and about 1,500,000 EpCAM proteins, between about 35,000 EpCAM proteins and about 1,900,000 EpCAM proteins, between about 35,000 EpCAM proteins and about 4x10 EpCAM proteins. 6 EpCAM proteins, approximately 35,000 EpCAM proteins ~ approximately 6x10 6 EpCAM proteins, approximately 35,000 EpCAM proteins ~ approximately 7x10 6 EpCAM proteins, approximately 35,000 EpCAM proteins ~ approximately 15x10 6EpCAM proteins, approximately 35,000 EpCAM proteins ~ approximately 2 x 10 7 EpCAM proteins, about 85,000 EpCAM proteins to about 170,000 EpCAM proteins, about 85,000 EpCAM proteins to about 300,000 EpCAM proteins, about 85,000 EpCAM proteins to about 400,000 EpCAM proteins, about 85,000 EpCAM proteins to about 650,000 EpCAM proteins, about 85,000 EpCAM proteins to about 750,000 EpCAM proteins, about 85,000 EpCAM proteins to about 1,500,000 EpCAM proteins, about 85,000 EpCAM proteins to about 1,900,000 EpCAM proteins, about 85,000 EpCAM proteins to about 4x10 6 EpCAM proteins, approximately 85,000 EpCAM proteins ~ approximately 6x10 6 EpCAM proteins, approximately 85,000 EpCAM proteins ~ approximately 7x10 6 EpCAM proteins, approximately 85,000 EpCAM proteins ~ approximately 15x10 6 EpCAM protein, approximately 85,000 EpCAM protein ~ approximately 2 x 10 7 EpCAM proteins, about 170,000 EpCAM proteins to about 300,000 EpCAM proteins, about 170,000 EpCAM proteins to about 400,000 EpCAM proteins, about 170,000 EpCAM proteins to about 650,000 EpCAM proteins, about 170,000 EpCAM proteins to about 750,000 EpCAM proteins, about 170,000 EpCAM proteins to about 1,500,000 EpCAM proteins, about 170,000 EpCAM proteins to about 1,900,000 EpCAM proteins, about 170,000 EpCAM proteins to about 4x10 6 EpCAM proteins, approximately 170,000 EpCAM proteins ~ approximately 6x10 6 EpCAM proteins, approximately 170,000 EpCAM proteins ~ approximately 7x106 EpCAM proteins, approximately 170,000 EpCAM proteins ~ approximately 15x10 6 EpCAM proteins, approximately 170,000 EpCAM proteins ~ approximately 2 x 10 7 EpCAM proteins, about 300,000 EpCAM proteins to about 400,000 EpCAM proteins, about 300,000 EpCAM proteins to about 650,000 EpCAM proteins, about 300,000 EpCAM proteins to about 750,000 EpCAM proteins, about 300,000 EpCAM proteins to about 1,500,000 EpCAM proteins, about 300,000 EpCAM proteins to about 1,900,000 EpCAM proteins, about 300,000 EpCAM proteins to about 4x10 6 EpCAM proteins, approximately 300,000 EpCAM proteins ~ approximately 6x10 6 EpCAM proteins, approximately 300,000 EpCAM proteins ~ approximately 7x10 6 EpCAM proteins, approximately 300,000 EpCAM proteins ~ approximately 15x10 6 EpCAM proteins, approximately 300,000 EpCAM proteins ~ approximately 2 x 10 7 EpCAM proteins, about 400,000 EpCAM proteins to about 650,000 EpCAM proteins, about 400,000 EpCAM proteins to about 750,000 EpCAM proteins, about 400,000 EpCAM proteins to about 1,500,000 EpCAM proteins, about 400,000 EpCAM proteins to about 1,900,000 EpCAM proteins, about 400,000 EpCAM proteins to about 4x10 6 EpCAM proteins, approximately 400,000 EpCAM proteins ~ approximately 6x10 6 EpCAM proteins, approximately 400,000 EpCAM proteins ~ approximately 7x10 6 EpCAM proteins, approximately 400,000 EpCAM proteins ~ approximately 15x10 6EpCAM proteins, approximately 400,000 EpCAM proteins ~ approximately 2 x 10 7 EpCAM proteins, about 650,000 EpCAM proteins to about 750,000 EpCAM proteins, about 650,000 EpCAM proteins to about 1,500,000 EpCAM proteins, about 650,000 EpCAM proteins to about 1,900,000 EpCAM proteins, about 650,000 EpCAM proteins to about 4x10 6 EpCAM proteins, approximately 650,000 EpCAM proteins ~ approximately 6x10 6 EpCAM proteins, approximately 650,000 EpCAM proteins ~ approximately 7x10 6 EpCAM proteins, approximately 650,000 EpCAM proteins ~ approximately 15x10 6 EpCAM proteins, approximately 650,000 EpCAM proteins ~ approximately 2 x 10 7 EpCAM proteins, about 750,000 EpCAM proteins to about 1,500,000 EpCAM proteins, about 750,000 EpCAM proteins to about 1,900,000 EpCAM proteins, about 750,000 EpCAM proteins to about 4x10 6 EpCAM proteins, approximately 750,000 EpCAM proteins ~ approximately 6x10 6 EpCAM proteins, approximately 750,000 EpCAM proteins ~ approximately 7x10 6 EpCAM proteins, approximately 750,000 EpCAM proteins ~ approximately 15x10 6 EpCAM proteins, approximately 750,000 EpCAM proteins ~ approximately 2 x 10 7 EpCAM proteins, about 1,500,000 EpCAM proteins to about 1,900,000 EpCAM proteins, about 1,500,000 EpCAM proteins to about 4x10 6 EpCAM proteins, approximately 1,500,000 EpCAM proteins ~ approximately 6x10 6 EpCAM proteins, approximately 1,500,000 EpCAM proteins ~ approximately 7x10 6EpCAM proteins, approximately 1,500,000 EpCAM proteins ~ approximately 15x10 6 EpCAM proteins, approximately 1,500,000 EpCAM proteins ~ approximately 2 x 10 7 EpCAM proteins, approximately 1,900,000 EpCAM proteins ~ approximately 4x10 6 EpCAM proteins, approximately 1,900,000 EpCAM proteins ~ approximately 6x10 6 EpCAM proteins, approximately 1,900,000 EpCAM proteins ~ approximately 7x10 6 EpCAM proteins, approximately 1,900,000 EpCAM proteins ~ approximately 15x10 6 EpCAM proteins, approximately 1,900,000 EpCAM proteins ~ approximately 2 x 10 7 EpCAM protein, approximately 4x10 6 EpCAM protein ~approximately 6x10 6 EpCAM protein, approximately 4x10 6 EpCAM protein ~approximately 7x10 6 EpCAM protein, approximately 4x10 6 EpCAM protein ~approximately 15x10 6 EpCAM protein, approximately 4x10 6 EpCAM protein ~ approximately 2 x 10 7 EpCAM protein, approximately 6x10 6 EpCAM protein ~approximately 7x10 6 EpCAM protein, approximately 6x10 6 EpCAM protein ~approximately 15x10 6 EpCAM protein, approximately 6x10 6 EpCAM protein ~ approximately 2 x 10 7 of EpCAM protein, or approximately 15x10 6 EpCAM protein ~ approximately 2 x 10 7The cell expresses EpCAM proteins. In some cases, the EpCAM protein is expressed on the surface of the cell. In some cases, the cell is a tumor cell. In some cases, the cell is derived from ductal pancreatic adenocarcinoma, ovarian clear cell adenocarcinoma, colon adenocarcinoma, lung adenocarcinoma, lung squamous cell carcinoma, small cell lung carcinoma, hepatocellular carcinoma, gastric adenocarcinoma, bile duct carcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, prostate cancer, endometrial carcinoma, ovarian adenocarcinoma, or vulvar squamous cell carcinoma. In some cases, the number of EpCAM proteins expressed on the cell is measured by flow cytometry. In some cases, the number of EpCAM proteins expressed on the cell is measured by quantitative flow cytometry.

[0432] In some embodiments, a multispecific (e.g., bispecific) protein having a CD47-binding domain and an EpCAM-binding domain has enhanced affinity for cells expressing CD47 and EpCAM compared to a bivalent protein having one or more CD47-binding domains and / or a bivalent protein having one or more EpCAM-binding domains. In some examples, a multispecific (e.g., bispecific) protein has 1.5, 2, 3, 4, 5, or 10-fold higher affinity for CD47-expressing cells than a bivalent protein that binds CD47 or a bivalent protein that binds EpCAM. In some embodiments, a multispecific (e.g., bispecific) protein having a CD47-binding domain and an EpCAM-binding domain has enhanced affinity for cells expressing higher levels of CD47 than EpCAM compared to a bivalent protein having a CD47-binding domain. In some examples, a multispecific (e.g., bispecific) protein has 1.5, 2, 3, 4, 5, or 10-fold higher affinity for cells that have higher EpCAM expression than CD47 expression compared to a bivalent protein that binds CD47.

[0433] In some embodiments, a multispecific (e.g., bispecific) antibody having a CD47-binding domain and an EpCAM-binding domain has reduced red blood cell (RBC) binding compared to CD47 BMK-1 or CD47 BMK-2 (such as those described herein). In some cases, the reduction in RBC binding is at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100% compared to CD47 BMK-1. In some cases, the reduction in RBC binding is at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100% compared to CD47 BMK-2.

[0434] In some embodiments, multispecific (e.g., bispecific) antibodies of the present disclosure comprising a first component that binds CD47 and a second component that binds EGFR bind (e.g., preferentially bind) to cells expressing the target antigen of the multispecific (e.g., bispecific) protein on their surface with at least 2-50 fold, 10-100 fold, 2 fold, 5 fold, 10 fold, 25 fold, 50 fold, or 100 fold, or 20-50%, 50-100%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% or more greater affinity than the binding affinity of an antibody that is bivalent for only CD47 or EGFR to the cells.

[0435] In some embodiments, the multispecific (e.g., bispecific) proteins provided herein bind to target cells that express higher levels of EGFR than CD47 on their surface, e.g., the ratio of EGFR to CD47 protein expression on the target cell surface is greater than about 1, 1.5, 2.0, 2.5, 5, 10, 15, 20, 25, 50, 100, or 200, as measured by flow cytometry.

[0436] In some embodiments, the multispecific (e.g., bispecific) proteins provided herein bind to target cells that express higher levels of CD47 than EGFR on their surface, e.g., the ratio of CD47 to EGFR protein expression on the target cell surface is about 1, 1.5, 2.0, 2.5, 5, 10, 15, 20, 50, 100, or greater than 200, as measured by flow cytometry.

[0437] In some embodiments, the multispecific (e.g., bispecific) proteins provided herein bind to target cells that express equal levels of CD47 and EGFR on their surface, e.g., the ratio of CD47 to EGFR protein expression on the target cell surface is about 1, as measured by flow cytometry.

[0438] In some cases, the cells express between about 35,000 CD47 proteins and about 250,000 CD47 proteins. In some cases, the cells express at least about 35,000 CD47 proteins. In some cases, the cells express up to about 250,000 CD47 proteins. In some cases, the cells express between about 35,000 CD47 proteins and about 40,000 CD47 proteins, between about 35,000 CD47 proteins and about 45,000 CD47 proteins, between about 35,000 CD47 proteins and about 60,000 CD47 proteins, between about 35,000 CD47 proteins and about 100,000 CD47 proteins, between about 35,000 CD47 proteins and about 150,000 CD47 proteins, between about 35,0 00 CD47 proteins to about 250,000 CD47 proteins, about 40,000 CD47 proteins to about 45,000 CD47 proteins, about 40,000 CD47 proteins to about 60,000 CD47 proteins, about 40,000 CD47 proteins to about 120,000 CD47 proteins, about 40,000 CD47 proteins to about 150,000 CD47 proteins, about 40,000 CD47 proteins to about 2 50,000 CD47 proteins, approximately 45,000 CD47 proteins to approximately 60,000 CD47 proteins, approximately 45,000 CD47 proteins to approximately 120,000 CD47 proteins, approximately 45,000 CD47 proteins to approximately 150,000 CD47 proteins, approximately 45,000 CD47 proteins to approximately 250,000 CD47 proteins, approximately 60,000 CD47 proteins to approximately 120,000 CD47 proteins The CD47 proteins express about 60,000 to about 150,000 CD47 proteins, about 60,000 to about 250,000 CD47 proteins, about 120,000 to about 150,000 CD47 proteins, about 120,000 to about 250,000 CD47 proteins, or about 150,000 to about 250,000 CD47 proteins.In some cases, the CD47 protein is expressed on the surface of the cell. In some cases, the cell is a tumor cell. In some cases, the cell is derived from ductal pancreatic adenocarcinoma, ovarian clear cell adenocarcinoma, colon adenocarcinoma, lung adenocarcinoma, lung squamous cell carcinoma, small cell lung carcinoma, hepatocellular carcinoma, gastric adenocarcinoma, esophageal carcinoma, cholangiocarcinoma, head and neck squamous cell carcinoma, prostate cancer, endometrial carcinoma, ovarian adenocarcinoma, or vulvar squamous cell carcinoma. In some cases, the number of CD47 proteins expressed on the cell is measured by flow cytometry. In some cases, the number of CD47 proteins expressed on the cell is measured by quantitative flow cytometry.

[0439] In some cases, the cells contain between about 35,000 EGFR proteins and about 2x10 7 EGFR proteins. In some cases, the cells express at least about 35,000 EGFR proteins. In some cases, the cells express at most about 2x10 7 In some cases, the cells express between about 35,000 EGFR proteins and about 85,000 EGFR proteins, between about 35,000 EGFR proteins and about 170,000 EGFR proteins, between about 35,000 EGFR proteins and about 300,000 EGFR proteins, between about 35,000 EGFR proteins and about 400,000 EGFR proteins, between about 35,000 EGFR proteins and about 650,000 EGFR proteins, between about 35,000 EGFR proteins and about 750,000 EGFR proteins, between about 35,000 EGFR proteins and about 1,500,000 EGFR proteins, between about 35,000 EGFR proteins and about 1,900,000 EGFR proteins, between about 35,000 EGFR proteins and about 4x10 EGFR proteins. 6 EGFR proteins, approximately 35,000 EGFR proteins ~ approximately 6x10 6 EGFR proteins, approximately 35,000 EGFR proteins ~ approximately 7x10 6 EGFR proteins, approximately 35,000 EGFR proteins ~ approximately 15x10 6EGFR proteins, approximately 35,000 EGFR proteins ~ approximately 2 x 10 7 EGFR proteins, about 85,000 EGFR proteins to about 170,000 EGFR proteins, about 85,000 EGFR proteins to about 300,000 EGFR proteins, about 85,000 EGFR proteins to about 400,000 EGFR proteins, about 85,000 EGFR proteins to about 650,000 EGFR proteins, about 85,000 EGFR proteins to about 750,000 EGFR proteins, about 85,000 EGFR proteins to about 1,500,000 EGFR proteins, about 85,000 EGFR proteins to about 1,900,000 EGFR proteins, about 85,000 EGFR proteins to about 4x10 6 EGFR proteins, approximately 85,000 EGFR proteins ~ approximately 6x10 6 EGFR proteins, approximately 85,000 EGFR proteins ~ approximately 7x10 6 EGFR proteins, approximately 85,000 EGFR proteins ~ approximately 15x10 6 EGFR protein, approximately 85,000 EGFR protein ~ approximately 2 x 10 7 EGFR proteins, about 170,000 EGFR proteins to about 300,000 EGFR proteins, about 170,000 EGFR proteins to about 400,000 EGFR proteins, about 170,000 EGFR proteins to about 650,000 EGFR proteins, about 170,000 EGFR proteins to about 750,000 EGFR proteins, about 170,000 EGFR proteins to about 1,500,000 EGFR proteins, about 170,000 EGFR proteins to about 1,900,000 EGFR proteins, about 170,000 EGFR proteins to about 4x10 6 EGFR proteins, approximately 170,000 EGFR proteins ~ approximately 6x10 6 EGFR proteins, approximately 170,000 EGFR proteins ~ approximately 7x10 6EGFR proteins, approximately 170,000 EGFR proteins ~ approximately 15x10 6 EGFR proteins, approximately 170,000 EGFR proteins ~ approximately 2 x 10 7 EGFR proteins, about 300,000 EGFR proteins to about 400,000 EGFR proteins, about 300,000 EGFR proteins to about 650,000 EGFR proteins, about 300,000 EGFR proteins to about 750,000 EGFR proteins, about 300,000 EGFR proteins to about 1,500,000 EGFR proteins, about 300,000 EGFR proteins to about 1,900,000 EGFR proteins, about 300,000 EGFR proteins to about 4x10 6 EGFR proteins, approximately 300,000 EGFR proteins ~ approximately 6x10 6 EGFR proteins, approximately 300,000 EGFR proteins ~ approximately 7x10 6 EGFR proteins, approximately 300,000 EGFR proteins ~ approximately 15x10 6 EGFR proteins, approximately 300,000 EGFR proteins ~ approximately 2 x 10 7 EGFR proteins, about 400,000 EGFR proteins to about 650,000 EGFR proteins, about 400,000 EGFR proteins to about 750,000 EGFR proteins, about 400,000 EGFR proteins to about 1,500,000 EGFR proteins, about 400,000 EGFR proteins to about 1,900,000 EGFR proteins, about 400,000 EGFR proteins to about 4x10 6 EGFR proteins, approximately 400,000 EGFR proteins ~ approximately 6x10 6 EGFR proteins, approximately 400,000 EGFR proteins ~ approximately 7x10 6 EGFR proteins, approximately 400,000 EGFR proteins ~ approximately 15x10 6 EGFR proteins, approximately 400,000 EGFR proteins ~ approximately 2 x 10 7EGFR proteins, about 650,000 EGFR proteins to about 750,000 EGFR proteins, about 650,000 EGFR proteins to about 1,500,000 EGFR proteins, about 650,000 EGFR proteins to about 1,900,000 EGFR proteins, about 650,000 EGFR proteins to about 4x10 6 EGFR proteins, approximately 650,000 EGFR proteins ~ approximately 6x10 6 EGFR proteins, approximately 650,000 EGFR proteins ~ approximately 7x10 6 EGFR proteins, approximately 650,000 EGFR proteins ~ approximately 15x10 6 EGFR proteins, approximately 650,000 EGFR proteins ~ approximately 2 x 10 7 EGFR proteins, about 750,000 EGFR proteins to about 1,500,000 EGFR proteins, about 750,000 EGFR proteins to about 1,900,000 EGFR proteins, about 750,000 EGFR proteins to about 4x10 6 EGFR proteins, approximately 750,000 EGFR proteins ~ approximately 6x10 6 EGFR proteins, approximately 750,000 EGFR proteins ~ approximately 7x10 6 EGFR proteins, approximately 750,000 EGFR proteins ~ approximately 15x10 6 EGFR proteins, approximately 750,000 EGFR proteins ~ approximately 2 x 10 7 EGFR proteins, about 1,500,000 EGFR proteins to about 1,900,000 EGFR proteins, about 1,500,000 EGFR proteins to about 4x10 6 EGFR proteins, approximately 1,500,000 EGFR proteins ~ approximately 6x10 6 EGFR proteins, approximately 1,500,000 EGFR proteins ~ approximately 7x10 6 EGFR proteins, approximately 1,500,000 EGFR proteins ~ approximately 15x10 6EGFR proteins, approximately 1,500,000 EGFR proteins ~ approximately 2 x 10 7 EGFR proteins, approximately 1,900,000 EGFR proteins ~ approximately 4x10 6 EGFR proteins, approximately 1,900,000 EGFR proteins ~ approximately 6x10 6 EGFR proteins, approximately 1,900,000 EGFR proteins ~ approximately 7x10 6 EGFR proteins, approximately 1,900,000 EGFR proteins ~ approximately 15x10 6 EGFR proteins, approximately 1,900,000 EGFR proteins ~ approximately 2 x 10 7 EGFR protein, approximately 4x10 6 EGFR protein ~ approximately 6 x 10 6 EGFR protein, approximately 4x10 6 EGFR protein ~approximately 7x10 6 EGFR protein, approximately 4x10 6 EGFR protein ~ approximately 15 x 10 6 EGFR protein, approximately 4x10 6 EGFR protein ~ approximately 2 x 10 7 EGFR protein, approximately 6x10 6 EGFR protein ~approximately 7x10 6 EGFR protein, approximately 6x10 6 EGFR protein ~ approximately 15 x 10 6 EGFR protein, approximately 6x10 6 EGFR protein ~ approximately 2 x 10 7 of EGFR protein, or approximately 15x10 6 EGFR protein ~ approximately 2 x 10 7The cell expresses EGFR proteins. In some cases, the EGFR proteins are expressed on the surface of the cell. In some cases, the cell is a tumor cell. In some cases, the cell is derived from ductal pancreatic adenocarcinoma, ovarian clear cell adenocarcinoma, colon adenocarcinoma, lung adenocarcinoma, lung squamous cell carcinoma, small cell lung carcinoma, hepatocellular carcinoma, gastric adenocarcinoma, esophageal carcinoma, cholangiocarcinoma, head and neck squamous cell carcinoma, prostate cancer, endometrial cancer, ovarian adenocarcinoma, or vulvar squamous cell carcinoma. In some cases, the number of EGFR proteins expressed on the cell is measured by flow cytometry. In some cases, the number of EGFR proteins expressed on the cell is measured by quantitative flow cytometry.

[0440] In some embodiments, a multispecific (e.g., bispecific) protein having a CD47-binding domain and an EGFR-binding domain has enhanced affinity for cells expressing CD47 and EGFR compared to a bivalent protein having one or more CD47-binding domains and / or a bivalent protein having one or more EGFR-binding domains. In some examples, a multispecific (e.g., bispecific) protein has 1.5-, 2-, 3-, 4-, 5-, or 10-fold higher affinity for CD47-expressing cells than a bivalent protein that binds CD47 or a bivalent protein that binds EGFR. In some embodiments, a multispecific (e.g., bispecific) protein having a CD47-binding domain and an EGFR-binding domain has enhanced affinity for cells expressing higher levels of CD47 than EGFR compared to a bivalent protein having a CD47-binding domain. In some examples, a multispecific (e.g., bispecific) protein has 1.5-, 2-, 3-, 4-, 5-, or 10-fold higher affinity for cells having higher EGFR expression than CD47 expression compared to a bivalent protein that binds CD47.

[0441] In some embodiments, a multispecific (e.g., bispecific) antibody having a CD47-binding domain and an EGFR-binding domain has reduced red blood cell (RBC) binding compared to CD47 BMK-1 or CD47 BMK-2 (such as those described herein). In some cases, the reduced RBC binding is at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100% reduced compared to CD47 BMK-1. In some cases, the reduced RBC binding is at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100% reduced compared to CD47 BMK-2.

[0442] Immunological activity of polyspecific antibodies on target cells In some embodiments, a multispecific antibody having a CD47-binding domain and an EpCAM-binding domain has higher immunoreactivity against CD47-expressing cells than a bivalent antibody having a CD47-binding domain and / or a bivalent antibody having an EpCAM-binding domain. In some examples, the multispecific antibody has 1.5, 2, 3, 4, 5, or 10 times higher immunoreactivity than a bivalent antibody having a CD47-binding domain and / or a bivalent antibody having an EpCAM-binding domain. The various immunoreactivity of a multispecific antibody can be measured by in vitro assays such as ADCC assays and ADCP assays. In some examples, the multispecific antibody has 1.5, 2, 3, 4, 5, or 10 times higher ADCC activity than a bivalent antibody having a CD47-binding domain and / or a bivalent antibody having an EpCAM-binding domain. In some examples, the multispecific antibody has 1.5, 2, 3, 4, 5, or 10 times higher ADCP activity than a bivalent antibody having a CD47-binding domain and / or a bivalent antibody having an EpCAM-binding domain.

[0443] In some embodiments, a multispecific antibody having a CD47-binding domain and an EpCAM-binding domain has higher immunoreactivity against CD47-expressing cells than a bivalent antibody having a CD47-binding domain and / or a bivalent antibody having an EpCAM-binding domain. In some examples, the multispecific antibody has 10-20%, 21-30%, 31-40%, 41-50%, or at least 51% higher immunoreactivity than a bivalent antibody having a CD47-binding domain and / or a bivalent antibody having an EpCAM-binding domain. The various immunoreactivity of multispecific antibodies can be measured by in vitro assays such as ADCC assays and ADCP assays. In some examples, the multispecific antibody has 10-20%, 21-30%, 31-40%, 41-50%, or at least 51% higher ADCC activity than a bivalent antibody having a CD47-binding domain and / or a bivalent antibody having an EpCAM-binding domain. In some examples, the multispecific antibody has 10-20%, 21-30%, 31-40%, 41-50%, or at least 51% greater ADCP activity than a bivalent antibody having a CD47-binding domain and / or a bivalent antibody having an EpCAM-binding domain.

[0444] In some embodiments, a multispecific antibody is described herein, comprising a first targeting moiety that specifically binds to CD47 and a second targeting moiety that specifically binds to EpCAM. In some examples, the multispecific antibody further comprises an enhanced ADCP effect compared to the ADCP effect of a reference antibody, CD47BMK-1 (such as those described herein). In some examples, the multispecific antibody further comprises an enhanced ADCC effect compared to the ADCC effect of a reference antibody, CD47BMK-2. In some cases, the enhanced ADCP effect is at least 2-fold, 3-fold, 4-fold, or more higher than the ADCP effect of the reference antibody, CD47BMK-1. In some cases, the enhanced ADCP effect is at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more higher than the CD47BMK-1 effect of the reference antibody, CD47BMK-1. In some cases, the enhanced ADCC is at least 2-fold, 3-fold, 4-fold, 5-fold, or more times higher than the ADCC effect of the reference antibody CD47 BMK-2. In some cases, the enhanced ADCC is at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more times higher than the ADCC effect of the reference antibody CD47 BMK-2.

[0445] In some embodiments, a multispecific antibody is described herein, comprising a first targeting moiety that specifically binds to CD47 and a second targeting moiety that specifically binds to EpCAM. In some examples, the multispecific antibody further comprises an enhanced ADCP effect compared to the ADCP effect of a reference antibody, CD47BMK-1 (such as those described herein). In some examples, the multispecific antibody further comprises an enhanced ADCC effect compared to the ADCC effect of a reference antibody, CD47BMK-2. In some cases, the enhanced ADCP effect is at least 2-fold, 3-fold, 4-fold, or more higher than the ADCP effect of the reference antibody, CD47BMK-2. In some cases, the enhanced ADCP effect is at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more higher than the CD47BMK-2 effect of the reference antibody, CD47BMK-2. In some cases, the enhanced ADCC is at least 2-fold, 3-fold, 4-fold, 5-fold, or more times higher than the ADCC effect of the reference antibody CD47 BMK-2. In some cases, the enhanced ADCC is at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more times higher than the ADCC effect of the reference antibody CD47 BMK-2.

[0446] In some embodiments, multispecific antibodies comprising a first component that specifically binds CD47 and a second component that specifically binds EpCAM are described herein, wherein the multispecific antibodies mediate ADCC more efficiently than bivalent antibodies comprising either the first component or the second component, and the ADCC activity is determined using an in vitro cytotoxicity assay. In some embodiments, the multispecific antibodies mediate maximal cytotoxicity that is at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 75%, or at least about 100% greater in ADCC assays and in vitro ADCC assays than bivalent antibodies comprising either the first component or the second component. In some embodiments, the multispecific antibodies mediate maximal cytotoxicity that is at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, or at least 10-fold greater in ADCC assays and in vitro ADCC assays than bivalent antibodies comprising either the first component or the second component.

[0447] In some embodiments, described herein are multispecific antibodies comprising a first component that specifically binds CD47 and a second component that specifically binds EpCAM, wherein the multispecific antibodies mediate antibody-dependent cellular phagocytosis (ADCP) more efficiently than bivalent antibodies comprising either the first component or the second component, and ADCP activity is determined using an in vitro FACS-based phagocytosis assay. In some embodiments, the multispecific antibodies mediate at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 75%, or at least about 100% greater maximal phagocytosis in ADCP and in vitro ADCC assays than bivalent antibodies comprising either the first component or the second component.

[0448] In some examples, the multispecific antibody further comprises improved killing of cancer cells by immune cells compared to killing by immune cells of a reference antibody CD47 BMK-1 (such as those described herein). In some cases, the killing of cancer cells is improved by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more compared to cancer cells killed in the presence of the reference antibody CD47 BMK-1. In some cases, the immune cells are natural killer cells. In some cases, the immune cells are phagocytes. In some cases, the immune cells are macrophages.

[0449] In some examples, the multispecific antibody further comprises improved killing of cancer cells by immune cells compared to killing by immune cells of a reference antibody CD47 BMK-2 (such as those described herein). In some cases, the killing of cancer cells is improved by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more compared to cancer cells killed in the presence of the reference antibody CD47 BMK-2. In some cases, the immune cells are natural killer cells. In some cases, the immune cells are phagocytes. In some cases, the immune cells are macrophages.

[0450] Immune activity can also be measured in cell line-derived xenograft assays, in which transformed cells are injected into mice to form tumors. In some examples, a multispecific protein having a CD47-binding domain and an EpCAM-binding domain inhibits the growth of tumors containing CD47-expressing cells to a greater extent than a bivalent protein having the same CD47-binding domain and / or a bivalent protein having the same EpCAM-binding domain. In some examples, the multispecific protein exhibits 1.5, 2, 3, 4, 5, or 10-fold greater inhibition of xenograft tumor growth compared to a bivalent protein having a CD47-binding domain and / or a bivalent protein having an EpCAM-binding domain.

[0451] In some embodiments, a multispecific antibody having a CD47-binding domain and an EGFR-binding domain has higher immunoreactivity against CD47-expressing cells compared to a bivalent antibody having a CD47-binding domain and / or a bivalent antibody having an EGFR-binding domain. In some examples, the multispecific antibody has 1.5, 2, 3, 4, 5, or 10 times higher immunoreactivity than a bivalent antibody having a CD47-binding domain and / or a bivalent antibody having an EGFR-binding domain. The various immunoreactivity of a multispecific antibody can be measured by in vitro assays such as ADCC assays and ADCP assays. In some examples, the multispecific antibody has 1.5, 2, 3, 4, 5, or 10 times higher ADCC activity than a bivalent antibody having a CD47-binding domain and / or a bivalent antibody having an EGFR-binding domain. In some examples, the multispecific antibody has 1.5, 2, 3, 4, 5, or 10 times higher ADCP activity than a bivalent antibody having a CD47-binding domain and / or a bivalent antibody having an EGFR-binding domain.

[0452] In some embodiments, a multispecific antibody having a CD47-binding domain and an EGFR-binding domain has higher immunoreactivity against CD47-expressing cells compared to a bivalent antibody having a CD47-binding domain and / or a bivalent antibody having an EGFR-binding domain. In some examples, the multispecific antibody has 10-20%, 21-30%, 31-40%, 41-50%, or at least 51% higher immunoreactivity than a bivalent antibody having a CD47-binding domain and / or a bivalent antibody having an EGFR-binding domain. The various immunoreactivity of multispecific antibodies can be measured by in vitro assays such as ADCC assays and ADCP assays. In some examples, the multispecific antibody has 10-20%, 21-30%, 31-40%, 41-50%, or at least 51% higher ADCC activity than a bivalent antibody having a CD47-binding domain and / or a bivalent antibody having an EGFR-binding domain. In some examples, the multispecific antibody has 10-20%, 21-30%, 31-40%, 41-50%, or at least 51% greater ADCP activity than a bivalent antibody having a CD47-binding domain and / or a bivalent antibody having an EGFR-binding domain.

[0453] In some embodiments, a multispecific antibody is described herein, comprising a first targeting moiety that specifically binds to CD47 and a second targeting moiety that specifically binds to EGFR. In some examples, the multispecific antibody further comprises an enhanced ADCP effect compared to the ADCP effect of a reference antibody, CD47 BMK-1 (such as those described herein). In some examples, the multispecific antibody further comprises an enhanced ADCC effect compared to the ADCC effect of a reference antibody, CD47 BMK-1. In some cases, the enhanced ADCP is at least 2-fold, 3-fold, 4-fold, or more higher than the ADCP effect of the reference antibody, CD47 BMK-1. In some cases, the enhanced ADCP is at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more higher than the ADCP effect of the reference antibody, CD47 BMK-1. In some cases, the enhanced ADCC is at least 1-fold, 3-fold, 4-fold, 5-fold, or more higher than the ADCC effect of the reference antibody, CD47 BMK-1. In some cases, the enhanced ADCC is at least 30%, 40%, 50%, 60%, 70%, 80%, 90% or more higher than the ADCC effect of the reference antibody CD47 BMK-1.

[0454] In some embodiments, a multispecific antibody is described herein, comprising a first targeting moiety that specifically binds to CD47 and a second targeting moiety that specifically binds to EGFR. In some examples, the multispecific antibody further comprises an enhanced ADCP effect compared to the ADCP effect of a reference antibody, CD47 BMK-2 (such as those described herein). In some examples, the multispecific antibody further comprises an enhanced ADCC effect compared to the ADCC effect of a reference antibody, CD47 BMK-2. In some cases, the enhanced ADCP is at least 2-fold, 3-fold, 4-fold, or more higher than the ADCP effect of the reference antibody, CD47 BMK-2. In some cases, the enhanced ADCP is at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more higher than the ADCP effect of the reference antibody, CD47 BMK-2. In some cases, the enhanced ADCC is at least 2-fold, 3-fold, 4-fold, 5-fold, or more higher than the ADCC effect of the reference antibody, CD47 BMK-2. In some cases, the enhanced ADCC is at least 30%, 40%, 50%, 60%, 70%, 80%, 90% or more higher than the ADCC effect of the reference antibody CD47 BMK-2.

[0455] In some embodiments, multispecific antibodies comprising a first component that specifically binds CD47 and a second component that specifically binds EGFR are described herein, wherein the multispecific antibodies mediate ADCC more efficiently than bivalent antibodies comprising either the first component or the second component, and the ADCC activity is determined using an in vitro cytotoxicity assay. In some embodiments, the multispecific antibodies mediate maximal cytotoxicity that is at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 75%, or at least about 100% greater in ADCC assays and in vitro ADCC assays than bivalent antibodies comprising either the first component or the second component. In some embodiments, the multispecific antibodies mediate maximal cytotoxicity that is at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, or at least 10-fold greater in ADCC assays and in vitro ADCC assays than bivalent antibodies comprising either the first component or the second component.

[0456] In some embodiments, described herein are multispecific antibodies comprising a first component that specifically binds CD47 and a second component that specifically binds EGFR, wherein the multispecific antibodies mediate antibody-dependent cellular phagocytosis (ADCP) more efficiently than bivalent antibodies comprising either the first component or the second component, and ADCP activity is determined using an in vitro FACS-based phagocytosis assay. In some embodiments, the multispecific antibodies mediate at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 75%, or at least about 100% greater maximal phagocytosis in ADCP and in vitro ADCC assays than bivalent antibodies comprising either the first component or the second component.

[0457] In some examples, the multispecific antibody further comprises improved killing of cancer cells by immune cells compared to killing by immune cells of a reference antibody CD47 BMK-1 (such as those described herein). In some cases, the killing of cancer cells is improved by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more compared to cancer cells killed in the presence of the reference antibody CD47 BMK-1. In some cases, the immune cells are natural killer cells. In some cases, the immune cells are phagocytes. In some cases, the immune cells are macrophages.

[0458] In some examples, the multispecific antibody further comprises improved killing of cancer cells by immune cells compared to killing by immune cells of a reference antibody CD47 BMK-2 (such as those described herein). In some cases, the killing of cancer cells is improved by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more compared to cancer cells killed in the presence of the reference antibody CD47 BMK-2. In some cases, the immune cells are natural killer cells. In some cases, the immune cells are phagocytes. In some cases, the immune cells are macrophages.

[0459] Immune activity can also be measured in cell line-derived xenograft assays, in which transformed cells are injected into mice to form tumors. In some examples, a multispecific protein having a CD47-binding domain and an EGFR-binding domain inhibits tumor growth containing CD47-expressing cells to a greater extent than a bivalent protein having the same CD47-binding domain and / or a bivalent protein having the same EGFR-binding domain. In some examples, the multispecific protein exhibits 1.5, 2, 3, 4, 5, or 10-fold greater inhibition of xenograft tumor growth compared to a bivalent protein having a CD47-binding domain and / or a bivalent protein having an EGFR-binding domain.

[0460] As used herein, "antibody-dependent cell-mediated cytotoxicity" and "ADCC" refer to a cell-mediated reaction in which nonspecific cytotoxic cells (e.g., natural killer (NK) cells, neutrophils, and macrophages) recognize bound antibodies on target cells, subsequently causing lysis of the target cells. In one embodiment, the target cells are human cells, such as tumor (or cancer) cells (e.g., myeloma cells). In some embodiments, the tumor cells are ductal pancreatic adenocarcinoma cells, ovarian clear cell adenocarcinoma cells, ovarian adenocarcinoma cells, colon adenocarcinoma cells, rectal adenocarcinoma cells, esophageal cancer cells, gastric cancer cells, esophageal cancer cells, non-small cell lung cancer cells, small cell lung cancer cells, endometrial cancer cells, hepatocellular carcinoma cells, cholangiocarcinoma cells, prostate adenocarcinoma cells, thyroid cancer cells, breast cancer cells, cervical cancer cells, renal cell carcinoma cells, testicular cancer cells, or vulvar squamous cell carcinoma cells. In some embodiments, the tumor cells are derived from an adenocarcinoma, lymphoma, or carcinoma. In some cases, the adenocarcinoma is ductal pancreatic adenocarcinoma, ovarian clear cell adenocarcinoma, colon adenocarcinoma, lung adenocarcinoma, gastric adenocarcinoma, or ovarian adenocarcinoma. In other cases, the carcinoma is lung squamous cell carcinoma, small cell lung carcinoma, hepatocellular carcinoma, prostate cancer, endometrial cancer, cholangiocarcinoma, or vulvar squamous cell carcinoma. Without wishing to be bound by any particular mechanism of action, cytotoxic cells that mediate ADCC generally express Fc receptors (FcR). NK cells, which are cells that mediate ADCC, express FcγRIII, while monocytes express FcγRI, FcγRII, FcγRIII, and / or FcγRIV. FcR expression on hematopoietic cells is summarized in Ravetch and Kinet, Annu. Rev. Immunol., 9:457-92 (1991).

[0461] To evaluate the ADCC activity of the multispecific proteins described herein, in some embodiments, an in vitro ADCC assay, such as a cytotoxicity assay using a cancer cell line, is performed. Useful effector cells for such assays include, but are not limited to, peripheral blood mononuclear cells (PBMCs) and natural killer (NK) cells. Alternatively or additionally, the ADCC activity of a multispecific protein of interest is evaluated in vivo, for example, in an animal, in some embodiments.

[0462] "Antibody-dependent cellular phagocytosis" or "ADCP" refers to the ability of phagocytes (e.g., macrophages) to eliminate antibody-coated target cells. In some embodiments, a phagocytosis assay is used to measure ADCP efficacy.

[0463] In some embodiments, the multispecific proteins described herein that bind to CD47 and EpCAM mediate antibody-dependent cellular phagocytosis of at least 50% of cells in an exponentially growing population of CD47 / EpCAM+ cancer cells. In some embodiments, the tumor (or cancer) cells are derived from adenocarcinoma, lymphoma, or carcinoma. In some cases, the adenocarcinoma is ductal pancreatic adenocarcinoma, ovarian clear cell adenocarcinoma, colon adenocarcinoma, lung adenocarcinoma, gastric adenocarcinoma, or ovarian adenocarcinoma.

[0464] In some embodiments, the multispecific proteins described herein bind to CD47, and EpCAM mediates inhibition of the CD47-SIRPα interaction. In some embodiments, the multispecific antibody inhibits SIRPα binding to CD47 by at least 50%. In some embodiments, binding inhibition is measured by ELISA. In some embodiments, binding inhibition is measured in CD47+ cells. In some embodiments, the CD47+ cells are CD47+EpCAM+ tumor (or cancer) cells.

[0465] In some embodiments, the multispecific antibody has reduced binding to CD47+ non-tumor cells, such as red blood cells and platelets. In some cases, binding to CD47+ non-tumor cells is reduced by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% compared to a reference antibody, CD47 BMK-1 (such as those described herein). In some cases, binding of the multispecific antibody to CD47+ non-tumor cells is measured by a red blood cell (RBC) binding assay or a flow cytometry assay.

[0466] In some embodiments, the multispecific antibody has reduced binding to CD47+ non-tumor cells, such as red blood cells and platelets. In some cases, binding to CD47+ non-tumor cells is reduced by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% compared to a reference antibody, CD47 BMK-2 (such as those described herein). In some cases, binding of the multispecific antibody to CD47+ non-tumor cells is measured by a red blood cell (RBC) binding assay or a flow cytometry assay.

[0467] In some embodiments, the concentration of multispecific antibody required to induce RBC lysis is at least 2-fold, 3-fold, 4-fold, or more greater than the hemolytic effect of the reference antibody CD47 BMK-1 (such as those described herein).

[0468] In some embodiments, the concentration of multispecific antibody required to induce RBC lysis is at least 2-fold, 3-fold, 4-fold, or more greater than the hemolytic effect of the reference antibody CD47 BMK-2 (such as those described herein).

[0469] Production of antibodies or binding fragments thereof In some embodiments, the polypeptides described herein (e.g., antibodies and binding fragments thereof) are produced using any method known in the art to aid in the synthesis of polypeptides (e.g., antibodies), inter alia, by chemical synthesis or by recombinant expression, and are preferably produced by recombinant expression techniques.

[0470] In some examples, antibodies or binding fragments thereof are recombinantly expressed, and nucleic acids encoding the antibodies or binding fragments thereof are assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., 1994, BioTechniques 17:242), which involves synthesizing overlapping oligonucleotides containing portions of the antibody-encoding sequence, annealing and ligating those oligonucleotides, and then amplifying the ligated oligonucleotides by PCR.

[0471] Alternatively, nucleic acid molecules encoding antibodies are optionally generated from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated from any tissue or cell that expresses immunoglobulins) by PCR amplification using synthetic primers capable of hybridizing to the 3' and 5' ends of the sequence, or by cloning using oligonucleotide probes specific for the particular gene sequence.

[0472] In some examples, the antibody or binding fragment thereof is optionally produced by immunizing an animal such as a mouse to produce polyclonal antibodies, or more preferably, by producing monoclonal antibodies, e.g., as described by Kohler and Milstein (1975, Nature 256:495-497), or by Kozbor et al. (1983, Immunology Today 4:72), or Cole et al. (1985 in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp.77-96). Alternatively, clones encoding at least the Fab portion of the antibody are optionally obtained by screening Fab expression libraries for clones of FAb fragments that bind to a specific antigen (e.g., as described in Huse et al., 1989, Science 246:1275-1281) or by screening antibody libraries (see Clackson et al., 1991, Nature 352:624; Hane et al., 1997 Proc. Natl. Acad. Sci. USA 94:4937).

[0473] In some embodiments, techniques developed for producing "chimeric antibodies" (Morrison et al., 1984, Proc. Natl. Acad. Sci. 81:851-855; Neuberger et al., 1984, Nature 312:604-608; Takeda et al., 1985, Nature 314:452-454) are used by splicing genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity. Chimeric antibodies are molecules in which different portions are derived from different animal species, such as those having a variable region derived from a mouse monoclonal antibody and a human immunoglobulin constant region.

[0474] In some embodiments, techniques described for the production of single-chain antibodies (U.S. Pat. No. 4,694,778; Bird, 1988, Science 242:423-42; Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883, and Ward et al., 1989, Nature 334:544-54) are adapted to produce single-chain antibodies. Single-chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single-chain polypeptide. Techniques for the assembly of functional Fv fragments in E. coli are also optionally used (Skerra et al., 1988, Science 242:1038-1041).

[0475] In some embodiments, an expression vector containing an antibody nucleotide sequence or the antibody nucleotide sequence is introduced into host cells by conventional techniques (e.g., electroporation, liposome transfection, and calcium phosphate precipitation), and the transfected cells are then cultured by conventional techniques to produce the antibody. In certain embodiments, antibody expression is regulated by a constitutive, inducible, or tissue-specific promoter.

[0476] In some embodiments, various host-expression vector systems are utilized to express the antibodies or binding fragments thereof described herein. Such host-expression systems represent not only the vehicle in which the antibody coding sequence is produced and subsequently purified, but also cells that, when transformed or transfected with the appropriate nucleotide coding sequence, express the antibody or binding fragment thereof in situ. These include, but are not limited to, microorganisms such as bacteria (e.g., Escherichia coli and Bacillus subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA, or cosmid DNA expression vectors containing the antibody or its binding fragment coding sequence; yeast (e.g., Saccharomyces pichia) transformed with recombinant yeast expression vectors containing the antibody or its binding fragment coding sequence; insect cell systems infected with recombinant viral expression vectors (e.g., baculovirus) containing the antibody or its binding fragment coding sequence; plant cell systems infected with recombinant viral expression vectors (e.g., cauliflower mosaic virus (CaMV) and tobacco mosaic virus (TMV)) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing the antibody or its binding fragment coding sequence; and mammalian cell systems (e.g., COS, CHO, BH, 293, 293T, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., adenovirus late promoter, vaccinia virus 7.5K promoter).

[0477] For long-term, high-yield production of recombinant proteins, stable expression is preferred. In some instances, cell lines that stably express antibodies are optionally engineered. Rather than using expression vectors containing viral origins of replication, host cells are transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.) and a selectable marker. After introduction of the exogenous DNA, engineered cells are grown in rich medium for 1-2 days and then switched to selective medium. The selectable marker on the recombinant plasmid confers resistance to selection, allowing cells to stably integrate the plasmid into their chromosomes and grow to form foci, which are cloned and expanded into cell lines. This method can be advantageously used to engineer cell lines that express antibodies or their binding fragments.

[0478] In some examples, a number of selection systems are used, including, but not limited to, herpes simplex virus thymidine kinase (Wigler et al., 1977, Cell 11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 192, Proc. Natl. Acad. Sci. USA 48:202), and adenine phosphoribosyltransferase (Lowy et al., 1980, Cell 22:817) genes utilized in tk cells, hgprt cells, or aprt cells, respectively. Similarly, antimetabolite resistance has been used as a selection criterion for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., 1980, Proc. Natl. Acad. Sci. USA 77:357; O'Hare et al., 1981, Proc. Natl. Acad. Sci. USA 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA 78:2072); and neo, which confers resistance to the aminoglycoside G-418 (Clinical Pharmacy 12:488-505; Wu and Wu, 1991, Biotherapy). 3:87-95; Tolstoshev, 1993, Ann. Rev. Pharmacol. Toxicol. 32:573-596; Mulligan, 1993, Science 260:926-932, and Morgan and Anderson, 1993, Ann. Rev. Biochem. 62:191-217; May, 1993, TIB TECH 11(5):155-215), and hygro, which confers resistance to hygromycin (Santerre et al., 1984, Gene 30:147).Methods generally known in the art of recombinant DNA technology that can be used are described in Ausubel et al. (eds., 1993, Current Protocols in Molecular Biology, John Wiley & Sons, NY; Kriegler, 1990, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY; and Chapters 12 and 13, Dracopoli et al. (eds), 1994, Current Protocols in Human Genetics, John Wiley & Sons, NY.; Colberre-Garapin et al., 1981, J. Mol. Biol. 150:1).

[0479] In some instances, antibody expression levels are increased by vector amplification (for a review, see Bebbington and Hentschel, *The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning*, Vol. 3 (Academic Press, New York, 1987)). If the marker in the antibody expression vector system is amplifiable, increasing the level of inhibitor present in the host cell culture will increase the number of copies of the marker gene. Because the amplified region is related to the antibody nucleotide sequence, antibody production will also increase (Crouse et al., 1983, Mol. Cell Biol. 3:257).

[0480] In some examples, any method for purification of antibodies known in the art is used, for example, by chromatography (e.g., ion exchange, a...

Claims

1. A multispecific antibody comprising a CD47-binding domain and an EpCAM-binding domain.

2. The multispecific antibody of claim 1 , wherein the multispecific antibody is bispecific, trispecific, or tetraspecific.

3. The multispecific antibody of claim 2, wherein the multispecific antibody is bispecific.

4. The multispecific antibody of claim 1 , wherein the multispecific antibody is bivalent, trivalent, or tetravalent.

5. The multispecific antibody of claim 4, wherein the multispecific antibody is bivalent.

6. 2. The multispecific antibody of claim 1, wherein the multispecific antibody has a higher affinity for CD47 expressed on the surface of tumor cells than for CD47 expressed on the surface of normal cells, such as red blood cells, platelets, T cells, B cells, or NK cells.

7. The multispecific antibody of claim 6, wherein the tumor cells express EpCAM.

8. The multispecific antibody of any one of claims 1 to 7, wherein the concentration of said multispecific antibody required for half-maximal binding to (e.g. human) red blood cells is greater than about 200 nanomolar (nM).

9. The multispecific antibody of claim 1, wherein the multispecific antibody binds to (e.g., human) CD47 with a dissociation constant (KD) of less than about 100 nanomolar (nM).

10. 10. The multispecific antibody of claim 9, wherein the multispecific antibody binds to (e.g., human) CD47 with a dissociation constant (KD) of about 1 nanomolar (nM) to about 100 nM, about 1 nM to about 50 nM, or about 5 nM to about 50 nM.

11. The multispecific antibody of claim 1 , wherein the multispecific antibody binds to EpCAM with a dissociation constant (KD) of less than about 500 nanomolar (nM).

12. 12. The multispecific antibody of claim 11, wherein the multispecific antibody binds to EpCAM with a dissociation constant (KD) of about 0.2 nanomolar (nM) to about 500 nM, about 1 nM to about 300 nM, about 5 nM to about 200 nM, or about 10 nM to about 150 nM.

13. The multispecific antibody of claim 1, wherein the dissociation constant (KD) is determined by surface plasmon resonance.

14. The multispecific antibody of claim 1 , wherein the EpCAM binding domain is a human or engineered human EpCAM binding domain.

15. The multispecific antibody of claim 1 , wherein the EpCAM binding domain comprises an antibody that specifically binds to EpCAM, or a functional fragment or variant thereof.

16. The multispecific antibody of claim 15 , wherein the antibody, or a functional fragment or variant thereof, that specifically binds to EpCAM comprises an anti-EpCAM heavy chain and an anti-EpCAM light chain.

17. The multispecific antibody of claim 16 , wherein the anti-EpCAM heavy chain comprises an anti-EpCAM heavy chain variable domain.

18. The multispecific antibody of claim 16 , wherein the anti-EpCAM heavy chain variable domain comprises a variable domain of an IgG1, IgG2, IgG3, or IgG4 heavy chain.

19. The multispecific antibody of claim 16 , wherein the anti-EpCAM light chain comprises an anti-EpCAM light chain variable domain.

20. The multispecific antibody of claim 19 , wherein the anti-EpCAM light chain variable domain comprises a kappa or lambda light chain.

21. The multispecific antibody of claim 16 , wherein the EpCAM binding domain comprises a single-chain variable fragment (scFv).

22. The multispecific antibody of claim 16 , wherein the EpCAM binding domain comprises an antigen-binding fragment (Fab).

23. The multispecific antibody of claim 16 , wherein the EpCAM binding domain comprises a T cell receptor (TCR) constant region.

24. The multispecific antibody of claim 23 , wherein the TCR constant region of the EpCAM binding domain comprises a TCR alpha constant domain and a TCR beta constant domain.

25. The multispecific antibody of claim 23, wherein the EpCAM binding domain comprises a VH-EpCAM domain and a VL-EpCAM domain, the VH-EpCAM domain being fused to a TCR alpha constant domain and the VL-EpCAM domain being fused to a TCR beta constant domain.

26. The multispecific antibody of claim 23, wherein the EpCAM binding domain comprises a VH-EpCAM domain and a VL-EpCAM domain, the VH-EpCAM domain being fused to a TCRβ constant domain and the VL-EpCAM domain being fused to a TCRα constant domain.

27. The multispecific antibody of claim 23, wherein the EpCAM binding domain comprises a VH-EpCAM domain and a VL-EpCAM domain, the VH-EpCAM domain being fused to a CH1 IgG domain and the VL-EpCAM domain being fused to a CL IgG domain.

28. The multispecific antibody of claim 1 , wherein the CD47 binding domain is a human or engineered human CD47 binding domain.

29. The multispecific antibody of claim 1 , wherein the CD47 binding domain comprises an antibody that specifically binds to CD47, or a functional fragment or functional variant thereof.

30. The multispecific antibody of claim 29 , wherein the CD47 binding domain comprises an anti-CD47 heavy chain and an anti-CD47 light chain.

31. The multispecific antibody of claim 30 , wherein the anti-CD47 heavy chain comprises an anti-CD47 heavy chain variable domain.

32. 32. The multispecific antibody of claim 31 , wherein the anti-CD47 heavy chain variable domain comprises the variable domain of an IgG1, IgG2, IgG3, or IgG4 heavy chain.

33. The multispecific antibody of claim 30 , wherein the anti-CD47 light chain comprises an anti-CD47 light chain variable domain.

34. The multispecific antibody of claim 33, wherein the anti-CD47 light chain variable domain comprises a kappa or lambda light chain variable domain.

35. The multispecific antibody of claim 30, wherein the anti-CD47 heavy chain variable domain comprises the variable domain of an IgG1 heavy chain and the anti-CD47 light chain variable domain comprises a kappa light chain.

36. 31. The multispecific antibody of claim 30, wherein the anti-CD47 heavy chain variable domain comprises the variable domain of an IgG1 heavy chain and the anti-CD47 light chain variable domain comprises a lambda light chain.

37. The multispecific antibody of claim 30 , wherein the CD47 binding domain comprises a single chain variable fragment (scFv).

38. The multispecific antibody of claim 30 , wherein the CD47 binding domain comprises an antigen-binding fragment (Fab).

39. The multispecific antibody of claim 30, wherein the CD47 binding domain comprises a T cell receptor (TCR) constant region.

40. The multispecific antibody of claim 39 , wherein the TCR constant region of the CD47 binding domain comprises a TCR alpha constant domain and a TCR beta constant domain.

41. 40. The multispecific antibody of claim 39, wherein the CD47 binding domain comprises a VH-CD47 domain and a VL-CD47 domain, wherein the VH-CD47 domain is fused to a TCR alpha constant domain and the VL-CD47 domain is fused to a TCR beta constant domain.

42. 40. The multispecific antibody of claim 39, wherein the CD47 binding domain comprises a VH-CD47 domain and a VL-CD47 domain, wherein the VH-CD47 domain is fused to a TCR β constant domain and the VL-CD47 domain is fused to a TCR α constant domain.

43. 40. The multispecific antibody of claim 39, wherein the CD47 binding domain comprises a VH-CD47 domain and a VL-CD47 domain, wherein the VH-CD47 domain is fused to a CH1 IgG domain and the VL-CD47 domain is fused to a CL IgG domain.

44. The multispecific antibody of claim 1 further comprising an Fc domain.

45. The multispecific antibody of claim 44, wherein the Fc domain is a human Fc domain.

46. 45. The multispecific antibody of claim 44, wherein the isotype of the Fc domain is IgG1, IgG2, IgG3, or IgG4.

47. 2. The multispecific antibody of claim 1, wherein the Fc domain is a heterodimeric Fc domain, the heterodimeric Fc region comprising a knob chain and a hole chain forming a knob-into-hole (KiH) structure.

48. 48. The multispecific antibody of claim 47, wherein the knob chain comprises an IgG1, IgG2, IgG3, or IgG4 domain.

49. 48. The multispecific antibody of claim 47, wherein the knob strand comprises the mutation T366W and the hole strand comprises the mutations T366S, L368A, and Y407V, and the numbering of the amino acid positions is according to the EU index of Kabat et al.

50. 48. The multispecific antibody of claim 47, wherein the hole chain comprises an IgG1, IgG2, IgG3, or IgG4 domain.

51. The multispecific antibody of claim 1 , wherein the multispecific antibody has an asymmetric three-chain knob-into-hole structure.

52. The multispecific antibody of claim 1, wherein the EpCAM binding domain comprises three heavy chain (HC) complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, wherein the HC-CDR1, HC-CDR2, and HC-CDR3 of the EpCAM binding domain comprise an amino acid sequence selected from those set forth in Table 9.

53. The multispecific antibody of claim 1, wherein HC-CDR1 of the EpCAM binding domain comprises an amino acid sequence selected from SEQ ID NOs: 222, 225, 231, 234, 243, and 246.

54. The multispecific antibody of claim 1, wherein the HC-CDR2 of the EpCAM binding domain comprises an amino acid sequence selected from SEQ ID NOs: 223, 226, 232, 235, 244, and 247.

55. The multispecific antibody of claim 1, wherein the HC-CDR3 of the EpCAM binding domain comprises an amino acid sequence selected from SEQ ID NOs: 224, 227, 233, 236, 245, and 248.

56. The multispecific antibody of claim 1, wherein the EpCAM binding domain comprises three light chain (LC) complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, and the LC-CDR1, LC-CDR2, and LC-CDR3 of the EpCAM binding domain comprise amino acid sequences selected from those set forth in Table 10.

57. The multispecific antibody of claim 1, wherein the LC-CDR1 of the EpCAM binding domain comprises an amino acid sequence selected from SEQ ID NOs: 276, 279, 285, 288, 297, and 300.

58. The multispecific antibody of claim 1, wherein the LC-CDR2 of the EpCAM binding domain comprises an amino acid sequence selected from SEQ ID NOs: 277, 280, 286, 289, 298, and 301.

59. The multispecific antibody of claim 1, wherein the LC-CDR3 of the EpCAM binding domain comprises an amino acid sequence selected from SEQ ID NOs: 278, 281, 287, 290, 299, and 302.

60. The multispecific antibody of claim 1, wherein the EpCAM binding domain comprises a heavy chain framework region (HFR) comprising an amino acid sequence selected from those set forth in Table 11, and the HFR comprises 0 to 3 amino acid modifications.

61. 2. The multispecific antibody of claim 1, wherein the EpCAM binding domain comprises a heavy chain framework region (HFR) comprising an amino acid sequence selected from SEQ ID NOs: 331-334, 335-338, 343-346, 347-350, 355-358, and 359-362, and wherein the HFR comprises 0 to 3 amino acid modifications.

62. The multispecific antibody of claim 60, wherein the HFR of the EpCAM binding domain comprises 0 to 2 amino acid modifications.

63. The multispecific antibody of claim 60, wherein the HFR of the EpCAM binding domain comprises 0 to 1 amino acid modifications.

64. The multispecific antibody of claim 1, wherein the EpCAM binding domain comprises a light chain framework region (LFR) comprising an amino acid sequence selected from those set forth in Table 12, and the LFR comprises 0 to 3 amino acid modifications.

65. 2. The multispecific antibody of claim 1, wherein the EpCAM binding domain comprises a light chain framework region (LFR) comprising an amino acid sequence selected from SEQ ID NOs: 367-370, 371-374, 379-382, 383-386, 391-394, and 395-398, and the HFR comprises 0-3 amino acid modifications.

66. The multispecific antibody of claim 64, wherein the LFR of the EpCAM binding domain comprises 0 to 2 amino acid modifications.

67. The multispecific antibody of claim 64, wherein the LFR of the EpCAM binding domain comprises 0 to 1 amino acid modifications.

68. 2. The multispecific antibody of claim 1 , wherein the EpCAM binding domain comprises a heavy chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 13.

69. 2. The multispecific antibody of claim 1, wherein the EpCAM binding domain comprises a light chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 14.

70. 2. The multispecific antibody of claim 1 , wherein the EpCAM binding domain comprises a full-length heavy chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 15.

71. 2. The multispecific antibody of claim 1 , wherein the EpCAM binding domain comprises a full-length light chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 16.

72. 2. The multispecific antibody of claim 1, wherein the EpCAM binding domain comprises a single chain variable fragment (scFv) comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 17.

73. 2. The multispecific antibody of claim 1 , wherein the EpCAM binding domain comprises a TCR constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 18.

74. 2. The multispecific antibody of claim 1, wherein the EpCAM binding domain comprises a TCR alpha constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 18.

75. 2. The multispecific antibody of claim 1 , wherein the EpCAM binding domain comprises a TCR β constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 18.

76. 2. The multispecific antibody of claim 1, wherein the CD47 binding domain comprises three heavy chain (HC) complementarity determining regions (CDRs), HC-CDR1, HC-CDR2, and HC-CDR3, and wherein HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise an amino acid sequence selected from those set forth in Table 1, and at least one of HC-CDR1, HC-CDR2, and HC-CDR3 comprises 0 to 3 amino acid modifications.

77. The multispecific antibody of claim 76, wherein at least one of HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprises 0 to 2 amino acid modifications.

78. The multispecific antibody of claim 76, wherein at least one of HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprises 0 to 1 amino acid modifications.

79. 2. The multispecific antibody of claim 1, wherein the CD47 binding domain comprises three light chain (LC) complementarity determining regions (CDRs), LC-CDR1, LC-CDR2, and LC-CDR3, and wherein LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise an amino acid sequence selected from those set forth in Table 2, and at least one of LC-CDR1, LC-CDR2, and LC-CDR3 comprises 0 to 3 amino acid modifications.

80. The multispecific antibody of claim 79, wherein at least one of LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprises 0 to 2 amino acid modifications.

81. The multispecific antibody of claim 79, wherein at least one of LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprises 0 to 1 amino acid modifications.

82. 2. The multispecific antibody of claim 1, wherein the CD47 binding domain comprises a heavy chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 3.

83. 2. The multispecific antibody of claim 1 , wherein the CD47 binding domain comprises a light chain variable domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 4.

84. 2. The multispecific antibody of claim 1 , wherein the CD47 binding domain comprises a full-length heavy chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 5.

85. 2. The multispecific antibody of claim 1 , wherein the CD47 binding domain comprises a full-length light chain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 6.

86. 2. The multispecific antibody of claim 1, wherein the CD47 binding domain comprises a single chain variable fragment (scFv) comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 7.

87. 2. The multispecific antibody of claim 1, wherein the CD47 binding domain comprises a TCR constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 8.

88. 2. The multispecific antibody of claim 1 , wherein the CD47 binding domain comprises a TCR alpha constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 8.

89. 2. The multispecific antibody of claim 1, wherein the CD47 binding domain comprises a TCR β constant domain comprising a sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth in Table 8.

90. 2. The multispecific antibody of claim 1, comprising one or more sequences each having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a corresponding sequence set forth in Table 26.

91. 2. The multispecific antibody of claim 1, comprising one or more sequences each having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a corresponding sequence set forth in Table 27.

92. 2. The multispecific antibody of claim 1, comprising one or more sequences each having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a corresponding sequence set forth in Table 28.

93. 2. The multispecific antibody of claim 1, comprising one or more sequences each having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a corresponding sequence set forth in Table 29.

94. 2. The multispecific antibody of claim 1, comprising one or more sequences each having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a corresponding sequence set forth in Table 30.

95. 2. The multispecific antibody of claim 1, comprising one or more sequences each having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a corresponding sequence set forth in Table 31.

96. 2. The multispecific antibody of claim 1, comprising one or more sequences each having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a corresponding sequence set forth in Table 32.

97. 2. The multispecific antibody of claim 1, wherein the EpCAM binding domain comprises three heavy chain (HC) complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, and three light chain (LC) complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3, and the CD47 binding domain comprises three heavy chain (HC) complementarity determining regions (CDRs): HC-CDR1, HC-CDR2, and HC-CDR3, and the CD47 binding domain comprises three light chain (LC) complementarity determining regions (CDRs): LC-CDR1, LC-CDR2, and LC-CDR3.

98. The multispecific antibody of claim 1, wherein the HC-CDR2 of the EpCAM binding domain comprises the amino acid sequence set forth in SEQ ID NO:

235.

99. The multispecific antibody of claim 1, wherein the HC-CDR1, HC-CDR2, and HC-CDR3 of the EpCAM binding domain comprise the amino acid sequences set forth in SEQ ID NO: 234 for HC-CDR1, SEQ ID NO: 235 for HC-CDR2, and SEQ ID NO: 236 for HC-CDR3.

100. The multispecific antibody of claim 1, wherein the EpCAM binding domain comprises an amino acid sequence as set forth in SEQ ID NO:234 ​​for HC-CDR1, SEQ ID NO:235 for HC-CDR2, and SEQ ID NO:236 for HC-CDR3, and the EpCAM binding domain comprises an amino acid sequence as set forth in SEQ ID NO:288 for LC-CDR1, SEQ ID NO:289 for LC-CDR2, and SEQ ID NO:290 for LC-CDR3.

101. The multispecific antibody of claim 1, wherein the EpCAM binding domain comprises HC-CDR1, HC-CDR2, and HC-CDR3 of the EpCAM binding domain comprises the amino acid sequences set forth in SEQ ID NO: 234 for HC-CDR1, SEQ ID NO: 235 for HC-CDR2, and SEQ ID NO: 236 for HC-CDR3, the EpCAM binding domain comprises the amino acid sequences set forth in SEQ ID NO: 288 for LC-CDR1, SEQ ID NO: 289 for LC-CDR2, and SEQ ID NO: 290 for LC-CDR3, and the CD47 binding domain comprises the amino acid sequences set forth in SEQ ID NO: 1 for HC-CDR1, SEQ ID NO: 2 for HC-CDR2, and SEQ ID NO: 3 for HC-CDR3.

102. The EpCAM binding domain has HC-CDR1, HC-CDR2, and HC-CDR3 comprising the amino acid sequences set forth in SEQ ID NOs: 234 (HC-CDR1), 235 (HC-CDR2), and 236 (HC-CDR3); the EpCAM binding domain has LC-CDR1, LC-CDR2, and LC-CDR3 comprising the amino acid sequences set forth in SEQ ID NOs: 288 (LC-CDR1), 289 (LC-CDR2), and 290 (LC-CDR3); The multispecific antibody of claim 1, wherein the HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences set forth in SEQ ID NO: 1 for HC-CDR1, SEQ ID NO: 2 for HC-CDR2, and SEQ ID NO: 3 for HC-CDR3, and the LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences set forth in SEQ ID NO: 61 for LC-CDR1, SEQ ID NO: 62 for LC-CDR2, and SEQ ID NO: 63 for LC-CDR3.

103. The multispecific antibody of claim 1, wherein the multispecific antibody comprises an asymmetric three-chain knob-into-hole structure, the EpCAM binding domain comprises a single-chain variable fragment (scFv) and the CD47 binding domain comprises an antigen-binding fragment (Fab).

104. The multispecific antibody of claim 1 , wherein the multispecific antibody comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NOs: 482, 483, and 484.

105. The multispecific antibody of claim 1 , wherein the multispecific antibody comprises the amino acid sequences set forth in SEQ ID NOs: 482, 483, and 484.

106. The multispecific antibody of claim 1 , wherein the multispecific antibody comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NOs: 482, 483, and 507.

107. The multispecific antibody of claim 1 , wherein the multispecific antibody comprises the amino acid sequences set forth in SEQ ID NOs: 482, 483, and 507.

108. The multispecific antibody of claim 1, wherein the multispecific antibody comprises an asymmetric three-chain knob-into-hole structure, the CD47 binding domain comprises a single-chain variable fragment (scFv) and the EpCAM binding domain comprises an antigen-binding fragment (Fab).

109. The multispecific antibody of claim 1 , wherein the multispecific antibody comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NOs: 503, 504, and 505.

110. The multispecific antibody of claim 1 , wherein the multispecific antibody comprises the amino acid sequence set forth in SEQ ID NOs: 503, 504, and 505.

111. The multispecific antibody of claim 1, wherein the HC-CDR2 of the EpCAM binding domain comprises the amino acid sequence set forth in SEQ ID NO:

244.

112. The multispecific antibody of claim 1, wherein the HC-CDR1, HC-CDR2, and HC-CDR3 of the EpCAM binding domain comprise the amino acid sequences set forth in SEQ ID NO: 243 for HC-CDR1, SEQ ID NO: 244 for HC-CDR2, and SEQ ID NO: 245 for HC-CDR3.

113. The multispecific antibody of claim 1, wherein the HC-CDR1, HC-CDR2, and HC-CDR3 of the EpCAM binding domain comprise the amino acid sequences set forth in SEQ ID NO: 243 for HC-CDR1, SEQ ID NO: 244 for HC-CDR2, and SEQ ID NO: 245 for HC-CDR3, and the LC-CDR1, LC-CDR2, and LC-CDR3 of the EpCAM binding domain comprise the amino acid sequences set forth in SEQ ID NO: 297 for LC-CDR1, SEQ ID NO: 298 for LC-CDR2, and SEQ ID NO: 299 for LC-CDR3.

114. The multispecific antibody of claim 1, wherein the EpCAM binding domain comprises the amino acid sequences set forth in SEQ ID NO:243 for HC-CDR1, SEQ ID NO:244 for HC-CDR2, and SEQ ID NO:245 for HC-CDR3, the EpCAM binding domain comprises the amino acid sequences set forth in SEQ ID NO:297 for LC-CDR1, SEQ ID NO:298 for LC-CDR2, and SEQ ID NO:299 for LC-CDR3, and the CD47 binding domain comprises the amino acid sequences set forth in SEQ ID NO:1 for HC-CDR1, SEQ ID NO:2 for HC-CDR2, and SEQ ID NO:3 for HC-CDR3.

115. The EpCAM binding domain has HC-CDR1, HC-CDR2, and HC-CDR3 comprising the amino acid sequences set forth in SEQ ID NO: 243 for HC-CDR1, SEQ ID NO: 244 for HC-CDR2, and SEQ ID NO: 245 for HC-CDR3, and the EpCAM binding domain has LC-CDR1, LC-CDR2, and LC-CDR3 comprising the amino acid sequences set forth in SEQ ID NO: 297 for LC-CDR1, SEQ ID NO: 298 for LC-CDR2, and SEQ ID NO: 299 for LC-CDR3, The multispecific antibody of claim 1, wherein the HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences set forth in SEQ ID NO: 1 for HC-CDR1, SEQ ID NO: 2 for HC-CDR2, and SEQ ID NO: 3 for HC-CDR3, and the LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences set forth in SEQ ID NO: 61 for LC-CDR1, SEQ ID NO: 62 for LC-CDR2, and SEQ ID NO: 63 for LC-CDR3.

116. The multispecific antibody of claim 1, wherein the multispecific antibody comprises an asymmetric three-chain knob-into-hole structure, the EpCAM binding domain comprises a single-chain variable fragment (scFv) and the CD47 binding domain comprises an antigen-binding fragment (Fab).

117. The multispecific antibody of claim 1, wherein the multispecific antibody comprises an asymmetric three-chain knob-into-hole structure, the CD47 binding domain comprises a single-chain variable fragment (scFv) and the EpCAM binding domain comprises an antigen-binding fragment (Fab).

118. The multispecific antibody of claim 1 , wherein the multispecific antibody comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NOs: 485, 486, and 487.

119. The multispecific antibody of claim 1 , wherein the multispecific antibody comprises the amino acid sequences set forth in SEQ ID NOs: 485, 486, and 487.

120. The multispecific antibody of claim 1, wherein the HC-CDR1, HC-CDR2, and HC-CDR3 of the EpCAM binding domain comprise the amino acid sequences set forth in SEQ ID NO: 222 for HC-CDR1, SEQ ID NO: 223 for HC-CDR2, and SEQ ID NO: 224 for HC-CDR3.

121. The multispecific antibody of claim 1, wherein the HC-CDR1, HC-CDR2, and HC-CDR3 of the EpCAM binding domain comprise the amino acid sequences set forth in SEQ ID NO: 222 for HC-CDR1, SEQ ID NO: 223 for HC-CDR2, and SEQ ID NO: 224 for HC-CDR3, and the LC-CDR1, LC-CDR2, and LC-CDR3 of the EpCAM binding domain comprise the amino acid sequences set forth in SEQ ID NO: 276 for LC-CDR1, SEQ ID NO: 277 for LC-CDR2, and SEQ ID NO: 275 for LC-CDR3.

122. The multispecific antibody of claim 1, wherein the EpCAM binding domain comprises the amino acid sequences set forth in SEQ ID NO:222 for HC-CDR1, SEQ ID NO:223 for HC-CDR2, and SEQ ID NO:224 for HC-CDR3, the EpCAM binding domain comprises the amino acid sequences set forth in SEQ ID NO:276 for LC-CDR1, SEQ ID NO:277 for LC-CDR2, and SEQ ID NO:275 for LC-CDR3, and the CD47 binding domain comprises the amino acid sequences set forth in SEQ ID NO:1 for HC-CDR1, SEQ ID NO:2 for HC-CDR2, and SEQ ID NO:3 for HC-CDR3.

123. The EpCAM binding domain has HC-CDR1, HC-CDR2, and HC-CDR3 comprising the amino acid sequences set forth in SEQ ID NO: 222 for HC-CDR1, SEQ ID NO: 223 for HC-CDR2, and SEQ ID NO: 224 for HC-CDR3, and the EpCAM binding domain has LC-CDR1, LC-CDR2, and LC-CDR3 comprising the amino acid sequences set forth in SEQ ID NO: 276 for LC-CDR1, SEQ ID NO: 277 for LC-CDR2, and SEQ ID NO: 275 for LC-CDR3, The multispecific antibody of claim 1, wherein the HC-CDR1, HC-CDR2, and HC-CDR3 of the CD47 binding domain comprise the amino acid sequences set forth in SEQ ID NO: 1 for HC-CDR1, SEQ ID NO: 2 for HC-CDR2, and SEQ ID NO: 3 for HC-CDR3, and the LC-CDR1, LC-CDR2, and LC-CDR3 of the CD47 binding domain comprise the amino acid sequences set forth in SEQ ID NO: 61 for LC-CDR1, SEQ ID NO: 62 for LC-CDR2, and SEQ ID NO: 63 for LC-CDR3.

124. The multispecific antibody of claim 1, wherein the multispecific antibody comprises an asymmetric three-chain knob-into-hole structure, the EpCAM binding domain comprises a single-chain variable fragment (scFv) and the CD47 binding domain comprises an antigen-binding fragment (Fab).

125. The multispecific antibody of claim 1, wherein the multispecific antibody comprises an asymmetric three-chain knob-into-hole structure, the CD47 binding domain comprises a single-chain variable fragment (scFv) and the EpCAM binding domain comprises an antigen-binding fragment (Fab).

126. The multispecific antibody of claim 1 , wherein the multispecific antibody comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NOs: 482, 483, and 506.

127. The multispecific antibody of claim 1 , wherein the multispecific antibody comprises the amino acid sequences set forth in SEQ ID NOs: 482, 483, and 506.

128. The multispecific antibody of claim 1, wherein the multispecific antibody at less than about 1 nanomolar (nM) or less than about 0.01 nM increases the percentage of HCT-15 cells that are phagocytosed by macrophages by at least 4-fold compared to a non-specific IgG1 antibody control.

129. The multispecific antibody of claim 94, wherein the concentration of antibody required to mediate antibody-dependent cellular phagocytosis of EpCAM-positive CD47-positive tumor cells by macrophages is from about 0.001 nanomolar (nM) to about 3 nM.

130. The multispecific antibody of claim 129, wherein the EpCAM-positive CD47-positive tumor cells are HCT-15 cells.

131. The multispecific antibody of claim 129, wherein the EpCAM positive CD47 positive tumor cells are selected from ductal pancreatic adenocarcinoma cells, ovarian clear cell adenocarcinoma cells, ovarian adenocarcinoma cells, colon adenocarcinoma cells, rectal adenocarcinoma cells, esophageal cancer cells, gastric cancer cells, non-small cell lung cancer cells, small cell lung cancer cells, endometrial cancer cells, hepatocellular carcinoma cells, cholangiocarcinoma cells, prostate adenocarcinoma cells, thyroid cancer cells, breast cancer cells, cervical cancer cells, renal cell carcinoma cells, testicular cancer cells, or vulvar squamous cell carcinoma cells.

132. 2. The multispecific antibody of claim 1, wherein about 100 nanomolar (nM) of the multispecific antibody inhibits binding of SIRPα to CD47 on the surface of a cell by at least about 30%.

133. The multispecific antibody of claim 132, wherein the cell is a CD47+EpCAM+ tumor cell.

134. The multispecific antibody of claim 133, wherein the cell expresses at least as many EpCAM proteins on its surface as HCC-44 cells.

135. The multispecific antibody of claim 133, wherein the cell expresses at least 50,000, at least 100,000, at least 300,000, at least 600,000, or at least 1,500,000 EpCAM proteins on its surface.

136. The multispecific antibody of claim 1 , wherein the multispecific antibody at about 1000 nanomolar (nM) does not induce hemolysis of red blood cells in a hemagglutination assay.

137. A complex comprising the multispecific antibody of claim 1 and a CD47+EpCAM+ target cell.

138. The complex of claim 137, wherein the target cell expresses at least as much EpCAM protein on its surface as an HCC-44 cell.

139. The complex of claim 137, wherein the target cell expresses at least 50,000, at least 100,000, at least 300,000, at least 600,000, or at least 1,500,000 EpCAM proteins on its surface.

140. The conjugate of claim 137, wherein the CD47+EpCAM+ target cell is a cancer cell.

141. The complex of claim 140, wherein the cancer cell is a ductal pancreatic adenocarcinoma cell, an ovarian clear cell adenocarcinoma cell, an ovarian adenocarcinoma cell, a colon adenocarcinoma cell, a rectal adenocarcinoma cell, an esophageal cancer cell, a gastric cancer cell, a non-small cell lung cancer cell, a small cell lung cancer cell, an endometrial cancer cell, a hepatocellular carcinoma cell, a cholangiocarcinoma cell, a prostate adenocarcinoma cell, a thyroid cancer cell, a breast cancer cell, a cervical cancer cell, a renal cell carcinoma cell, a testicular cancer cell, or a vulvar squamous cell carcinoma cell.

142. A method for inducing phagocytosis of CD47+EpCAM+ target cells, comprising administering the multispecific antibody of claim 1.

143. 143. The method of claim 142, wherein the multispecific antibody is administered at a concentration of less than about 5 nanomolar (nM), less than about 2 nM, less than about 1 nM, less than about 0.5 nM, less than about 0.2 nM, less than about 0.1 nM, or less than about 0.05 nM.

144. The method of claim 142 or 143, wherein the CD47+EpCAM+ target cell is selected from an HCT-15 cell, an A431 cell, an HCC-44 cell, a SKOV-3 cell, an OVISE cell, or a CFPAC-1 cell.

145. The method of claim 142, wherein the CD47+EpCAM+ target cell is a ductal pancreatic adenocarcinoma cell, an ovarian clear cell adenocarcinoma cell, an ovarian adenocarcinoma cell, a colon adenocarcinoma cell, a rectal adenocarcinoma cell, an esophageal cancer cell, a gastric cancer cell, a non-small cell lung carcinoma cell, a small cell lung carcinoma cell, an endometrial cancer cell, a hepatocellular carcinoma cell, a cholangiocarcinoma cell, a prostate adenocarcinoma cell, a thyroid cancer cell, a breast cancer cell, a cervical cancer cell, a renal cell carcinoma cell, a testicular cancer cell, or a vulvar squamous cell carcinoma cell.

146. 2. A method of killing CD47+EpCAM+ target cells comprising administering a multispecific antibody according to claim 1, wherein the multispecific antibody inhibits binding of SIRPα to CD47 on the surface of the CD47+EpCAM+ target cells.

147. A method for killing CD47+EpCAM+ target cells comprising administering a multispecific antibody according to claim 1, wherein the multispecific antibody induces antibody-dependent cellular cytotoxicity that kills the CD47+EpCAM+ target cells.

148. 148. The method of claim 147, wherein the multispecific antibody is administered at a concentration of about 0.01 nanomolar (nM) to about 1 nM, about 0.01 nM to about 0.5 nM, about 0.01 nM to about 0.25 nM, about 0.01 nM to about 0.1 nM, about 0.01 to about 0.05 nM, or less than about 0.01 nM.

149. The method of claim 147, wherein the CD47+EpCAM+ target cells are selected from HCT-15 cells, A431 cells, HCC-44 cells, SKOV-3 cells, OVISE cells, or CFPAC-1 cells.

150. The method of claim 147, wherein the CD47+EpCAM+ target cell is a ductal pancreatic adenocarcinoma cell, an ovarian clear cell adenocarcinoma cell, an ovarian adenocarcinoma cell, a colon adenocarcinoma cell, a rectal adenocarcinoma cell, an esophageal cancer cell, a gastric cancer cell, a non-small cell lung cancer cell, a small cell lung cancer cell, an endometrial cancer cell, a hepatocellular carcinoma cell, a cholangiocarcinoma cell, a prostate adenocarcinoma cell, a thyroid cancer cell, a breast cancer cell, a cervical cancer cell, a renal cell carcinoma cell, a testicular cancer cell, or a vulvar squamous cell carcinoma cell.

Citation Information

Patent Citations

  • Anti-EpCAM antibodies and their use

    JP2010523096A

  • Anti-CD47 antibody and method of use thereof

    JP2015536351A

  • Targeted therapy for small cell lung cancer

    JP2017502048A

  • Epcam antibodies, activatable antibodies, and immunoconjugates, and uses thereof

    WO2020086665A1

  • Conditionally active Anti-epcam antibodies, antibody fragments, their immunoconjugates and uses thereof

    WO2020252095A1